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Abstract 
Billions of people are potentially at risk from mosquito-borne arboviruses belonging to the genera 
Alphavirus and Flavivirus, representing a serious, global, public health concern. Some of the 
medically important alphaviruses include chikungunya virus (CHIKV), Barmah Forest virus (BFV) 
and Ross River virus (RRV) while medically important flaviviruses include dengue viruses 
(DENV), Japanese encephalitis virus (JEV), Murray Valley encephalitis virus (MVEV), West Nile 
virus (WNV), and yellow fever virus (YFV).  Factors that may be contributing to the emergence 
and re-emergence of these viruses include ineffective vector control, increasing global travel, 
urbanisation and expanding host ranges.  The clinical signs associated with alphaviral and flaviviral 
disease can be non-specific, thus necessitating a laboratory diagnosis.    
 
Rapid diagnostic tests have been identified as an area of critical importance for alphavirus and 
flavivirus research, as they are essential tools for both the clinical treatment of patients and public 
health surveillance. Effective arbovirus surveillance requires a multi-faceted approach combining 
surveillance for fevers of unknown origin, particularly in travellers, as well as animal and 
entomological surveillance. Early detection of clinical cases, followed by the implementation of 
control measures such as vaccination, mosquito-control and raising public awareness, can be 
effective in limiting outbreaks.  Conversely, the failure of effective surveillance can have a huge 
economic and public health impact, even in developed countries.  The introduction, spread and 
establishment of WNV in the USA demonstrates the need for effective surveillance systems for 
both endemic and exotic diseases, and the high costs associated with a failure to rapidly implement 
effective public health measures. 
 
Multiplex suspension microarrays, using Luminex technology, have been reported to be cost-
efficient, and easy to design and perform.  Most importantly, their proven ability to detect multiple 
viruses in a single sample has suggested an important role for surveillance work. For these reasons, 
a suspension microarray for the detection of alphaviruses and flaviviruses was developed as a 
useful, rapid, diagnostic test for both clinical diagnosis and public health surveillance. Consensus 
primers were used for the amplification of alphaviruses and flaviviruses and virus-specific probes 
were either adapted from previously validated TaqMan assays or designed to enable a specific 
diagnosis. The multiplex test was validated against a panel of reference viruses, clinical samples 
where available, and individual virus-positive mosquitoes or mosquito pools. The standardised 
assay conditions that were developed will facilitate the multiplexing of all assays in future. 
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The multiplex suspension microarrays developed have been shown to be sensitive and virus-
specific.  The alphavirus suspension microarray could successfully detect Ross River virus (RRV), 
Barmah Forest virus (BFV), Chikungunya virus (CHIKV) and Sindbis virus (SINV). The 
encephalitic flavivirus suspension microarray which could initially detect four different encephalitic 
flaviviruses was expanded to an assay that was capable of detecting 12 different flaviviruses 
through the incorporation of 14 probes. This was accomplished without a loss in sensitivity in the 
assay from multiplexing. The flavivirus suspension microarray detected the dengue viruses (DENV-
1-4), Kokobera virus (KOKV), Sepik virus (SEPV), Stratford virus (STRATV) and yellow fever 
virus (YFV), as well as the encephalitic viruses, Japanese encephalitis virus (JEV), the Kunjin strain 
of West Nile virus (KUNV), Murray Valley encephalitis virus (MVEV) and West Nile virus 
(WNV). These viruses are either important global pathogens or endemic flaviviruses of public 
health interest in Australia. Some cross-reactivity was observed between closely related viruses; 
however use of the highest signal allowed the differentiation of the correct virus species. The 
suspension microarrays were found to be rapid, sensitive, specific and cost-effective.  
 
It is anticipated that these cost-effective diagnostic tests may enable adoption of improved 
surveillance programs and the routine screening of samples against a wider panel of viruses. We 
also report for the first time that this technology can be useful for detecting virus in mosquito pools.  
This has important implications for cost-effective vector-surveillance programs.  We also 
successfully explored the potential to use an amplification strategy that would allow the same PCR 
product to be used in both suspension microarray and chip microarray assays, potentially allowing 
epidemiological analysis to occur rapidly in-house. A novel synthetic amplification control was also 
incorporated in the protocol, as an additional quality control measure. In conclusion, we report a 
rapid, multiplex suspension microarray which has the potential to be a useful test as a screening tool 
for clinical diagnosis, and improve surveillance and diagnosis of endemic and exotic alphaviruses 
and flaviviruses in Australia.   
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Chapter 1: General Introduction & 
Literature Review 
  
 2 
1.1 General introduction 
Arboviruses are a large group of viruses transmitted by arthropods, of which at least 100 are 
pathogenic for humans. Both endemic and exotic arboviruses are of great public health significance 
to Australia. Endemic arboviruses can cause clinical disease, chronic illness and even death. The 
most significant medically are considered to be the flaviviruses, Murray Valley encephalitis virus 
(MVEV) and the Kunjin strain of West Nile virus (KUNV); and the alphaviruses, Ross River virus 
(RRV) and Barmah Forest virus (BFV).  Over 75 other flaviviruses and alphaviruses are endemic in 
Australia, and although they are not commonly associated with medical disease, they are of public 
health significance as they can interfere with clinical diagnosis due to cross-reactivity. 
 
Internationally, many arboviruses are considered to be emerging or re-emerging diseases, and have 
recently shown either a rapid increase in disease incidence or geographic range, or both.  Factors 
such as urbanisation, climate changes, increased frequency of travel, and the spread of reservoirs 
and vectors have been implicated, with all areas of the world at risk of increased arboviral activity 
(Sanchez-Seco et al., 2001, Mackenzie et al., 2004).  The threat of exotic or novel arboviruses being 
introduced or established in Australia exists, particularly as species of mosquitoes known to be 
possible vectors of these viruses are already present.  However, despite the wide distribution of 
arboviruses and significant impact on human health, there are limited commercial sources for 
diagnostic assays for some of these viruses (Russell et al., 2007). 
 
Surveillance to rapidly detect the introduction of exotic arboviruses into Australia, either via 
infected vertebrate host species or mosquito vectors, will be crucial to effectively implement control 
strategies and prevent these viruses from becoming established.  Exotic arboviruses with the 
potential to cause disease outbreaks in Australia include the flaviviruses, dengue viruses (DENVs), 
Japanese encephalitis virus (JEV), West Nile virus (WNV), and yellow fever virus (YFV); and the 
alphaviruses, chikungunya virus (CHIKV), Getah virus (GETV), and Sindbis virus (SINV).   
 
At the time this project commenced, the importance of exotic disease surveillance strategies for 
Australia had been highlighted by several recent outbreaks in north Queensland (Hanna et al., 1999, 
McBride, 2005, Hanna et al., 2006).  The spread of WNV throughout the United States of America 
(USA) in 1999 also demonstrated the fact that emerging arboviruses can cause serious public health 
issues and become established, even in developed countries with extensive public health programs 
(Charrel et al., 2007). Meanwhile, dengue fever continues to have a large impact in Rio de Janairo 
and Singapore, despite economic development (Pickering et al., 2002).   It seems inevitable that the 
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prevention and control of emerging and re-emerging arboviruses will remain a key public health 
issue in the future, both internationally, and within Australia. The capacity to detect undescribed 
arboviruses is also an important issue, particularly with respect to emerging diseases (Sanchez-Seco 
et al., 2001, Ritchie et al., 2003). 
 
Another factor that could dramatically impact on the public health importance of arboviruses, is the 
introduction of the mosquito Aedes albopictus to mainland Australia. Ae albopictus is an invasive 
species that has rapidly spread to most continents of the world, largely due to the shipment of tyres 
(Tatem et al., 2006). It has currently reached the Torres Strait (between Papua New Guinea and 
mainland Australia) and is known to be an aggressive feeder and competent vector of many 
arboviruses, including CHIKV and DENV (Gubler, 2003). It has also been shown in laboratory 
experiments to be an effective vector of JEV, WNV, RRV and YFV; and vertical transmission of 
virus from the female mosquito to offspring is known to be more efficient for some arbovirus than 
for Ae aegypti  (Gratz, 2004).  Public health officials world-wide are concerned about the 
implications this may have for disease transmission.  For example, a CHIKV outbreak in Italy in 
2007 was precipitated by an infectious traveller visiting a region where the mosquito species Ae 
albopictus had become established (Rezza, 2008). This resulted in an outbreak that affected several 
hundred people and caused one fatality (Rezza et al., 2007), and highlights the dangers now faced in 
a world where global travel is common.  
 
The issues discussed above are further compounded in Australia, where arboviruses that cause 
clinically indistinguishable disease are already present.  The need for diagnostic tests to enable 
proactive surveillance and a specific diagnosis of arboviral disease is paramount, as early 
intervention and mosquito control is vital in preventing outbreaks or establishment of exotic 
viruses. This thesis describes research to develop a cost-effective, multiplex, molecular assay for the 
detection  of both endemic and exotic arboviruses of public health significance to Australia.   
 
The science discussed in the literature review within this introductory chapter was relevant at the 
start of the research project.  However, science developments since that time are described in 
individual research chapters and conclusions.  
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1.2 Arboviruses of public health significance to Australia 
The term “arthropod-borne” was introduced in 1942 to describe members of a group of animal 
viruses then recognized as causing encephalitis; and by 1963, further abbreviation to the term 
“arbovirus” was officially endorsed (WHO, 1967).  Arboviruses are viruses that are maintained in 
nature in a transmission cycle between vertebrate hosts and arthropod vectors (Figure 1.1).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The natural cycle of arboviruses  
 
Although endemic arboviruses such as BFV and RRV currently represent the highest burden of 
disease in Australia, the potential for exotic arboviruses to cause explosive outbreaks in new 
territories is well understood.  Importation of exotic diseases in travellers is increasingly being 
recognised internationally; and therefore clinicians face a challenging task in selecting appropriate 
tests given the non-specific clinical signs and overlapping geographic distribution of many of these 
viruses.  The arboviruses of potential public health significance to Australia are briefly outlined in 
Table 1.1 and include members of the alphavirus and flavivirus families.  Initially, the alphaviruses 
and flaviviruses were grouped together taxonomically.  However, when the complete genome 
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sequence for YFV was determined in 1985 it became clear that the flaviviruses were a separate 
family to the alphaviruses (Rice et al., 1985). Although the two families are morphologically similar 
in some ways, their genomic structure and replication strategies are distinct.   
 
Table 1.1 Arboviruses of potential public health significance to Australia  
Virus  Year of 
Isolation 
Origin of 
Isolate   
Geographic 
Distribution 
Principal Vector 
Species 
Human Disease 
Barmah Forest  (BFV) 1974 Australia Australia Aedes vigilax, 
Aedes 
camptorhynchus 
Fever, arthritis, rash 
Chikungunya  
(CHIKV) 
1953 Tanzania Africa, Asia, 
Indian Ocean 
countries 
Aedes aegypti, 
Aedes albopictus, 
various other 
Aedes spp 
Fever, arthralgia, 
myalgia, rash 
Dengue 1  
(DENV-1) 
1944 Hawaii 
Most tropical 
and subtropical 
regions of the 
world 
Aedes  aegypti, 
Aedes albopictus 
 
Fever, rash, 
haemorrhagic fever 
(HF) 
Dengue 2 
(DENV-2) 
1944 New Guinea 
Dengue 3 
(DENV-3) 
1957 Philippines 
Dengue 4 
(DENV-4) 
1961 Philippines 
Edge Hill 
(EHV) 
1961 Australia Australia Aedes vigilax, 
Culex. spp., 
Anopheles spp. 
Rarely myalgia, 
arthralgia 
Getah (GETV) 1955 Malaysia Eurasia, Asia, 
Pacific islands 
and Australasia 
Culex spp. Fever 
Japanese encephalitis  
(JEV) 
1935 Japan Asia Culex 
tritaeniorhynchus 
Encephalitis 
Kokobera 
(KOKV) 
1960 Australia Australia, Papua 
New Guinea, 
Asia 
Culex 
annulorostris 
Polyarticular 
disease 
Kunjin 
(KUNV) 
1960 Australia Australia, Papua 
New Guinea 
Culex spp. Fever, rash 
Murray Valley 
encephalitis (MVEV) 
1951 Australia Australia, Papua 
New Guinea 
Culex 
annulorostris 
Encephalitis 
Ross River  (RRV) 1959 Australia Australia, South 
Pacific Islands 
Culex 
annulorostris, 
Aedes vigilax, 
Aedes 
camptorhynchus 
Arthralgia, myalgia, 
rash 
Sindbis (SINV) 1952 Egypt Africa, Asia, 
Europe, 
Australia 
Culex spp., 
Culiseta spp., 
Aedes spp.,  
Fever, arthralgia, 
myalgia, rash 
Stratford (STRV) 1961 Australia Australia Aedes vigilax Asymptomatic 
West Nile 
(WNV) 
1937 Uganda Worldwide Culex spp. Fever, rash, 
encephalitis 
Yellow fever 
(YFV) 
1927 Ghana Africa, South 
America 
Aedes  aegypti, 
Aedes spp. 
Haemogogus spp 
Fever, haemorrhage, 
jaundice 
Zika (ZIKV) 1947 Uganda Africa, Asia Aedes aegytpi Fever, rash 
 
Information collated from the following references (White & Fenner, 1970, Knipe & Howley, 2007, Maguire et al., 
1967, ICTVdB, 2006, Hall et al., 1991, Boughton et al., 1986, Marchette et al., 1969) 
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1.3  Alphaviruses 
The genus Alphavirus, in the family Togaviridae, is composed of enveloped, single-stranded, 
positive-sense RNA viruses. The alphavirus genome is approximately 11.7kb and features a 
5’methylated cap and 3’poly(A) sequences. These viruses have a nearly world-wide distribution and 
are principally mosquito-borne.   There are at least 29 species, containing both New World & Old 
World members (Eshoo et al., 2007). They can be classified into eight antigenic complexes and 
share a minimum amino acid sequence identity of approximately 40% in the structural proteins and 
60% in the non-structural proteins (Fauquet et al., 2005).  The structural proteins are encoded by the 
3’ part of the genome and the non-stuctural proteins by the 5’ part (refer Figure 1.2).   
 
 
 
 
 
 
 
Figure 1.2: Genomic structure of the alphaviruses 
Studies of alphavirus genomics have focused on partial genome sequences (Levinson et al., 1990, 
Weaver et al., 1993) ; or more recently complete genome studies (Powers et al., 2001, Luers et al., 
2005).  These sequencing studies have agreed remarkably well with previous antigenic 
classifications.   
 
The alphaviruses have been shown to have a much lower mutation rate than typical RNA viruses, 
and exhibit long periods of evolutionary stasis  (Holland & Domingo, 1998). However, the 
development of universal primers to enable the rapid identification of known and unknown 
alphaviruses has not been a key study area.  The only two published studies at the time the project 
commenced targeted different regions of genome, namely NS1 and NS4 respectively (Pfeffer et al., 
1997, Sanchez-Seco et al., 2001).   The primers published by Pfeffer et al. (1997) have been the 
most widely adopted and have been utilised in numerous studies including a duplex RT-PCR 
reaction for the detection of Brazilian alphaviruses and flaviviruses (de Morais Bronzoni et al., 
2005), a macroarray for the simultaneous detection of alphaviruses and orthopox viruses 
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(Fitzgibbon & Sagripanti, 2006) and an RT-PCR-enzyme linked immuno-assay for the detection of 
alphaviruses in clinical samples and mosquito pools (Wang et al., 2006).  Broad-range alphavirus 
primers that target the NS1 region of genome have also proven to be successful in the detection of a 
variety of alphaviruses in mosquito extracts (Eshoo et al., 2007).  Therefore, genus-specific 
alphavirus primers targeting the NS1 conserved region have proven very useful in a clinical and 
surveillance capacity.   
 
In humans, alphaviruses cause diseases ranging from non-specific, flu-like symptoms to arthritic 
and/or rash syndromes to severe encephalitis that can be fatal (Wang et al., 2006).  Many of the 
alphaviruses, such as RRV, CHIKV and BFV, are also considered to be emerging diseases with the 
potential to cause epidemics or spread geographically (Gubler, 2002). In 2006, multiple outbreaks 
of CHIKV resulted in an estimated 2 million cases worldwide (Charrel et al., 2007).  This coincided 
with the second reported case of CHIKV importation into Australia; a traveller from Mauritius 
(Druce et al., 2007).  The case was rapidly diagnosed and no local transmission occurred. However, 
it raised serious concerns as the ability of local mosquito species to spread the disease was 
unknown.  It also highlighted the increased likelihood of exotic disease importation during events 
such as the Commonwealth Games or when large outbreaks are occurring internationally. These 
issues, along with the similarity of clinical presentation of both endemic and exotic alphaviruses, 
present challenges to disease control and prevention.  
 
At the time this project commenced, the two mosquito-borne diseases with the highest 
representation in Australia during the 2005-2006 reporting period were Ross River and Barmah 
Forest disease, with 5,515 and 1,895 notifications respectively (Liu et al., 2006).   
1.4 Flaviviruses 
The genus Flavivirus, in the family Flaviviridae, is composed of enveloped, single stranded, 
positive-sense RNA viruses. The genome is approximately 10.5kb and features a 5’ methylated cap, 
but in most cases the RNA is not polyadenylated at the 3’ end (Cann, 2005).   Mosquito-borne 
members of this family provide some of the most important examples of emerging diseases today 
(Gubler, 2002, Mackenzie et al., 2004).  The genus contains over 70 viruses, of which 
approximately 40 are mosquito-borne (Mackenzie et al., 2004).  The flaviviruses share a complex 
antigenic relationship with common group epitopes on the envelope protein (Dyer et al., 2007). 
They are divided into 12 serocomplexes (Grard et al., 2007). Unlike the alphavirus genome, the 
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structural proteins are encoded by the 5’ part of the genome and the nonstuctural proteins (NS) in 
the 3’ part (Figure 1.3).  
 
 
 
 
 
 
Figure 1.3:  Genomic structure of the flaviviruses 
 
Studies of flavivirus genomics have focused on either the complete virus genome, or partial 
sequences of either the E gene or NS5-3’UTR region.  The complete genome structure of YFV was 
published in 1985 (Rice et al., 1985), and was followed by WNV (Castle et al., 1986), DENV4 
(Zhao et al., 1986), KUNV (Coia et al., 1988), JEV (Sumiyoshi et al., 1987), DENV2 (Hahn et al., 
1988) and DENV3 (Osatomi & Sumiyoshi, 1990). Partial sequence studies that focused on the E 
gene were also published over the same period, and confirmed the previous classification of 
flaviviruses based on antigenic relationships. In 1998, the most comprehensive study yet of the 
flavivirus phylogeny was undertaken, utilising published and unpublished sequences from the NS5-
3’UTR region of over 70 flaviviruses, and established the highly conserved nature of the region  
(Kuno et al., 1998).  
 
The development of universal primers to enable the rapid identification of known and unknown 
flaviviruses has been the focus of many studies aimed at improving diagnosis of flaviviruses for 
clinical or surveillance purposes.  The first universal primer pair for the detection of mosquito-
borne flaviviruses was published in 1993 and targeted the NS5-3’UTR region (Tanaka, 1993).  The 
majority of universal primer pairs which have since been published have also targeted the NS5 or 
NS5-3’UTR region, based on its highly conserved nature (Fulop et al., 1993, Chang et al., 1994, 
Pierre et al., 1994, Kuno et al., 1998, Scaramozzino et al., 2001, Moureau et al., 2007, Maher-
Sturgess et al., 2008). These studies have demonstrated the usefulness of universal primer pairs for 
the detection of flaviviruses in diagnostic samples and identification of emerging or uncharacterised 
species of flavivirus.   
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Many flaviviruses are considered serious emerging or re-emerging disease threats.  Of all the 
arboviruses, the dengue viruses have the largest geographical range and cause the greatest morbidity 
and mortality, with an estimated 50-100 million people infected each year (Gubler, 2002). There are 
an estimated 2.5-3 billion people at risk of DENV infection, and no vaccine is currently available 
(Gubler, 2002, Russell et al., 2007).  The past 15 years have also seen the emergence of WNV in 
North America and the re-emergence of YFV epidemics, while JEV remains the leading cause of 
viral encephalitis in the world, with an estimated 10,000 deaths annually (Mackenzie et al., 2004).  
Globally, billions of people are considered to be at risk from disease caused by flaviviruses. 
 
Although Australia is geographically remote, outbreaks of exotic flaviviruses have occurred; in 
particular DENV and JEV in northern Queensland.  A large outbreak of DENV-2 in 2003 and 2004 
proved difficult to control and there were concerns it could become endemic in the region (Hanna et 
al., 2006). This outbreak was associated with the first fatalities related to dengue fever acquired in 
Australia in over a century (McBride, 2005).   An outbreak of DENV-4 was also reported in the 
Torres Strait in 2005 (McBride, 2005). Since 1995, activity of JEV has also consistently been 
reported in the Torres Strait region (Ritchie et al., 2006).  JEV activity has been detected on the 
Australian mainland with two distinct genotypes isolated in 1995 and 2004 (Hanna et al., 1999, 
Mackenzie, 2005, Van Den Hurk et al., 2006). There does not yet appear to be enzootic activity of 
either virus on the mainland; however, the appearance of different strains of both JEV and DENV 
into the region is suggestive of new incursions occurring.  The potential for these viruses to become 
established therefore exists, as appropriate vectors and hosts are present in the region. 
 
At the time this project commenced, the Communicable Diseases Network of Australia had reported 
numerous flavivirus notifications for the 2005-2006 reporting period. These included 200 dengue 
cases, two KUNV infections, one case of Murray Valley encephalitis and 43 flavivirus infections 
that were either acquired overseas or the country of acquisition was unknown (Liu et al., 2006).  
 
1.5 Diagnosis 
Diagnosis of clinical disease caused by alphaviruses and flaviviruses is difficult as they cause non-
specific, prodromal illness and frequently other viruses that commonly cause similar clinical signs 
are present in the region, especially in the tropics (Wang et al., 2006). However, the accurate 
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detection of endemic and exotic arboviruses is important for the clinical management of patients, 
prevention and control of disease outbreaks and for exotic disease surveillance. 
 
Numerous diagnostic tests are available for the detection of alphaviruses and flaviviruses.  These 
methods are based on the detection of virus, viral antibody or viral nucleic acids; in samples such as 
serum, cerebrospinal fluid or mosquito pools. 
1.5.1 Virus isolation 
The gold standard for the clinical diagnosis of viral infections is still considered to be virus isolation 
(White & Fenner, 1970). However, identification of flaviviruses by culture usually takes more than 
two weeks and viral infectivity is only preserved if the samples are maintained in a cold chain, 
whereby samples must remain below -50°C (Pierre et al., 1994). Specialised biological containment 
facilities, equipment and procedures may also be required (Wang et al., 2006). Therefore, virus 
isolation is frequently used for confirmation, rather than surveillance or preliminary clinical 
diagnosis, due to the fact that results are sometimes not available for weeks and it is technically 
demanding. It has also been hypothesized that for some arboviruses, such as RRV, the failure to 
obtain positive virus isolation results from seropositive patients may be due to neutralization of 
virus by antibodies, rather than the short period of viraemia (Sellner et al., 1995). Therefore, RT-
PCR may be preferable to culture methods for the detection of some arboviruses in serum and 
synovial biopsies; and has already been used successfully for this purpose (Soden et al., 2000).  
1.5.2 Serology 
Serological assays are diagnostic tests which can identify antibody responses to known antigens, or 
vice versa.  They have the capacity to detect immune responses to infectious agents and are 
important for the diagnosis of convalescent or recovered patients. Serology has been considered the 
most important tool for diagnosis of the endemic arboviruses, as it is less technically demanding 
than virus isolation and viraemia is often short lived (Flexman et al., 1998, Harley et al., 2001). 
Once viraemia has passed, serology is the only option to determine whether exposure to a virus has 
occurred. A disadvantage of serological assays is that they may not diagnose acute cases, as the 
development of specific antibodies can be slow in some infections (Nordstrom et al., 2005). 
Additionally, confirmation of diagnosis by serology requires the demonstration of a four-fold or 
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greater rise in titre in paired sera collected 10-14 days apart, and thus does not provide a rapid 
diagnosis. 
 
Serological cross-reactivity against related viruses is known to occur, decreasing the specificity of 
the diagnostic test (Nordstrom et al., 2005).  Cross-reactivity of IgM antibodies between members 
of the same genus, such as alphavirus and flavivirus, is well established, and can result in either 
non-specific or false positive results (Calisher et al., 1986, Taylor et al., 2005, Niedrig et al., 2007). 
False positive ELISA results for RRV have also be caused by rubella or Q fever (Harley et al., 
2001). Meanwhile, diagnosis based on virus-specific IgM antibodies alone may result in false 
positives, as IgM can persist for months or years after infection with some alphaviruses and 
flaviviruses (Russell & Dwyer, 2000, Roehrig et al., 2003).  Therefore, diagnosis based on serology 
alone requires careful interpretation when other closely related viruses causing similar clinical 
presentations and producing cross-reactive serological responses are in circulation, as they 
frequently are in Australia (Griffin, 2001). 
 
Examples of serological assays include microsphere immunoassays (MIA), enzyme-linked 
immunosorbent assays (ELISA), Western blot and complement fixation assays.  Reference tests 
include haemagglutination-inhibition and plaque reduction neutralisation test, but both are 
extremely labour intensive and have largely been replaced by ELISA.  
 
1.5.3 Molecular diagnostics 
The term molecular diagnostics has a relatively narrow clinical definition, namely, “the use of 
nucleic acids as analytes in assays designed to investigate given disease states” (Cartwright, 1998).  
In many cases, molecular diagnostics are considered to be the preferred option for viral diagnosis 
(Nordstrom et al., 2005).  Compared to culture or antigen based diagnostic assays, molecular assays 
have the potential for the highest sensitivity (Brunstein & Thomas, 2006). They are also capable of 
detecting acute infections and the results can be available within hours.   Methods which can detect 
arboviruses during the acute phase of the infection are critical, so that disease prevention and 
mosquito control measures can be rapidly implemented (Wang et al., 2006).  Finally, molecular 
assays have the capacity to detect viral RNA in samples without the need for a cold chain, making 
them particularly useful for vector surveillance (Johansen et al., 2002). Therefore, for clinical and 
surveillance purposes, molecular diagnostics such as polymerase chain reaction (PCR), reverse 
transcription (RT)-PCR, real-time PCR, sequencing and microarrays offer many advantages. 
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The importance of molecular diagnostic tools was highlighted during the Commonwealth Games in 
2006, when RT-PCR and sequencing alone enabled the diagnosis and isolation of CHIKV in a 
traveller, without the availability of serology or virus isolation results (Druce et al., 2007). The 
ability to rapidly screen potentially infectious visitors or returning travellers to Australia for exotic 
viruses will rely on the availability of appropriate molecular diagnostic tests. 
 
Genus-specific and multiplex molecular methods have been described for the detection of both 
alphaviruses and flaviviruses. RT-PCR assays and real-time RT-PCR, in particular, have proven to 
be rapid, sensitive and specific (Pfeffer et al., 1997, Scaramozzino et al., 2001, Sanchez-Seco et al., 
2001, Pyke et al., 2004, Dyer et al., 2007).     However, RT-PCR assays are limited in that they 
cannot easily be multiplexed to detect and type many viral pathogens simultaneously (Deregt et al., 
2006b). For fluorescent reporting real-time RT-PCR assays, the limit for most instruments is five 
targets, while gel-resolved endpoint analysed molecular assays rarely effectively include more than 
8 or 10 targets (Brunstein & Thomas, 2006).    
 
The importance of a universal diagnostic RT-PCR protocol for detection of multiple families of 
arboviruses in endemic areas has long been recognised.  In 1998, a study evaluated the potential to 
optimise RT-PCR conditions to enable a standard protocol for detection and identification of all 
arboviruses.  This study investigated the use of universal primers for flaviviruses and alphaviruses 
as an initial screening tool, followed by more specific tests to make a definitive diagnosis.  It was 
found that this protocol provided many advantages with respect to rapidity of results and cost-
benefits (Kuno, 1998).   
 
There is currently no multiplex molecular test available for the detection of all alphaviruses and 
flaviviruses of public health significance to Australia. However, the latest developments in 
microarray technology, suggest there is the potential to develop one; and this was the focus of my 
PhD project. 
 
1.5.3.1 Molecular assays for clinical diagnosis 
An understanding of the dynamics of arbovirus infection is important for designing protocols for 
clinical diagnosis.  The typical course of mosquito-borne arbovirus infection in man, following 
transmission of the virus via a mosquito, is an initial phase of increasing viraemia for approximately 
the first week.  An immune response then begins to mount, with viral loads decreasing as IgM and 
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IgA antibody develop, following shortly by IgG antibody.  A schematic representation of this 
complex interaction is demonstrated below for CHIKV (Figure 1.4).  However, often data on the 
complex relationship between clinical signs, duration of viraemia and the immune response are not 
well defined, particularly for those arboviruses endemic to Australia.   
 
 
 
Figure 1.4 Schematic representation of immune response against CHIKV infection.  CHIKV 
viraemia lasts between 2 and 10 days.  Rapid virus elimination occurs before the expansion of 
neutralising antibodies (IgG).  Clinical symptoms (fever) disappear when CHIKV viremia drops 
below the level of detection.  Adapted from (Kam et al., 2009) 
 
RT-PCR has increasingly been shown to be of great value in the clinical diagnosis of acute 
arbovirus infection.  Studies have found the combined use of RT-PCR and serology can 
dramatically improve the probability of detecting disease (Poersch et al., 2005, Tilley et al., 2006). 
For example, the combined use of RT-PCR and serology for the detection of WNV in symptomatic 
cases during the USA outbreak improved the detection rate for samples from 58% for serology 
alone to 94% for serology and RT-PCR combined (Tilley et al., 2006).   The study found the mean 
plasma viral load was 7.5 x 10
3
 copies/mL, with 56% of patients tested during the first 8 days of 
illness testing positive on RT-PCR. RT-PCR has also proven to be very successful for the detection 
of CHIKV during outbreak situations as prolonged viraemia of up to 12 days can be seen, with high 
viral loads of up to more than 10
8
 copies/ml (Laurent et al., 2007).   RT-PCR has also been 
successfully used to detect other arboviruses, such as DENV and SINV, in blood samples from 
symptomatic patients (Brown et al., 1996, Kurkela et al., 2005).  Therefore,  molecular assays are 
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an important component of arbovirus diagnosis in the clinical setting, although their role is 
restricted to the detection of acute cases, and alternative tests are necessary for those patients 
presenting after the viraemic phase. 
 
Although beyond the scope of this study, it is also anticipated that the RT-PCR tests developed 
during the course of this project should be useful in veterinary diagnostic laboratories for the 
detection of arboviral disease in animals.  Man is a dead-end host for the majority of the arboviruses 
we aim to target (refer Figure 1.1).  In contrast, the viral load reached in samples from amplifying 
hosts, is generally higher than from samples collected from humans.  Therefore, if the arbovirus 
microarrays developed from this project prove to be sensitive enough for the detection of 
symptomatic human cases, it is to be expected they would also detect viral RNA in samples 
collected from amplifying hosts.   
 
1.5.3.2 Molecular assays for vector surveillance 
The gold standard for surveillance is virus detection in field-caught mosquitoes (Johansen et al., 
2002). Mosquito-based surveillance systems generally consist of collecting mosquitoes in 
specialised traps, pooling the mosquitoes by species and using virus isolation or molecular methods 
to detect any arboviruses.  Mosquito-based surveillance systems are often used in conjunction with 
sentinel animals, which are also deployed as an early warning system.  Sentinel animals are 
routinely tested for evidence of seroconversion to selected arboviruses, and provide an indication of 
arbovirus activity; albeit with a lag of several weeks while the immune response develops. 
 
At the time this project commenced, mosquito-based surveillance systems to monitor JEV activity 
in north Queensland, had proven to be a suitable alternative to the use of sentinel pigs (Ritchie et 
al., 2003).  Mosquito-based surveillance offers several advantages to sentinel-animal surveillance. 
The system operates at a reduced cost in the field, is appropriate for remote areas, the mosquito 
pools can be used to monitor for other arboviruses and there is reduced risk of injury to personnel 
(Ritchie et al., 2003). Additional disadvantages of sentinel-animal surveillance include the use of 
live animals and the costs associated with their establishment and maintenance. The fact that they 
may act as amplifying hosts and pose a public health risk if placed near communities, is also a 
major disadvantage. 
 
Mosquito-based surveillance has proven to be effective when combined with molecular diagnostic 
techniques (Johansen et al., 2002, Ritchie et al., 2003, Ritchie et al., 2007).  RT-PCR has been used 
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to detect both flaviviruses (Pyke et al., 2004, Lanciotti et al., 2000) and alphaviruses in mosquito 
pools (Eshoo et al., 2007, Wang et al., 2006).  These studies demonstrate that molecular assays have 
the appropriate sensitivity to detect the viral titres produced in infected mosquitoes, even in pooled 
samples.   
 
To date, although molecular diagnostic tests have increasingly been utilised with success for vector-
based surveillance, the usefulness of microarray technology for this purpose has not been 
extensively investigated.  We believe there is a high likelihood of successfully utilising microarray 
technology for this purpose, with the additional advantage that pools of mosquitoes could be 
screened for a larger range of viruses in the one diagnostic test. 
1.6 Microarrays 
A microarray refers to a collection of probes arrayed on a solid surface, such as a microchip or 
carboxylated bead.  These probes may either be cDNA, oligonucleotides or fragments of PCR 
products and can be used for the identification of complementary nucleotide sequences (Clewley, 
2004, Feilotter, 2004).  Microarrays are commonly used to study gene expression, but have also 
been successfully developed for the detection or identification of pathogens (Ghindilis et al., 2007).  
 
There are numerous commercial microarrays available. Flow cytometry systems and protein chip 
arrays, such as Luminex and Combimatrix respectively, have proven to be sensitive, specific and 
rapid for the detection of viral infections in multiplexed arrays (Deregt et al., 2006, Brunstein & 
Thomas, 2006, Schmitt et al., 2006, Oh et al., 2007, Lee et al., 2007) (Lodes et al., 2006, Lodes et 
al., 2007).  Additionally, they have the capacity to include very large numbers of targets or analytes.  
Luminex technology has the capacity to be multiplexed for up to 100 analytes, whilst Combimatrix 
CustomArrays can be designed for thousands of analytes. 
 
Regardless of the pathogen, microarrays use the same general principles for pathogen detection. For 
RNA viruses, such as alphaviruses and flaviviruses, RNA is extracted from the sample and RT-PCR 
is used for amplification. The amplicon is then labelled, for example with biotin. Species-specific 
oligonucleotide probes will hybridize with complementary, labelled PCR amplicons and positive 
samples can be detected using a fluorescent reporter.  
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Universal primer pairs, selected for their ability to amplify genetic sequences that are highly 
conserved within a viral family, can be used in association with microarrays (Deregt et al., 2006, 
Lodes et al., 2006).  The use of universal primers removes the need to perform multiple PCRs using 
separate primer pairs for each target virus. This significantly decreases sample processing, turn-
around time and reagent costs, especially if the PCR is multiplexed with the ability to amplify more 
than one viral family. The specificity of the assay can be maintained by the use of virus-specific 
probes.  Flavivirus-universal primer pairs and alphavirus-universal primer pairs have previously 
been described and could be utilised for this purpose (Scaramozzino et al., 2001, Pierre et al., 1994, 
Kuno et al., 1998, Pfeffer et al., 1997,  Sanchez-Seco et al., 2001).   
 
Although microarrays have been reported to be sensitive and specific diagnostic tests, they still 
present diagnostic challenges.  Carefully designed oligonucleotide probes do not always pass 
validation, and can produce either an unacceptably low positive signal or high background signal 
(Das et al., 2006, Diaz & Fell, 2004).  Although the reasons for this are still not completely 
understood, contributing factors may include the efficiency of PCR and hybridization.  The use of 
universal primers for viral amplification has many practical advantages, but can potentially decrease 
amplification efficiency.  The sensitivity of universal primer pairs may be lower than for virus-
specific primers (Dyer et al., 2007) and variation in the sensitivity of different universal primer 
pairs also exists (Scaramozzino et al., 2001).  However, the alternative option, which is to multiplex 
virus-specific primers can result in unexpected interactions and reduced sensitivity (Boonham et al., 
2007).  All the above factors need to be investigated if the sensitivity of a microarray is to be 
optimised.   
 
1.6.1 Suspension microarrays 
At the time this project commenced, the original application of the Luminex system, detection of 
viral nucleic acids, had only recently been applied diagnostically (Deregt et al., 2006b). The 
Luminex system, like most flow cytometry systems, employs microspheres, lasers, fluidics and 
optics.  However, its point of difference is the patented polystyrene beads, of which there are 100 
uniquely identifiable bead sets. Each polystyrene bead set is filled with red and infrared dyes of 
varying intensity, creating a unique spectral signature.  As each bead set has a unique signature, the 
different bead sets can be multiplexed in one assay and the Luminex analyser can distinguish which 
set it belongs to.   This enables the suspension microarray to be multiplexed for up to 100 different 
analytes. In the suspension microarrays developed during this project, bead sets were coupled to 
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virus-specific probes to target complementary biotinylated PCR products that may be present in the 
sample. As the sample passes through the Luminex analyzer, a light source excites the internal dyes 
in each microsphere, allowing identification of the beadset, and of any labelled reporter dye that has 
bound to the biotinylated PCR product (Figure 1.5).  Many readings are made on each bead set, 
which further validates the results, and the powerful software supplied with the system, allows rapid 
analysis.   
   
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Key components of a suspension microarray 
Suspension microarrays are reported to have many advantages over conventional microarray 
technologies.  Significant probe design expertise is not required and the Luminex system is 
generally considered to be user-friendly and cost-effective, with one study estimating the cost of a 
10-plex suspension microarray as $4.00 compared to a chip microarray at $400 (Wilson et al., 
2005). Suspension microarrays also allow rapid sample processing, with results available in less 
than an hour post-PCR amplification (Das et al., 2006); and some laboratories are able to provide 
same day results (Mahony et al., 2007). Additionally, the three-dimensional nature of the 
suspension micorarray offers advantages over two-dimensional microarrays, such as chips, as 
higher concentrations of probes are available, exposure of components to reagents is consistent and 
hybridization times are shorter (Spiro et al., 2000, Das et al., 2006).  This enables easier quality 
control analysis, modification of assay formats and statistical superiority over conventional chip 
microarrays (Dunbar, 2006, Diaz et al., 2006). 
 
Multiplexed suspension microarrays for closely related pathogens have been developed and 
validated, without associated loss of sensitivity or specificity (Das et al., 2006, Diaz & Fell, 2004, 
Deregt et al., 2006b).  Importantly, their proven ability to detect multiple infections in a single 
 
 18 
sample has suggested an important role for surveillance work (Page et al., 2006, Lin et al., 2008, 
Wallace et al., 2005, Bandyopadhyay et al., 2007). Finally, the cost of the suspension microarrays is 
extremely low compared to many other molecular assays, with one study estimating the total cost as 
low as $0.16 per test, excluding laboratory personnel (Bandyopadhyay et al., 2007). 
 
A disadvantage of suspension microarrays is that they typically contain only one virus-specific 
probe per virus; unlike a chip microarray which usually includes multiple.  This is because the 
ability to identify probes is restricted by the number of commercially available microsphere sets.  
This restricts the number of probes to less than 100, compared to a chip microarray which can 
include thousands.  However, to date the suspension microarrays developed for virus diagnosis have 
targeted far fewer than 100 analytes, and so the flexibility to include multiple probes for the one 
target has existed.  Additionally, suspension microrarrays offer significantly improved multiplexing 
capabilities compared to other molecular diagnostic tests such as SybrGreen and TaqMan assays. 
1.6.2  Chip microarrays 
Commercial chip microarrays, have been available for over a decade and may contain tens of 
thousands of probes spotted onto a single chip (Feilotter, 2004).   Although there are many types of 
microarray chips available, the technology adopted at QHFSS is the Combimatrix chip, which 
utilises unique, CustomArray technology (Figure 1.6).  Unlike a spotted array, oligonucleotides are 
synthesized directly onto the chip. The oligonucleotides are of the highest quality, as 
electrochemical detritylation is used to control DNA synthesis. This is claimed to maximize the 
sensitivity of the microarray. Combimatrix DNA microarray technology has recently been 
developed to detect and type viral pathogens (Liu et al., 2006, Lodes et al., 2006).  As with 
suspension microarrays, genus-specific universal PCR primers can be multiplexed in a one-tube 
RT-PCR reaction to produce biotin-labeled, single-strand target for hybridization to the probe array. 
 
 
 
 
 
 
 
 
 
 19 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Key components of the CustomArray chip 
 
The Combimatrix system allows the analysis of over two thousands probes in parallel. As well as 
utilising high-quality probes, the CustomArray also has inbuilt factory quality controls.  Due to the 
very large number of probes available with Combimatrix technology, the system offers the ability to 
include numerous virus-specific probes.  Multiple probes per pathogen (approximately 30 to 100) 
can be used to overcome potential variability in pathogen genomes and also to provide sequence 
information at disparate loci (Lodes et al., 2007).  This is important as minor genetic differences 
among strains can have epidemiological implications.  Rapid differentiation of not only arbovirus 
species, but subtypes and genotypes is useful for surveillance and disease control.    
 
A disadvantage of the Combimatrix system is that hybridization of the amplicon to the probes 
requires between four and fifteen hours.  In contrast, the hybrization step in a suspension micorarray 
takes only 20 minutes.  Therefore, sample processing takes longer using the Combimatrix system. 
The difference in cost is also significant, with a Combimatrix chip array costing $2000 and only 
reusable 4 times.   
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1.6.3 Alphavirus and flavivirus microarrays 
Due to the highly similar presentation of clinical signs associated with arbovirus infections and the 
frequent presence of more than one arbovirus in a region, microarrays capable of detecting both 
alphaviruses and flaviviruses would be useful for both medical and surveillance purposes. As both 
alphaviruses and flaviviruses are known to co-circulate in outbreak situations (Johansen et al., 
2001), a multiplexed microarray for the detection of both genera would be particularly useful, and 
would reduce labour and laboratory costs. Amplification of both alphaviruses and flaviviruses using 
genus-specific primers has been achieved in a duplex RT-PCR, eliminating the need for separate 
PCR reactions (de Morais Bronzoni et al., 2005). Similarly, microarrays have been developed 
which are capable of detecting viruses belonging to different genera (Chou et al., 2006, Lodes et al., 
2007, Korimbocus et al., 2005), indicating that there is also the potential to develop a microarray for 
both the alphaviruses and flaviviruses.   
 
At the time this project commenced, several chip microarrays had been successfully developed to 
detect and identify flaviviruses.  A chip microarray capable of identifying seven different 
flaviviruses had been developed and was reported to have equivalent sensitivity to conventional 
RT-PCR (Nordstrom et al., 2005).  A combined chip micorarray to detect five flaviviruses, in 
combination with a number of different herpesviruses and enterovirus had also been developed 
(Korimbocus et al., 2005).  Neither of these assays was capable of detecting many of the 
flaviviruses of public health significance to Australia, but they did provide an indication that such 
an array may be achievable.  There were no published reports of microarrays for the detection and 
typing of alphaviruses, but conserved primer sites capable of amplifying all known members of this 
virus family were available (Wang et al., 2006, Sanchez-Seco et al., 2001, Pfeffer et al., 1997).  
This suggested that a microarray approach for the detection and species identification of 
alphaviruses might also be achievable.   
 
1.7 Aims of the present study 
Microarray technology has widely been touted as the future of molecular diagnostics over the past 
decade.  To date, it has largely failed to live up to expectations due to the high costs associated with 
the chip microarrays (Clewley, 2004, Garaizar et al., 2006). However, microarrays do offer the 
potential to screen for multiple pathogens simultaneously; a feature which is highly desirable for 
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surveillance.  Recently, suspension microarrays using flow cytometry technology (Luminex) have 
proven effective in the diagnostic setting and have the advantages of low cost, labour and skill 
requirements for conducting the assays and the capability to be multiplexed for up to 100 different 
targets. Multiplex tests offer the capacity to test a sample for several different pathogens 
simultaneously, decreasing costs associated with labour and reagents.  Therefore, this technology 
offers real promise for the development of an assay for clinical diagnostics and surveillance. 
 
The importance of developing improved surveillance capabilities for emerging arboviral disease is 
critical (Mackenzie et al., 2004). Development of PCR based assays for the detection of arboviruses 
in pools of mosquitoes has also been identified as a key priority for more timely and cost effective 
surveillance (Spencer et al., 2001).  Such tests would allow better surveillance, and as specific 
treatments for diseases become available, early and accurate diagnosis of disease will allow better 
treatment outcomes.  The investment is well justified if it helps to prevent the establishment of an 
exotic virus, limits the extent of outbreaks or provides better treatment of patients. 
 
The overarching objective of this study was to investigate the potential to use suspension 
microarray technology to develop a multiplexed, cost-effective method to screen for multiple 
alphaviruses and flaviviruses for clinical and surveillance purposes.  The aims for this thesis were as 
follows: 
 
 To determine whether previously validated molecular assays could be adapted to suspension 
microarray format.  This included the use of already published consensus primers and 
TaqMan probes 
 To determine whether a cost-effective multiplexed suspension microarray for the detection 
of flaviviruses of public health importance to Australia could be developed  
 To determine whether a cost-effective multiplexed suspension microarray for the detection 
of alphaviruses of public health importance to Australia could be developed  
 To determine whether the suspension microarray technology may be compatible for use in 
mosquito-based surveillance programs 
 To determine whether amplification strategies used for chip microarrays, that preferentially 
generate single stranded PCR product, are also suitable for suspension microarrays. This 
would enable the two technologies to be developed in tandem, with samples positive on the 
initial screening suspension microarray then suitable to be used directly on the chip 
microarray for further epidemiological analysis 
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Using suspension microarray technology, we estimate the cost of performing a multiplex screening 
test for four alphaviruses as $6.90 or fourteen flaviviruses as $8.50 per sample.  This represents a 
large cost saving to the current TaqMan assays run in the QHFSS diagnostic laboratory which cost 
$16 to test a research sample for a single virus or $32 for a clinical sample (if a report and licensing 
fee are applicable).  This cost saving does not take into account the labour costs saved from needing 
to run multiple assays.  Additionally, to save both costs and labour expenses, diagnostic work-up 
usually stops with the detection of a relevant virus and therefore co-infections may be missed.  
There is also a strong reliance on the diagnostician selecting the most appropriate test based on 
appropriate travel histories. Therefore, the development of multiplex suspension microarrays would 
not only dramatically reduce costs, but may improve our surveillance capabilities. 
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Chapter 2: Development of a Suspension 
Microarray for the Detection of 
Alphaviruses of Public Health 
Importance to Australia  
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2.1 Introduction 
The alphaviruses, Ross River virus (RRV) and Barmah Forest virus (BFV) are of significant public 
health concern in Australia.  Although the life threatening encephalitic Flaviviruses Murray Valley 
encephalitis (MVEV) and Kunjin virus (KUNV) are of major public concern; arguably it is the 
arthitic viruses RRV and BFV which are most important from a public health perspective (Russell, 
1998).  RRV and BFV cause clinically indistinguishable disease sometimes called epidemic 
polyarthritis (EPA) (Russell & Dwyer, 2000).  The disease is painful, debilitating and can cause 
ongoing symptoms for months (Toivanen, 2008, Flexman et al., 1998).  According to the 
Commonwealth Health Department National Notifiable Diseases Surveillance System, there were 
54, 608 cases of RRV, and 18, 919 cases of BFV reported between 2000 and 2012 (Commonwealth 
Department of Health and Ageing, 2013).  However, these are widely accepted to be underestimates 
due to under presentation and underuse of diagnostic testing in endemic areas (Russell, 1998, 
Russell & Dwyer, 2000, Kelly-Hope et al., 2002).  In particular, BFV notification is likely to be 
underestimated, with only 36-58% of epidemic polyarthritis cases tested for BFV antibodies (Quinn 
et al., 2005).  However, in the past decades RRV outbreaks have increased notably in urban estates 
and tourist destinations and RRV is increasingly being identified in travellers returning from 
Australia (Tong et al., 2008, Tappe et al., 2009, Hossain et al., 2009). Man-mosquito-man RRV 
transmission cycles have been noted overseas and are suspected in Australian outbreaks in capital 
cities (Burness et al., 1988, Hossain et al., 2009).   These viruses have a serious social and economic 
impact, especially as they frequently affect people in their peak years of productivity. 
 
The importance of CHIKV as a public health problem both nationally and internationally has 
increased dramatically since the global re-emergence of CHIKV in 2004.  An explosive epidemic of 
CHIKV occurred in the Reunion Islands in 2005 and affected almost 35% of the population 
(Toivanen, 2008).  The virus has since caused epidemics throughout Africa, the Indian Ocean, India 
and Malaysia and affected millions of people (Gould et al., 2010). These epidemics have been 
associated with fatalities, a feature not previously associated with CHIKV disease.  The number of 
deaths attributable to CHIKV is unknown, but case fatality ratios have been estimated as high as 
1:1000 (Josseran et al., 2006, Manimunda et al., 2011).  Human-to-human CHIKV transmission 
cycles are common in Asia (Schuffenecker et al., 2006), and involve the vector, Aedes agypti, 
which is present in Australia.  Although CHIKV is still exotic, the increasing number of imported 
cases diagnosed in travellers visiting or returning to Australia is of great concern. In contrast to the 
single notified case of CHIKV in Australia for the period 1991-2006, there have been 225 reported 
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cases between 2006 and July 2013 (Commonwealth Department of Health and Ageing, 2013).  
However, to date there have been no reported cases of local transmission. 
 
Conversely, SINV is endemic and widely distributed in Australia, and is the most commonly 
isolated arbovirus from mosquitoes (Mackenzie et al., 1994). It is rarely associated with clinical 
disease (Johansen et al., 2005), although seroepidemiological studies have suggested frequent 
subclinical infections do occur (Sammels et al., 1999). Overseas, SINV has been linked with 
chronic, debilitating polyarthritis, which may persist for years (Toivanen, 2008). Research on SINV 
in Australia is mainly limited to field isolations from mosquitoes and routine testing of EPA cases 
does not include SINV.  Therefore, it is possible that there is underreporting of SINV in Australia, 
with the causative agent of many cases of EPA undetermined and an underuse of diagnostic tests in 
endemic regions. Our understanding of the potential for more pathogenic strains of the virus to 
emerge or be introduced to Australia is also limited. However, in Finland where large outbreaks of 
SINV related disease occur regularly, the range of SINV has been found to have spread, and it is 
considered that many factors could contribute to a spread internationally (Laine et al., 2004). This is 
supported by evidence of migratory birds introducing SINV to the resident UK bird population 
(Buckley et al., 2003). Thus, the public health importance of alphaviruses on a global level is of 
ever increasing concern. 
 
One potentially pathogenic alphavirus on which there is little current information is Getah virus.  
This virus is known to be pathogenic to both humans and livestock (Hu et al., 2012).  A sero-
epidemiological survey of the Indo-Australia archipelago in the 1970s found little evidence of this 
virus, except in Queensland, where 5% of samples were seropositive (Kanamitsu et al., 1979).  
However, recent surveillance studies throughout Asia have indicated the presence of GETV, while 
phylogenetic studies have indicated changes in the global distribution, indicating it is a re-emerging 
virus (Feng et al., 2012, Hu et al., 2012, Seo et al., 2012, Sugiyama et al., 2009, Zhai et al., 2008).  
Therefore, inclusion of GETV in the diagnostic panel for arbovirus screening would be desirable to 
better understand the presence and distribution of this virus in Australia. 
 
The public health burden for the endemic alphaviruses is substantial, with the costs for testing, 
treating and lost earnings due to RRV alone, estimated to be between A$2.7 and A$5.6 million an 
average year, in 2001 (Harley et al., 2001).  However, the disease burden may increase substantially 
in the future.  Seroprevalence rates for RRV vary between communities, but have been found to be 
increasing in some locations (Boughton et al., 1984, Hawkes et al., 1993, Russell, 2002). Factors 
that could lead to increased seroprevalence include urbanisation near wetlands, increased travel, 
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climate variability, population growth and effectiveness of vector control programs (Tong et al., 
2005). Population growth in some RRV endemic regions is predicted to have a dramatic effect, with 
population growth in one region estimated to increase the local incidence of RRV by as much as 8% 
between 2000 and 2021 (Ryan et al., 2006).   
 
The economic and personal cost of the introduction or establishment of an exotic virus such as 
CHIKV in Australia, could also pose a substantial burden, especially given the high CHIKV 
transmission rates seen overseas and the naive population.  Although CHIKV does not have a 
known animal reservoir in Australia, humans are amplification hosts for CHIKV, and other 
vertebrates are not required for high levels of transmission to occur (Knope et al., 2013).  This has 
the potential to result in local transmission following the importation of CHIKV in a cycle similar 
to the exotic virus DENV.  Imported DENV cases have been detected in Queensland every year 
over the past decade, and these have been linked with local transmission and disease outbreaks 
(Huang, 2013).  The largest outbreak of DENV occurred in 2008, with 912 confirmed cases of 
DENV acquired in Queensland and one death (Ritchie et al., 2013). The vector in these outbreaks 
has been Ae aegypti, a common domestic species which has been found in laboratory conditions to 
also be susceptible to CHIKV and readily transmit it (van den Hurk et al., 2010).  There is the 
potential that in the right conditions, CHIKV could cause disease outbreaks of similar public health 
importance to DENV.  While currently the number of imported CHIKV cases each year is much 
lower than for DENV, a recent publication in Communicable Diseases Intelligence, which aimed to 
assess the threat of CHIKV emergence in Australia, concluded that Australia is at risk of local 
transmission due to regular importation of the virus, the availability of competent mosquito vectors 
and an appropriate climate for exotic vectors (Viennet et al., 2013).  This is particularly of concern 
as globalisation and climate change are predicted to favour the spread of both arboviruses and their 
vectors over the coming decades (Laine et al., 2004, Rezza, 2008).  At present, no specific treatment 
or vaccine is available for any of these alphaviruses (Gould et al., 2010). Therefore, the best 
strategy to prevent disease lies in vector control programs combined with public health warnings of 
virus activity (Hall et al., 2010).  The cost of vector control programs has been shown to be offset 
by the reduced incidence and cost of disease (Tong et al., 2008). Thus, improvements in public 
health strategy to more effectively and efficiently employ vector control programs, offer one of the 
best solutions for decreasing the public health burden of these diseases. 
 
Mosquito surveillance programs play a pivotal role in public health strategy and exotic disease 
preparedness. Mosquito surveillance in Australia has shown that many arboviruses can be co-
circulating at the same time; even during outbreaks of clinical disease (Standfast, 1984, Marshall et 
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al., 1982a).  Concurrent infections with both RRV and BFV in humans have also been identified 
(Mackenzie et al., 1994).  There are a number of mosquito species in Australia that are effective 
vectors of alphaviruses and there is evidence that many of these are also competent vectors of 
CHIKV, at least in the laboratory setting (van den Hurk et al., 2010).  Therefore, mosquito 
surveillance may also play an important role in the detection of future exotic disease incursions. 
 
Surveillance for alphaviruses is currently included in many state mosquito monitoring programs, 
though at present there is no national program to strategically target the alphaviruses; and operating 
costs, man-power and accessing remote areas are all barriers to the adoption of one.  Current 
systems include the routine trapping and processing of mosquito pools for virus isolation and 
reporting infected cases using the National Notifiable Diseases Surveillance System (NNDSS).  
Alphavirus surveillance in Australia currently does not include sentinel systems using domestic 
animals, such as chickens or pigs, which are employed for flavivirus surveillance.  Screening the 
blood donor pool has also been advocated from two different perspectives.  Surveillance for RRV 
using the blood donor pool may enable early intervention, with a spike in anti-RRV IgM noted to 
proceed an outbreak of EPA; but to date it has not been adopted (Aaskov et al., 1998).  On the other 
hand, there is considerable risk of transfusion transmitted alphavirus, as asymptomatic viraemia 
does occur (Dunstan et al., 2008, Barber et al., 2009, Petersen & Busch, 2010). It is highly likely 
that transfusion-related transmission of CHIKV infections has occurred in epidemic areas, in a 
similar manner to transfusion transmission of WNV after its introduction into the USA (Petersen & 
Busch, 2010). Screening of blood donations was introduced in the USA during the WNV outbreaks 
using nucleic acid testing in mini-pool formats (Montgomery et al., 2006).  Potentially infectious 
blood donations were identified and removed from the blood donor pool, and this was found to have 
a cost-benefit (Petersen & Busch, 2010). The importance of this type of screening to maintain the 
safety of blood supplies during outbreaks is clear, and relies upon the availability of appropriate 
molecular diagnostic tests. The value of molecular diagnostic tests is already recognized, and they 
have been successfully adopted for both mosquito surveillance (Frances et al., 2004) and clinical 
diagnosis (Druce et al., 2007).   However, costs including labour currently limit widespread 
adoption.  The development of new tests to enhance surveillance has been recognized as an 
important component for Australia’s exotic disease preparedness for some time now. 
 
Molecular methods, such as RT-PCR, are increasingly employed for the diagnosis of alphaviruses. 
Since the outbreak of CHIKV, there has been a proliferation of RT-PCR assays for diagnosis of this 
agent (Sharma et al., 2010, Ho et al., 2010, Telles et al., 2009, Parida et al., 2008, Edwards et al., 
2007, Santhosh et al., 2007). Molecular tests have also been developed for the detection of RRV 
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(Sellner et al., 1994, Hall, 2009), SINV (Sane et al., 2011) and BFV (A Pyke, unpublished data). 
RT-PCR appears to be as sensitive as virus inoculation in some circumstances; however, cost and 
labour are two limiting factors when a specific diagnostic test must be used for each of the four 
alphaviruses of public health importance in Australia.  Therefore, the development of a new 
molecular test using multiplexed technology could remove these obstacles and provide a screening 
test for surveillance purposes without dramatically increasing costs or labour. A multiplex test may 
also reduce the number of false negative results obtained using current diagnostic protocols. 
Currently, there is reliance upon clinicians to select appropriate tests.  However, SINV testing is 
rarely requested, and BFV is less regularly requested than RRV, which may be resulting in an 
underrepresentation of these diseases.  Similarly, testing for CHIKV requires obtaining a careful 
travel history.  Routine screening using a multiplex assay could help overcome these issues and 
result in improved diagnostic outcomes for clinicians. 
 
The development of multiplex tests for alphaviruses has already proven successful. An approach 
has been described by Wang and Frances (Wang et al., 2006), and suggests that the development of 
a similar test targeted for the four alphaviruses of main concern in Australia is possible.  This could 
also be adopted for mosquito surveillance, in a similar manner to the test developed by Eshoo and 
coworkers (Eshoo et al., 2007). Not only would such a test allow better surveillance, but as specific 
treatments for diseases become available, early and accurate diagnosis of disease will allow better 
treatment outcomes.  The investment is well justified if it helps to prevent the establishment of an 
exotic virus, limits the extent of outbreaks or provides better treatment of patients. 
 
This chapter reports the development of a suspension microarray for the detection of endemic and 
exotic alphaviruses to Australia that may have application as a screening assay for mosquito 
surveillance and clinical samples.   
2.2 Materials and Methods 
2.2.1 Viruses 
The virus strains used for the initial development of the alphavirus microsphere microarray are 
listed in Table 2.1 and were obtained from Queensland Health Forensic and Scientific Services, 
Brisbane, Australia.  All viruses were propagated in either porcine stable equine kidney (PS-EK) or 
Aedes albopictus (C6/36) cell lines. Three strains of CHIKV were included in the panel.  The 
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Mauritius strain of CHIKV was isolated from a traveller to Melbourne in March 2006 (kindly 
supplied by J.D. Druce, Victorian Infectious Diseases Laboratory, Melbourne, Australia).  This 
isolate shared 100% homology with other viral sequences from Reunion Island in the region 
amplified in the NSP4 region (Druce et al., 2007) and contained the E1-A226V mutation (van den 
Hurk et al., 2010). 
Table 2.1:  Virus strains used for development of the alphavirus suspension microarray 
Virus Strain Virus Titre Before Extraction 
(TCID50 units/mL) 
Barmah forest (BFV) BH2193 10
8.9 
Chikungunya (CHIKV) BKM459  10
5.6 
 Mauritius06 N/A 
 Malaysia08 N/A 
Ross River (RRV) T48 10
7.5 
 Stokker N/A 
 109 N/A 
 MRM3078 
71981 
N/A 
N/A 
Sindbis (SINV) MRM39 10
9.2 
 361/2001 N/A 
 
N/A indicates viral titre is not available 
2.2.2 Virus positive mosquitoes 
Virus-positive mosquitoes from previously published vector-competence studies were used to 
validate the suspension microarray.  These samples included Aedes vigilax mosquitoes infected with 
BFV strain BH2193 and RRV strain 389A, and Aedes aegypti mosquitoes infected with a strain of 
CHIKV isolated from the Reunion Island outbreak in 2006.  The methods used to infect these 
mosquitoes with virus have been previously described (Johnson, 2009, van den Hurk et al., 2010). 
Briefly, mosquitoes were fed on stock virus diluted in defibrinated sheep blood and 1% sucrose, via 
either pledgets or a membrane feeding apparatus.  Following feeding, mosquitoes were briefly 
anaesthetised with CO2 gas and those which had blood-fed were selected and placed in an 
environmental growth chamber.  Mosquitoes were maintained on 10% sucrose post-infection at 
28°C and 75% relative humidity (RH).  The incubation period varied from 11 to 15 days, according 
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to the virus, before the mosquitoes were killed with CO2 gas.  For mosquitoes that were to be 
analysed individually, mosquitoes were placed in 1mL growth media (GM) containing 3% foetal 
bovine serum (FBS) with three sterile glass beads and stored at -80°C.   
 
Virus positive pools were produced by adding a single infected mosquito into a pool of 99 
uninfected Ae. aegypti mosquitoes.  The uninfected Ae. aegypti mosquitoes used for the mosquito 
pools were stored without media at -80°C, prior to use.  Mosquitoes used to spike the mosquito 
pools were confirmed to be virus positive by removing the head to test by TaqMan assay. The 
mosquito body was stored at -80°C until results were confirmed, then added into the pool.  
Mosquito pools were in limited supply; and provided a practical restraint on our ability to validate 
this assay within a short timeframe at the end of the project.   
2.2.3 RNA extraction  
2.2.3.1 RNA extraction from viral culture 
Viral RNA was extracted from cell culture using the QIAmp® Viral RNA Mini kit (Qiagen, 
Victoria, Australia), according to manufacturer’s instructions. The extracted RNA was diluted 10-
fold in RNase-free water and stored at -80°C.  
  
2.2.3.2 RNA extraction from mosquitoes 
Individual mosquitoes were homogenized by shaking in a Spex 8000 Mill (Spex Industries, Edison, 
NJ) for 3 minutes.  The grind was then filtered through a 0.2µm Supor® membrane filter (Pall 
Corporation, Ann Arbor, MI) and a 140µL aliquot was extracted using the QIAmp® Viral RNA 
Mini kit (Qiagen, Victoria, Australia), according to manufacturer’s instructions. 
 
Individual mosquitoes used to spike the mosquito pools were confirmed to be positive prior to 
addition to the pool by excising the head and testing by TaqMan RT-PCR.  The samples were then 
refrozen at -80°C until results were confirmed.  The virus-positive body was then spiked into a pool 
of 99 laboratory bred Ae. aegypti mosquitoes. Two different protocols were used to extract the 
mosquito pools.  Initially, the pools were homogenized in 10ml of Optim-MEM® (Invitrogen 
Corporation, California, USA), using a SPEX 8000 mixer/mill (Spex Industries, Edison, USA), 
centrifuged for 5 minutes and then filtered and extracted as described above.  In the second method, 
the pool was placed in a tube containing 1mL of Opti-Mem, 1mL Trizol and five sterile glass beads 
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and homogenized by shaking in a Spex 8000 Mill for approximately 5 minutes.  The pool was then 
centrifuged for 15 minutes and the supernatant removed and discarded.  The ground pool was then 
incubated at room temperature for 5 minutes before 200µL of chloroform was added and the pool 
vortexed for 15 seconds.  The pool was aliquoted in 440µl volumes to Manual Phase Lock Gel ™ 
Heavy tubes (5 Prime www.5Prime.com; Prod #2302810), and processed following manufacturers 
instruction.  The pool was purified and extracted using the RNeasy® Mini Kit, according the 
manufacturer’s instructions. This second extraction method proved the most successful. 
2.2.4 Polymerase Chain Reaction (PCR) 
2.2.4.1 Symmetrical PCR 
For RT-PCR a one-step kit SuperScript III with Platimun® Taq (Invitrogen, Victoria, Australia) 
was used according to manufacturer’s instructions.  A 4µL volume of extracted RNA was added to 
each 50µL reaction. Amplification was carried out using previously described universal primers 
M2W and cM3W (Pfeffer et al., 1997) (Table 2.2).  The reverse primer was biotinylated to produce 
biotin-labelled PCR products.   
2.2.4.2 Asymmetrical amplification 
Two different methods were employed to generate asymmetrical PCR product. The first method 
involved including the reverse primer in a concentration eight times greater than the forward 
primer. If two rounds of amplification were required, the first round employed symmetrical PCR 
using the unbiotinylated reverse primer as described by Pfeffer (Pfeffer et al., 1997).  This method 
of asymmetrical amplification was used for the preliminary multiplexing and specificity studies.   
 
In the second method, the reverse primer cM3W was modified to increase the melting temperature 
to 65°C and a three stage RT-PCR reaction employed. The variation of the forward and reverse 
primers’ melting temperature allowed additional rounds of amplification to occur at a higher 
temperature, favouring reverse primer extension (Figure 2.1).   
 
The amplification protocol varied according to whether one or two rounds of amplification were 
used.  If only one round of amplification was required then the biotinylated, modified reverse 
primer M13-cM3W was used.  The following protocol of cycling times and temperatures was 
employed for the 3 stage RT-PCR reaction: 1 cycle of 50°C for 30 minutes, 1 cycle of 94°C for 2 
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minutes; 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds and 68°C for 1 minute; 30 cycles of 
94°C for 30 seconds and 68°C for 1 minute; and finally one cycle of 72°C for 5 minutes. 
 
When two rounds of amplification were required, the first round used the primers and method 
described by Pfeffer et al., (1997), with minor adjustments to the cycling conditions. The following 
protocol of cycling times and temperatures was used: 1 cycle of 50°C for 30 minutes; 1 cycle of 
94°C for 2 minutes; 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds and 68°C for 1 minute; 
and finally one cycle of 68°C for 5 minutes.  For the second round of amplification, 4µL of first 
round product were added to a 50µL reaction containing the biotinylated, modified reverse primer 
m13-cM3W.  The three-stage RT-PCR reaction for the second round of amplification used the 
following protocol: 1 cycle of 94°C for 2 minutes; 40 cycles of 94°C for 15 seconds, 55°C for 30 
seconds and 68°C for 1 minute; 30 cycles of 94°C for 30 seconds and 68°C for 1 minute; and 
finally one cycle of 72°C for 5 minutes.  
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Figure 2.1: Asymmetrical amplification and labelling of viral extract.   
The one-tube RT-PCR reaction includes three stages: A) Reverse transcription reaction to produce first 
strand cDNA for viral targets (vRNA); B) Low temperature (56°C), exponential amplification of target and 
C) High temperature (68°C), linear amplification to product single strand, biotin-labeled target. Target is 
labeled by the use of biotinylated reverse primer 
 
2.2.4.3 Amplification controls, including gel electrophoresis 
Positive and negative controls were included for every amplification experiment.  The positive 
amplification control used synthetic RNA as the template, following minor modifications of the 
method described by Smith et al., (2006) (Figure 2.2).  The reverse primer m13-cM3W and Alpha 
Synthetic Control Probe sequences are listed in Table 2.2.  The inclusion of synthetic controls 
reduces both the potential for cross-contamination to occur, as well as the health and safety risks 
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associated with handling live virus (Smith et al., 2006).   The negative amplification control used 
the negative extraction control as the sample template.   
 
Briefly, for the preparation of synthetic controls, first round primer pairs were chosen using the 
primer design software Primer Express™ Version 2.0.0 (Perkin-Elmer, Applied Biosystems, USA) 
to produce a product of approximately 401 bp in length from pUC18 DNA, a product approximately 
the same size as the amplicons generated for the suspension microarray. The first round primers 
were designed so that the ApaLI containing multiple cloning site of the plasmid would be located 
approximately in the middle of the resulting amplicon to allow later digestion of the product by 
ApaLI digestion. The primers were designed to incorporate the addition of the forward primer 
sequence of M2W to the 5′ end of a pUC18 specific sequence (5′978-
CTCGTGCGCTCTCCTGTTC
996
-3′) to produce a primer 42 bp in length.   The cM3W reverse 
primer sequence was added to the 5’ end of a pUC18 specific sequence (5’-
1357
GAGTTGGTAGCTCTTGATCCGG
1379
-3’) in the order 5’-[cM3W]-[pUC18 (rev) sequence]-3’ 
to produce a primer of 50 bp in length.  Finally, a probe with similar design parameters to those 
used for the alphavirus suspension microarray was designed that was complementary to the 
amplified region of pUC18.  This 26bp probe was called Alpha-Synthetic Probe 
TTTGGTATCTGCGCTCTGCTGAAGCC. The pUC18 plasmid used in this study was purchased 
from New England Biolabs, USA.  
 
All first round amplified products were separated on a 1.5% agarose gel at 90 volts for 45 minutes 
and viewed by UV transillumination to confirm amplification of positive samples, and lack of 
contamination in negative controls.  The second round amplified products could not be viewed in 
this manner as single-stranded DNA is not visible by this method (Spiro et al., 2000, Deregt et al., 
2006a). 
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Figure 2.2: Strategy for the generation of synthetic control for use in the suspension 
microarray assays 
 
2.2.5 Sequencing 
RNA was extracted and subjected to RT-PCR analysis using the protocol and primers discussed 
above.  Amplified DNA products were sequenced using Applied Biosystems Big Dye Terminator 
sequencing reagents (Applied Biosystems, Foster City, CA) and an Applied Biosystems Prism 
3130x1 Genetic Analyser (Griffith University Sequencing Facility, Brisbane, Australia).  Sequences 
were then analysed using ChromasPro (Technelysium Pty Ltd, Tewantin, Australia).  
pUC18
Restriction site
pUC forward sequence
Virus forward sequence
Virus reverse sequence
pUC reverse sequence
PCR amplification
Synthetic Control
Add Synthetic control to the Luminex assay
Virus reverse primer
Virus forward primer Synthetic control probe
 
 36 
2.2.6 Oligonucleotide probe design 
Probes for the detection of BFV, CHIKV, RRV and SINV were designed for the alphavirus 
suspension microarray using the program Primer Express™ 2.0 (PE Applied Biosystems, USA).  
The target region for the probe was based on the NSP1 region amplified by the universal primers 
M2W and cM3W (Pfeffer et al., 1997). The GenBank accession numbers for the virus strains used 
for initial probe design were U73745 (BFV), DQ678928 (CHIKV), GQ433359 (RRV) and 
AF061236 (SINV). All probes selected were ones that met the following parameters as closely as 
possible: length (22mer), GC content (30-70%) and melting temperature (69°C). Probes that bound 
to the middle or 3’end of the amplicon were preferentially selected where possible. Probes were 
excluded that formed hairpins or strong secondary structures, or displayed a run of more than three 
Gs or Cs at the 5’ or 3’ end. Finally, a NCBI Blast (Altschul et al., 1990) was conducted with the 
candidate probes to ensure they matched as many specific virus strains as possible and showed no 
indication of cross-reactivity with other alphaviruses, microorganisms or contaminants.  A synthetic 
control probe was also designed, as described in the previous section.  The probes which passed 
screening and were included in the suspension microarray are listed below in Table 2.2.  
Table 2.2: Nucleotide sequences of primers and probes used for the alphavirus suspension 
microarray  
Primer or Probe Sequence Size 
(bp) 
M2W(A)
a 5’YAGAGCDTTTTCGCAYSTRGCHA3’  23 
M2W(T)
a
 5’YAGAGCDTTTTCGCAYSTRGCHT3’  23 
cM3W
a 5’ACATRAANKGNGTNGTRTCRAANCCDAYCC3’  30 
M13-cM3W 5’biotinTCACGAACATRAANKGNGTNGTRTCRAANCCDAYCC  36 
BFVprobe 5'aminoC12ACGCATCCTGCAGATACCGCGG3'   22 
CHIKV probe 5’aminoC12CCACCAGGCGATTAAAGGAGTCCGA3’  25 
RRV probe 5’aminoC12TCATGGCAACCCCCGATCTGGA3’  22 
SINV probe 5aminoC12CAGGCTGAATACTCCGTTATGCAGGACGT3’   29 
Alpha-Synthetic 
Control probe 
5aminoC12TTTGGTATCTGCGCTCTGCTGAAGCC3’  26 
a The M2W and cM3W primers have previously been described by Pfeffer et al., (1997) 
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2.2.7 Oligonucleotide probe bead preparation  
Bead coupling of the probes to carboxylated beads was performed according to the manufacturer’s 
guidelines.  In brief, HPLC-grade, virus-specific probes were synthesized by Geneworks Pty Ltd 
(Thebarton, Australia) with an amino-modified 12-carbon spacer at the 5’ end.  The amino-
modified, 12-carbon spacer was used for covalent attachment of the probe to the carboxylated 
beads.  For each probe, 2.5 x 10
6
 microspheres (Luminex Corp; Austin, TX), 0.2 to 0.4nmol of 
probe, 25µg of 1-ethyl-3-dimethylaminopropyl carbodiimide (EDC) and 25µL of 0.1M 2-
morpholinoethane sulfonic acid (MES, pH 4.5) was combined. The coupling reaction was incubated 
in the dark for 30 minutes at room temperature on a plate shaker.  An additional 25µg of EDC was 
added and the mixture was again incubated in the dark for 30 minutes as before.  The microspheres 
were then washed in 0.5mL 0.02% Tween-20 followed by a second wash in 0.1% sodium lauryl 
sulfate (SDS).  Coupled microspheres were then suspended in 50µL of TE buffer (10mM Tris-HCl, 
1mM ethylenediamine tetraacetic acid, pH 8.0), enumerated using a haemocytometer and stored in 
the dark at 4°C until use.  To confirm successful bead coupling and consistency of results, the same 
panel of samples were used to validate all coupling reactions, to ensure there was no great variation 
in signal between batches.   
2.2.8 Multiplex alphavirus suspension microarray  
Hybridization of the probes and PCR product was performed according to the manufacturer’s 
guidelines.  Briefly, each set of probe-coupled beads was diluted to a final concentration of 150 
microspheres/µL in 1.5M TMAC hybridization buffer (1.5M tetramethyl ammonium chloride, 
75mM Tris, 6mM EDTA, and 0.15% Sarkosyl, pH 8.0).  Thirty-three microlitres of bead mix and 
5µL of PCR product were diluted in TE buffer to a total volume of 50µL in a 96 well Eppendorf 
twin.tec PCR plate (Hamburg, Germany).  The reaction mixture was denatured in a thermocycler at 
95°C for 5 minutes and then probes and the PCR product were allowed to hybridize for 20 minutes 
at 56°C.  The conjugate, phycoerythrin-R-streptavidin (Qiagen, Victoria, Australia) was diluted 
1:100 in 1M TMAC Hybridization buffer and 75µL added to each well. The plate was incubated for 
an additional 5 minutes at 56°C and the samples then analysed in the Bio-Plex xMap flow 
cytometer (Bio-Rad, California, USA) using the default settings, and the platform heater set to 
56°C.  Each sample was repeated in triplicate and blank and negative controls were included in each 
assay. A diagrammatic representation of the DNA suspension array is presented in Figure 2.3. 
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Figure 2.3: Suspension microarray for the detection of alphaviruses 
2.2.9 Analysis of hybridisation results 
The BioPlex xMap system calculated the median fluorescent intensity (MFI) values of each bead set 
in a well. The MFI value was calculated from the signal of at least 100 beads. Raw data was 
exported from the Bio-Plex™ Manager Software 4.0 to Microsoft Excel for analysis. The sample-
to-background (S/B) ratio was calculated for each sample by dividing the mean MFI of the sample 
by the mean background fluorescent intensity (BFI) of the negative controls of that run, using a 
modified protocol of Das, et al., (2006). A positive sample was defined as a sample with a MFI at 
least twice the BFI for that bead-probe set.  This definition for a positive sample was found to be 
more stringent than a cut-off of twice the standard deviation above the negative during the 
preliminary studies.  It is the most widely used method in the literature relating to suspension 
microarrays. 
2.2.10 TaqMan RT-PCR  
To validate the alphavirus suspension microarray, the assay was compared to the current gold 
standard molecular assays used for the detection of alphaviruses. The validated TaqMan assays 
routinely used at QLD Health Forensic and Scientific Services were used to run samples in parallel 
or confirm results.  Probe and primer pairs targeting the alphaviruses of interest were designed as 
Add biotinylated
ssDNA
generated with 
asymmetric PCR
Hybridisation
Red Laser=ID microsphere
Green Laser=MFI of reporter
Bead with 
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Add Reporter
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previously described (Pyke et al., 2004, van den Hurk et al., 2010) and are listed below in Table 2.3. 
Virus samples were run in triplicate. 
 
In brief, amplification and detection of the alphavirus RNA was conducted in a single tube one-step 
RT-PCR in a final volume of 20µL. Amplification and real time detection were performed with the 
ABI Prism 7700 sequence detection system (PE Applied Biosystems, USA).  The reaction mix was 
prepared using the Superscript III Platinum one-step qRT-PCR system (Invitrogen, Carlsbad, CA) 
and contained 0.4 µL Superscript™ III RT/Platinum® Taq mix, 9.5 µL of 2x Reaction Mix, 370nM 
primers, 180nM dual labelled probe, 47nM ROX Reference Dye, and 5 µL of extracted viral RNA 
or diluted synthetic control. The cycling conditions were as recommended by the manufacturer 
(Fast Mode, PE Applied Biosystems, Foster City, CA) and consisted of one cycle at 50°C for 5 
minutes one cycle at 95°C for 10 minutes and 40 cycles at 95°C for 3 sec and 60°C for 30 sec. The 
threshold cycle number (Ct) was determined for each sample.  All oligonucleotides and probes were 
synthesized by GeneWorks Pty. Ltd. (Adelaide, Australia).  
 
Negative controls, and probe and primer controls, were also included. Negative RNA template 
controls included the negative extraction control or RNase-free water.  A negative result was 
considered to be a Ct value of 40 or more cycles.  In addition, separate synthetic primer and probe 
positive controls were developed following minor modifications of the method described by Smith 
et al. (2006). These provided specific, nonviral reagents that eliminated potential contamination by 
viral RNA controls. Briefly, two high-performance liquid chromatography–purified 
oligonucleotides with complementary forward and reverse sequences were designed for each primer 
and probe control. The primer and probe synthetic controls were prepared individually to produce 
double-stranded DNA that could be used directly in the TaqMan RT-PCR. Each forward primer and 
its complementary reverse were diluted to 200µM, combined, and then annealed following a 
process of denaturation at 94°C for 1 min and hybridization at room temperature for 10 minutes. 
The optimal working dilution was then determined by titration and incorporated into the standard 
protocol.  The primer and probe control oligonucleotides were synthesized by GeneWorks Pty. Ltd. 
(Adelaide, Australia). 
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Table 2.3: TaqMan primers and probes used for the detection of alphaviruses  
Virus Oligonucleotide Sequence 
BFV
a
 Forward primer AGTGTGGCAGTACAACTCCCAAT 
 Reverse primer AAGGCACATGGATCTTTCCTTTC 
 Probe CGTGCCCAGGTCCGAAGTTACGG 
 Probe TGCGCCGTAGGGAACATGCC 
CHIKV
b 
MA 
 
Forward primer CCCGGTAAGAGCGGTGAA 
 Reverse primer CTTCCGGTATGTCGATGGAGAT 
 Probe CAACAACCCGCCGGTCCGC 
RRV
c
 Forward primer ACGGAAGAAGGGATTGAGTACCA 
 Reverse primer TCGTCAGTTGCGCCCATA 
 Probe TCCCAYTGGCACACGTCCCTCAG 
SINV
c
 Forward primer GGTCCCGAGCACGTGTTTA 
 Reverse primer TGATRTGTTTRAAGCCWTGCA 
 Probe TCCCAYTGGCACACGTCCCTCAG 
 
a BFV RT-PCR previously developed and routinely used at QHFSS (IL Smith unpubl. data 2004); 
referenced in (Johnson et al., 2009) 
b
CHIKV TaqMan RT-PCR (van den Hurk et al., 2010) 
c
RRV and SINV TaqMan RT-PCR previously developed and routinely used at QHFSS (A Pyke 
unpubl. data) 
2.2.11 Specificity and sensitivity studies, including TCID50 assays 
To investigate specificity, each probe was tested against a panel of alphaviruses (refer Table 2.1). 
Each virus-specific probe was also tested against different strains, where possible, to ensure it was 
both capable of detecting different virus strains and also did not show undesirable cross-reactivity 
with other alphaviruses.    
 
The sensitivity of the alphavirus suspension microarray was compared to both virus-specific 
TaqMan assays and RT-PCR followed by gel electrophoresis. The titre of the validation panel of 
virus strains, listed in table 2.1 were determined using TCID50 as described previously (van den 
Hurk et al., 2010).  Ten-fold dilutions of virus were inoculated onto confluent monolayers of Vero 
cells in 96-well plates. The plates were incubated at 37°C with 5% C02 for 7 days, after which they 
were examined for cytopathic effect.  Plates were then fixed with PBS/acetone and stored at -20°C.  
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Four replicates of each virus were performed and the mean determined.  The virus titre was 
estimated using the 50% endpoint method described by Reed and Meunch (1938).  Aliquots of 
140uL from each dilution were taken and extracted as described previously.  The extracts were then 
tested in triplicate on the TaqMan assay and alphavirus suspension microarray to determine the 
detection limit of each test.  Two different amplification methods to generate asymmetrical PCR 
product were also compared on the suspension microarray, to determine whether this was a means 
to improve the detection limit. Additionally, virus-positive mosquitoes were tested to determine the 
sensitivity of the assay for mosquito-surveillance purposes. 
 
2.3 Results 
2.3.1 Probe design  
Fourteen probes were designed and screened for inclusion in the suspension micorarray. The probes 
were designed for the conserved nsP1 region of the alphavirus genome. The screening process 
involved testing each probe against positive and negative samples in both uniplex and multiplex 
assays.  Suitable probes had a high sample-to-background ratio and low cross-reactivity. Despite the 
care taken to ensure the probes have similar hybridisation characteristics and met design guidelines 
detailed in the literature, only five probes passed the initial screening and were included in the 
multiplexed assay.  In general, the probes which failed initial screening did not produce an adequate 
signal in the presence of a positive sample.  However, one universal probe produced a high 
background signal and was excluded from the panel. The list of the probes designed can be found in 
Table 2.4. Probes included in the final panel ranged in length from 22-29bp and had melting 
temperatures of 58-63°C. 
2.3.2 Optimisation of the alphavirus suspension microarray 
Factors were investigated that would optimise generation, hybridisation and detection of 
biotinylated, PCR product.  Specifically, we also aimed to establish whether the optimisation 
conditions for the alphavirus suspension microarray would be similar to that for the flavivirus 
suspension microarray, with the aim of exploring the potential to multiplex the assays at a later date.  
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Table 2.4: Probes designed for the alphavirus suspension microarray   
Virus Target Probe Name Sequence Probe 
Size 
Probe Tm 
Alphavirus M2W2 TGYCCNVTGMDNWSYVCNGARGA 23 59 
Alphavirus Alpha Uni1 CGCACCSACGTCGCTDTACCACCAG 25 65 
Alphavirus Alpha-Uni2 GAVCACAAGTACCACTGCGTCTGCCC 26 64 
Alphavirus Alpha Synth TTTGGTATCTGCGCTGTGCTGAAGCC 26 61 
BFV
* 
BFV ACGCATCCTGCAGATACCGCGG 22 60 
CHIKV
* 
CHIKV CCACCAGGCGATTAAAGGAGTCCGA 25 61 
GETV GETV1 CGTGGTAGTGCACCCGCAAGG 22 62 
GETV GETV2 TGCCTGCAYACTGACGAGACGTGCC 25 63 
RRV RRV1 CGAACTACGCCCGGAAACTGGCA 23 61 
RRV RRV2 CGCACCGACCTCGCTTTATCATCAA 25 59 
RRV
* 
RRV3 TCATGGCAACCCCCGATCTGGA 22 58 
SINV SINV1 TACGCCGCCAAGCTGGCAGAAA 22 58 
SINV SINV2 CGGATGCTGAGACACCGTCGCTCT 24 62 
SINV
* 
SINV3 CAGGCTGAATACTCCGTTATGCAGGACGT 29 63 
 
*
Included in the multiplexed alphavirus suspension microarray
 
2.3.2.1 Optimisation of PCR amplification 
Preliminary validation of the alphavirus suspension microarray examined both symmetrical PCR 
and asymmetrical PCR.  Symmetric PCR generated double stranded PCR product, while 
asymmetric PCR favoured the production of single stranded PCR product.  The experiments were 
replicated using several alphaviruses with similar results, and the BFV results are included as an 
example (Figure 2.4). 
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Figure 2.4: Comparison of the S/B (sample-to-background) ratios produced by the BFV probe 
following hybridisation with BFV products from either symmetrical (Sym) or asymmetrical
+ 
(Asym) PCR.  
(
+
) The asymmetrical PCR product was produced using a forward to reverse primer ratio of 1:4 
 
We found that asymmetrical PCR products generated much higher MFIs than the symmetrical PCR 
product.  Symmetrical PCR generates double stranded PCR product, which can self-reanneal during 
hybridisation.  This resulted in a signal which was very similar to the control reactions. In 
comparison, the asymmetrical product is single stranded PCR and available to hybridise to the 
probe.  This resulted in a higher fluorescent signal as there is increased product bound to the probe.  
Therefore, an asymmetrical amplification strategy was examined for the alphavirus suspension 
microarray, to determine the optimal ratio of forward to reverse primers.  This was investigated in 
combination with the magnesium sulphate (MgS04) concentration in a checkerboard titration for 
several alphaviruses.  The results for BFV are shown in Figure 2.5.   
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Figure 2.5: Comparison of the S/B (sample-to-background) ratios produced by the BFV probe 
when hybridised against BFV product produced from PCR reactions using a range of primer 
ratios and MgS04 concentrations for the optimisation of the BFV suspension microarray 
 
Based on the results of several alphaviruses, it appeared that both MgS04 concentration and the 
forward to reverse primer ratio can influence the signal generated in the suspension microarray. An 
asymmetrical amplification strategy using reverse primer at eight times the concentration of the 
forward primer and an MgS04 concentration of 2mM, was adopted for experiments that relied on 
the primer ratio to generate asymmetric PCR product. 
 
2.3.2.2 Optimisation of probe conditions  
As recommended by the manufacturers, the optimal amount of probe to conjugate to the 
microspheres was determined by titration. A range of concentrations from 0.2 to 0.4 nmol, were 
tested to determine the best concentration for each probe.  
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The highest signal was achieved at a concentration of 0.3nmol for the BFV probe (Figure 2.6), 
however, for the other probes, 0.2nmol of probe coupled to the microspheres produced the highest 
signal. These results were used to develop the standard protocol for bead coupling.      
 
 
Figure 2.6: Effect of varying the amount of BFV probe coupled to the microspheres per 
reaction, on the S/B (sample-to-background) ratio generated after hybridisation with BFV 
PCR product 
2.3.2.3 Optimisation of hybridisation 
The hybridisation conditions of the suspension microarray were optimised after evaluating 
hybridisation temperatures and TMAC concentration.  In brief, a range of hybridisation 
temperatures (56-62°C) were investigated before selecting 56°C as the optimal hybridization 
temperature (data not shown). TMAC solution is known to have an influence in overcoming 
differences in melting temperatures between probes (Honore et al., 1993). A range of TMAC 
concentrations (1.5M to 3M TMAC) were also investigated before 1.5M was selected (data not 
shown).   
2.3.2.4 Minimisation of background signal 
The value of a wash step to reduce the background signal generated in the negative control samples 
was investigated.  Two different methods were compared (Figure 2.7).  Using the centrifuge method 
recommended by Bio-Plex, the 96-well plate was centrifuged at >2,250 x g for 3 minutes 
immediately after hybridisation, to pellet the microspheres.  The supernatant was removed using a 
multi-channel pipette. Alternatively, the reactions were transferred immediately after hybridisation 
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into a pre-wetted Millipore filter plate and the supernatant removed by vacuum filter.  The 
microspheres were then resuspended in 100µL of conjugate by gently pipetting up and down 
several times before the final hybridisation step and analysis with the Bio-Plex system. The 
centrifuge method produced a higher signal for both viruses.  The method also offered the 
advantage that the sample did not need to manually be transferred from a 96-well PCR plate to a 
Millipore-plate and back again.  This step added an additional risk for sample contamination to 
occur.  Therefore, the centrifuge method was selected as the best method for including a wash step 
in the protocol.    
 
 
Figure 2.7: Comparison of the S/B (sample-to-background) ratios obtained when two 
different wash methods were included in the protocol to minimise the background signal.  
Each column represents the mean S/B ratio of the probe ± standard error 
 
To assess the effect including a wash protocol in the suspension microarray protocol had on 
minimising the background signal of the alphavirus suspension microarray, it was compared to a 
no-wash protocol.  The wash protocol was conducted as described above. The no-wash protocol 
involved the addition of the conjugate directly into a 96 well plate after hybridisation.  The 
concentration of the conjugate was adjusted to ensure the same amount of streptavidin-RPE was 
used for each protocol.  The results from this study indicated that the inclusion of a wash step in the 
method for the alphavirus suspension array did not increase the strength of the signal-to-background 
ratio for a positive sample (Figure 2.8). Additionally, the potential for sample contamination or 
laboratory error to occur was increased by the inclusion of such a step.  Therefore, it was decided 
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that further investigation was not warranted and a no-wash protocol was adopted for the alphavirus 
suspension microarray. 
 
 
Figure 2.8: Comparison of the S/B (sample-to-background) ratios obtained when the protocol 
includes an additional wash step to minimise the background signal, to a protocol with no 
wash steps.  Each column represents the mean S/B ratio of the probe ± standard error 
 
2.3.2.5 Optimisation of signal 
Various dilutions of the conjugate, streptavidin-PE, were titrated to determine the most suitable 
dilution to optimise the hybridisation signal whilst minimising background signal. Addition of 
excessive conjugate is undesirable as it increases the cost of the assay.  However, if insufficient 
conjugate is available, it may have a detrimental effect upon the signal generated in a positive 
sample; as insufficient Strepavidin-RPE would be available to bind to the biotin-labelled PCR 
product.  The results for the conjugate titration indicated a dilution of 1:100 was appropriate for 
adoption in the standard protocol for the alphavirus suspension microarray (Figure 2.9). 
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Figure 2.9: Comparison of the S/B (sample-to-background) ratio obtained on titration of 
conjugate for optimisation of alphavirus suspension microarray.  Each column represents the 
mean S/B ratio of the probe ± standard error 
2.3.3 Specificity of the alphavirus suspension microarray 
For initial validation, the four multiplexed probes were tested against a panel of eleven alphaviruses 
(Table 2.5).  All four alphaviruses were detected, and the probes were virus specific.  Ten of the 
eleven virus strains were detected following one round of PCR amplification.   
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Table 2.5: Specificity of the alphavirus suspension microarray following one round of 
amplification 
               Mean S/B ratio of probe (SD) 
Virus  Strain BFV CHIKV RRV SINV 
BFV BH 2193 3.5 (0.4)  - - - 
CHIKV BKM459 - 28.8 (2.9) - - 
CHIKV Malaysia08 - - - - 
CHIKV Mauritius06 - 18.6 (0.9) - - 
RRV 109 - - 18.8 (0.6) - 
RRV 71981 - - 11.6 (0.6) - 
RRV T48 - - 21.8 (3.4) - 
RRV Stokker  - - 23.1 (0.9) - 
.RRV MRM3078 - - 18.6 (2.9) - 
SINV MRM39 - - - 19 (3.1) 
SINV 361/2001 - - - 17.1 (1.1) 
 
(-) indicates S/B (sample-to-background) ratio <2. Samples were run in triplicate and the S/B ratio 
of each replicate was calculated by dividing the MFI of the sample by the MFI of the negative 
control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard 
deviation) 
 
This result was considered promising but two issues warranted further investigation. The virus 
strain, CHIKV Malaysia08 was not detected; and the signal to background ratio for the BFV sample 
was comparatively low at a value of four.  To investigate whether these issues were due to a probe 
mismatch, or other causes, an aliquot of the same extracts underwent two rounds of PCR 
amplification. 
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Table 2.6: Specificity of the alphavirus suspension microarray following two rounds of 
amplification 
Virus  Strain Mean S/B ratio of probe (SD) 
  BFV CHIKV RRV SINV 
      
BFV BH 2193 19 (0.6) - - - 
CHIKV Malaysia08 - 11 (1.2) - 11(0.8) 
 
(-) indicates S/B (sample-to-background) ratio <2. Samples were run in triplicate and the S/B ratio 
of each replicate was calculated by dividing the MFI of the sample by the MFI of the negative 
control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard 
deviation) 
 
 
Following two rounds of amplification, the CHIKV Malaysia08 sample was detected and the 
sample to background ratio for the BFV probe was almost five-fold higher (Table 2.6). These 
results were considered satisfactory enough to warrant continuation with the next phase of 
validation.   
2.3.4 Sensitivity of the alphavirus suspension microarray 
The suspension microarray was evaluated to determine the effect on sensitivity when the assay was 
multiplexed and different amplification strategies were used.  The detection limit of the assay for 
each reference strain of virus was then determined and compared with the two diagnostic tests 
currently used at QHFSS, the TaqMan assay and with conventional RT-PCR followed by gel 
electrophoresis.  
  
2.3.4.1 Multiplex alphavirus suspension microarray 
To determine the effect of multiplexing the four alphavirus probes in the suspension microarray, the 
signal generated in response to a PCR product was compared when the probes were either pooled 
together in a four-plex assay (four probes included), or uniplex for the target virus of interest.  The 
assays were run in parallel, using a 10-fold dilution series to determine the limit of detection using 
two different amplification strategies; the reverse primer at eight times the concentration and the 3-
stage combimatrix protocol. All samples were run in triplicate and each reference virus from the 
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validation panel was tested in this way (Table 2.8). For example, Figure 2.10 demonstrates the 
signal produced when the same BFV-positive sample was run in parallel in either a uniplex or four-
plex assay. 
 
 
Figure 2.10: Comparison of the S/B (sample-to-background) ratios of the uniplex and 
multiplex BFV probe for detection of 10-fold serial dilutions of BFV strain BH2193 cell 
culture.  The experiment was run in triplicate and each column represents the mean S/B ratio 
of the probe ± standard error 
 
The detection limit for BFV in both the uniplex (BFV probe only) and multiplex (four alphavirus 
probes multiplexed) suspension microarray was at a virus dilution of 10
-3
.  There was a steady 
increase in signal as the amount of amplification product increased above the limit of detection. For 
all probes, the detection limit in both the uniplex and multiplex suspension microarray was the 
same; although the signal to background MFI ratio was consistently higher in the uniplex assay 
(Figure 2.10).  However, the advantages of multiplexing the assay far outweigh those of the slight 
increase in MFI and all tests for validation were conducted in multiplex format. 
 
2.3.4.2 Amplification strategy 
The strength of the signal produced in the alphavirus suspension microarray was influenced by the 
asymmetrical amplification strategy used. The virus template, hybridisation conditions and reagents 
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used for each strategy were identical, and all experiments conducted in parallel on the same day, so 
that any variation could only be accounted for by the amplification process.  Only one round of 
amplification was used (Table 2.7). In brief, the three strategies were: (1) using the modified reverse 
primer M13-cM3W detailed in the materials and methods section combined with the Combimatrix 
three-stage PCR reaction (M13-cM3W); (2); using the unmodified cM3W probe (which already has 
a higher Tm than the forward probe) in the same three-stage PCR reaction discussed above (cM3W) 
and (3) using a higher reverse-to-forward primer ratio (Asymmetrical 8:1).  
Table 2.7: Effect of different amplification strategies on signal produced by the alphavirus 
suspension microarray  
    Mean S/B ratio of probe (SD) 
Amplification Strategy  Sample BFV CHIKV RRV SINV 
M13-cM3W BFV 3.9 (0.6) - - - 
M13-cM3W CHIKV - 32.3 (1.2) - - 
M13-cM3W RRV - - 23.1 (0.0) - 
M13-cM3W SINV - - - 13.0 (3.8) 
cM3W BFV 3.7 (0.1) - - - 
cM3W CHIKV - 32.3 (1.8) - - 
cM3W RRV - - 18.3 (1.7) - 
cM3W SINV - - - 10.6 (0.7) 
Asymmetrical (8:1) BFV 3.6 (0.4) - - - 
Asymmetrical (8:1) CHIKV - 25.5 (1.6) - - 
Asymmetrical (8:1) RRV - - 8.2 (0.8) - 
Asymmetrical (8:1) SINV - - - 5.8 (0.3) 
 
(-) indicates S/B (sample-to-background) ratio <2. Samples were run in triplicate and the S/B ratio 
of each replicate was calculated by dividing the MFI of the sample by the MFI of the negative 
control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard 
deviation) 
 
All strategies produced adequate signal with all viruses and no adverse interaction in the multiplex 
format was observed.  Further, the three-stage strategies appeared to produce a stronger signal than 
the asymmetrical strategy initially used for assay development, so one virus was selected for further 
investigation in a sensitivity trial. Although ideally all viruses would have been evaluated to 
determine the optimal strategy for the majority of cases, this was not feasible due to time and cost 
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restraints. All alphaviruses were detectable using the various amplification strategies and so 
selection of just RRV for further evaluation was considered appropriate. 
 
To determine the effect the amplification strategy had upon the limit of detection of the alphavirus 
suspension microarray, the different amplification strategies were run in parallel on a dilution 
series. Serially diluted RRV was used to generate the first round of PCR product according to the 
standard protocol.  The first round product then underwent a second round of PCR using the three 
strategies discussed above but including a fourth. In brief, the four strategies were: (1) using the 
modified reverse primer M13-cM3W detailed in the materials and methods section combined with 
the Combimatrix three-stage PCR reaction (M13-cM3W); (2) using the unmodified cM3W probe 
(which already has a higher Tm than the forward probe) in the same three-stage PCR reaction 
discussed above (cM3W); (3) using a higher reverse-to-forward primer ratio (Asymmetrical 8:1) 
and (4) using 8 times the amount of modified M13-cM3W reverse primer to forward primer in the 
Combimatrix three-stage PCR cycle (Asymm+Combi).  The results are summarised in Figure 2.11. 
 
Figure 2.11: Comparison of four amplification strategies to optimise detection of RRV strain 
T48 on the alphavirus suspension microarray.   The experiment was run in triplicate and each 
column represents the mean S/B (sample-to-background) ratio of the probe ± standard error 
All viruses from the validation panel were tested to determine their limit of sensitivity using the two 
key amplification techniques, the modified primer M13-cM3W in a three-stage strategy; and 
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reverse primer at a ratio of 8 times greater than the forward primer; and were found to have the 
same limit of detection (results not shown).  As all amplification strategies had the same limit of 
detection, with the highest signal produced by using the modified primer M13-cM3W with the three 
stage PCR reaction for the second round of amplification, this latter strategy was used for all further 
test validation.   
2.3.4.3 Comparison of the alphavirus suspension microarray and TaqMan assay 
TaqMan is considered the current gold standard molecular diagnostic test for alphaviruses.  The 
TaqMan and the multiplex suspension microarray were run in parallel to compare the detection 
limits of both tests (Table 2.8).  Gel electrophoresis was also performed on the first round product, 
to confirm amplification had occurred.  
 
Table 2.8: Comparison of the detection limits of three diagnostic tests for alphaviruses   
    Detection Limit of Test (TCID50/mL) 
Virus Strain Gel (1 round) Multiplex Luminex TaqMan 
BFV BH2193 NA 8129 8 
CHIKV Mauritius06  NA 4 0.04 
RRV T48 354843 0.4 0.4 
SINV MRM39 14792 15 15 
2.3.5 Detection of virus infected mosquitoes 
The multiplexed alphavirus suspension microarray has proven capable of detecting either individual 
virus-infected mosquitoes or pools spiked with one virus-infected mosquito in 99 uninfected 
mosquitoes.  The sensitivity of the assay was sufficient that only one round of asymmetric PCR was 
required to detect the individual virus-infected mosquitoes.  The ability of the suspension 
microarray to detect an infected mosquito in a pool of 100 is similar to the requirements of a 
diagnostic test used for mosquito surveillance. 
2.3.5.1 Detection of individual virus-infected mosquitoes 
Initially, the suspension microarray was tested to ensure it was capable of detecting a single, virus-
positive mosquito.  To validate the assay, twenty individual virus-exposed mosquitoes were tested 
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in parallel on both the alphavirus suspension microarray and the TaqMan assay.  The suspension 
microarray detected positive mosquitoes for the alphaviruses BFV, CHIKV and RRV. Sindbis virus 
positive mosquitoes were not available for testing.  An alternative would have been to spike serum 
samples with SINV; however, time did not permit us to take validation to this level. 
Table 2.9: Detection of individual alphavirus positive mosquitoes with the alphavirus 
suspension microarray 
Virus Sample Mean S/B ratio of probe (SD) TaqMan(Ct) 
  BFV CHIKV RRV SINV  
BFV 144722 1.0 (0.1) - - - 28 
BFV 144723 4.9 (0.3) - - - 20 
BFV 144731 1.8 (0.2) - - - 22 
BFV 144734 11.9 (0.9) - - - 16 
BFV 144735 1.2 (0.1) - - - 40 
CHIKV 157937 - 22.2 (1.3) - - 18 
CHIKV 157931 - 6.7 (1.2) - - 24 
CHIKV 157933 - 18.5 (1.5) - - 20 
CHIKV 157945 - 20.5 (1.9) - - 19 
CHIKV 157936 - 20.6 (1.5) - - 17 
RRV 144662 - - 1.7 (0.1) - 40 
RRV 144666 - - 25.0 (3.7) - 18 
RRV 144665 - - 24.4 (4.5) - 17 
RRV 144605 - - 25.6 (3.4) - 20 
RRV 144603 - - 1.8 (0.1) - 40 
RRV E - - 26.2 (1.0) - 18 
RRV F - - 26.5 (1.0) - 19 
RRV G - - 27.1 (1.4) - 19 
RRV H - - 26.8 (2.0) - 19 
RRV I - - 28.7 (1.8) - 18 
 
(-) indicates S/B (sample-to-background) ratio <2. Samples were run in triplicate and the S/B ratio 
of each replicate was calculated by dividing the MFI of the sample by the MFI of the negative 
control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard 
deviation) 
 
 
Two RRV-exposed mosquitoes and one BFV-exposed mosquito were undetected on either the 
alphavirus suspension microarray or the TaqMan assay.  This would suggest that either the virus 
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titre was very low or the mosquito was not virus positive; thus, these samples were discounted from 
the comparison. The sensitivity of the Alphavirus suspension microarray compared to the TaqMan 
assay was 94% and the specificity 100%.  The BFV probe was the least sensitive.  However, the 
sensitivity of the suspension microarray for CHIKV and RRV was 100% and these two viruses are 
arguably the most important clinically. 
 
2.3.5.2 Detection of virus infected mosquitoes in mosquito pools 
Mosquitoes suspected to be virus positive were confirmed to be so by removal of the head and 
testing on TaqMan.  If the mosquito was positive, it was then spiked into a pool of 99 mosquitoes, 
extracted and tested in parallel on both the alphavirus suspension microarray and the TaqMan assay.   
 
This study was to demonstrate proof-of-concept, that suspension microarray technology may have 
potential for use in a vector-surveillance capacity.  Initially, three pools of mosquitoes, each spiked 
with a CHIKV-positive mosquito body, were tested. All were detected on the TaqMan assay with 
Ct values ranging from 28 to 29.  However, the suspension microarray failed to detect the virus, 
even with two rounds of amplification.  An alternative extraction method using Trizol, which was 
also routinely used by our laboratory for mosquito samples, was adopted for reasons outlined 
further in the discussion.  After adopting Trizol extraction, the results between the additional six 
pools tested were concordant between the TaqMan and alphavirus suspension microarray and can 
be found detailed in Table 2.10 and Table 2.11.  
 
Table 2.10: Identification of positive mosquito pools following Trizol extraction  
Sample      Mean S/B ratio of probe (SD)     TaqMan (Ct) 
  BFV CHIKV RRV SINV  
CHIKV Pool A - 22.9 (0.8) - - 28 
RRV Pool B - - 26.2 (3.6) - 25 
CHIKV Pool 1  - - - - 40 
CHIKV Pool 2 - - - - 40 
CHIKV Pool 3 - 9.9 (0.4) - - 30 
 
(-) indicates S/B (sample-to-background) ratio <2. Samples were run in triplicate and the S/B ratio 
of each replicate was calculated by dividing the MFI of the sample by the MFI of the negative 
control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard 
deviation) 
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Following Trizol extraction, all pools spiked with CHIKV and/or RRV-positive mosquito bodies 
were detected on both the TaqMan or suspension microarray with the exception of two pools 
(CHIKV pools 1 and 2) which were negative on both RNA detection platforms. Given the  heads of 
the mosquitoes used to spike these two pools were positive by TaqMan, it is unlikely that the 
corresponding bodies would be truly negative, based on the knowledge that virus replicates in the 
midgut prior to dissemination to the salivary glands in the head (van den Hurk et al., 2010).  In an 
attempt to determine if low viral load in the samples may have contributed to the negative results, 
comparison of TaqMan Ct values for the respective mosquito head extracts were compared with 
those of the positive and negative pools. The Ct values for the head extracts corresponding with the 
positive pools were found to be in the range of 18-22, whilst higher Ct values of 23 and 29 were 
obtained for the respective negative pools. Therefore, it is possible lower viral loads in Pools 1 and 
2 resulted in a failure to detect the virus by assay.  Future studies will be required to further 
investigate these issues and are outlined in the discussion section. However, the suspension 
microarray has shown the capability to detect a single virus-positive mosquito spiked in a pool of 99 
mosquitoes and similar findings were obtained from the flavivirus suspension microarray. Whilst 
additional work is required to optimise and validate the microarray method and determine the limit 
of detection for the assay, this data demonstrates it is potentially applicable to field surveillance of 
viruses from mosquito pools.  
 
2.3.5.3 Detection of mosquito pools spiked with multiple viruses 
Finally, the ability of the alphavirus suspension microarray to detect and correctly identify a pool of 
mosquitoes concurrently spiked with both endemic and exotic alphaviruses was tested.  A single 
RRV-positive mosquito and CHIKV-positive mosquito were spiked into a pool of 98 mosquitoes 
and again extracted using the Trizol method.  The pools were tested following either one or two 
rounds of amplification (Table 2.11).  
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Table 2.11: Detection of multiple alphaviruses (CHIKV and RRV) in a mosquito pool  
Amplification 
Strategy 
Mean S/B ratio of probe (SD) TaqMan 
(Ct) 
 BFV CHIKV RRV SINV  
One Round of 
Amplification 
- 4.0 (0.8) 9.3 (0.8) - CHIKV 29 
RRV 25 
N/A Two Rounds of 
Amplification 
-   16.6 (1.5) 19.9 (3.9)  - 
 
(N/A) indicates Not Applicable; (-) indicates S/B (sample-to-background) ratio <2. Samples were run 
in triplicate and the S/B ratio of each replicate was calculated by dividing the MFI of the sample by 
the MFI of the negative control.  The mean of these replicate values is the mean S/B ratio of the 
probe (±standard deviation) 
 
The suspension microarray was capable of accurately detecting a mosquito pool spiked with two 
different viruses.  The result again shows concordance with the TaqMan assay.  Two rounds of 
amplification did produce a stronger signal but one round was sufficient to detect both viruses.  
 
2.4 Discussion 
This study aimed to develop a Luminex based multiplex suspension microarray for the detection of 
alphaviruses of public health importance to Australia. The assay was also investigated for its ability 
to be used for vector surveillance purposes. 
2.4.1 Probe design 
In this study we decided to use previously validated consensus primers that target the nsP1 region of 
the alphavirus genome.  This is a highly conserved region of the alphavirus genome for which 
degenerate genus-specific primers have previously been published and validated (Pfeffer et al., 
1997). These primers are regularly used in our laboratory and continue to be useful tools for the 
detection of the alphaviruses internationally (Calzolari et al., 2010, Auguste et al., 2010). These 
consensus primers have also been validated for use in formats other than traditional RT-PCR, such 
as an RT-PCR-Enzyme-Linked Immunosorbent Assay, and were found to be sensitive for the 
detection of all important alphavirus human pathogens in the New World (Wang et al., 2006).   A 
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key advantage of using consensus primers is to eliminate the need to perform a multiplex PCR, 
which is reported to decrease assay sensitivity (Diaz et al., 2006); as well as reducing reagent costs 
and potential primer and probe interactions. By targeting a conserved region of the genome, an 
assay is also less vulnerable to sequence variations and point mutations (Pabbaraju et al., 2009). We 
were able to confirm by gel electrophoresis that these primers were capable of amplifying all 
alphaviruses on our panel.   
 
To develop the alphavirus suspension microarray, probes were designed for the nsP1 region of the 
genome.  Every effort was made during the design phase to ensure the annealing temperatures of 
the probes were similar, so that the hybridisation temperature required for the multiplex assay 
would be consistent. Probe design for the alphavirus suspension microarray proved more difficult 
than for the flavivirus suspension microarray, where many of the probes produced appropriate 
signal on the first design attempt.   For the alphavirus suspension microarray, only the BFV and 
CHIKV probes produced adequate signal on the first design attempt.  The probes for GETV, RRV 
and SINV were redesigned several times, as they produced low or no signal in the suspension 
microarray.  Two unsuccessful attempts were made to design a probe for GETV.  Inclusion of a 
probe specific for GETV probe was desirable in our alphavirus assay, as our understanding of the 
public health significance of this virus in Australia is limited.  However, design of the RRV and 
SINV probes was prioritised for initial attention and was successful on the third attempt.  Other 
studies have also found that a trial and error approach to probe design is required and that probes do 
require redesign despite care taken in the design process (Diaz et al., 2006, Ros-Garcia et al., 2012).   
 
Overall, the proportion of probes designed that did produce a signal in the alphavirus suspension 
assay was much lower than for the flavivirus assay (see following chapters).  It may be because the 
amplicon size in the alphavirus assay is only 400bp compared to the 600-800bp amplicon used in 
the flavivirus assay.  Previously developed suspension microarrays have used amplicons of 
approximately 400bp (Ros-Garcia et al., 2012, Kuriakose et al., 2012).  However, there is no 
general agreement in the literature on the optimal amplicon length for amplification. Several studies 
have shown that 700bp amplicons yield superior results to smaller amplicon sizes (Diaz & Fell, 
2004, Spiro et al., 2000). We found the small amplicon size of 400bp made it difficult to meet other 
criteria previously discussed as important for probe design; such as targeting the 3’region of the 
amplicon and avoiding secondary structures (Diaz & Fell, 2004, Page & Kurtzman, 2005).  
However, there may be factors other than amplicon size, such as the efficiency of PCR 
amplification, that contribute to optimising the signal produced in a suspension microarray.  
Sequencing was used to investigate the difficulty of designing a probe for the SINV, but probe 
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mismatch did not prove to be the issue.   Regardless of the difficulties encountered, we were 
eventually able to successfully design four virus-specific probes for the alphaviruses of greatest 
public importance for our assay.  
 
Inclusion of a universal alphavirus probe in the suspension array was highly desirable for several 
reasons.  A universal probe can act as an internal positive control or potentially detect viruses for 
which no specific probe was included, for example GETV. Additionally, a universal probe may also 
overcome any issues encountered if a point mutation occurs in the region targeted by the virus-
specific probe. Universal probes that target conserved regions of genome have been successfully 
incorporated into published suspension microarrays (Page & Kurtzman, 2005). We attempted 
several different approaches to design an alphavirus universal probe.  Initially, it was hoped the 
published second round universal primer sequence M2W2, that targets the region amplified by 
M2W/cM3W region would be suitable.  However, it was found to produce no signal and did not 
meet the ideal design parameters for a suspension microarray, as it was not designed specifically for 
this purpose.  Several other universal probes were also designed based on alignments made with the 
program ClustalX (Thompson, et al., 1997). The ClustalX alignments of the relevant sequences 
available in GenBank were used to identify regions of consensus and then evaluated using the 
program Primer Express to meet the design requirements of a probe.  This included incorporating 
redundancies where a universal region of consensus was not found.  Few appropriate sequences 
were identified due to the small size of the amplicon, the probe design requirements and the 
diversity of the alphavirus genome in the amplified region.  Two universal probes were tested, but 
neither passed preliminary validation.   Designing a suitable universal probe should be considered 
for future studies, but may prove impossible to achieve using the design parameters set and the 
amplified region selected. Although we were not able to include a universal probe, a synthetic probe 
was successfully designed, and this acted as a positive control.   
 
2.4.2 Protocol optimisation 
Various methods are described in the literature for the optimisation of suspension microarrays; with 
no one method universally adopted.  Therefore, some of the published methods were investigated at 
the outset of this project, to develop an optimised protocol for the detection of alphaviruses.  
Specifically, we aimed to establish whether the optimisation conditions for the alphavirus 
suspension microarray would be similar to that for the flavivirus suspension microarray, with the 
aim of exploring the potential to multiplex the assays at a later date.   
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Both symmetrical and asymmetrical PCR have been studied as a means of optimising suspension 
microarrays. Symmetrical PCR produces double-stranded DNA (dsDNA), while asymmetrical PCR 
favours the production of single-stranded DNA (ssDNA).  Some studies have found only marginal 
benefits to the use of asymmetrical PCR over conventional symmetrical PCR (Yu et al., 2011).  
However, the majority of studies have found asymmetrical PCR to improve signal strength (Lin et 
al., 2011, Deregt et al., 2006b, Das et al., 2006, Spiro et al., 2000).  We also found that asymmetric 
PCR, using a higher ratio of labelled primer to unlabelled primer, improved the strength of the 
probe signal. In some cases, the signal from products generated by symmetrical PCR was similar to 
that from negative control reactions, as has previously been reported by Deregt et al., (2006b). 
These results concur with those reported for the flavivirus suspension microarray in the following 
chapters.   The difference in results between the two amplification strategies has several 
explanations. Asymmetrical PCR increases the yield of labelled PCR product, resulting in higher 
MFI signals (Lin et al., 2011).  Single-stranded DNA also hybridises more efficiently than dsDNA 
(Spiro et al., 2000); and dsDNA may anneal to each other rather than the probe (Deregt et al., 
2006b). Therefore, we decided to adopt an asymmetrical amplification strategy for our alphavirus 
and flavivirus suspension microarrays.  
 
More than one method can be used to generate asymmetrical PCR for use in suspension 
microarrays.  Most studies have used an increased ratio of labelled reverse primer to forward primer 
to generate ssDNA.  However, other studies have used exonuclease to digest one of the amplicon 
strands (Spiro et al., 2000, LeBlanc et al., 2010). Asymmetric PCR has also been used successfully 
in chip microarray assays and has been shown to increase the sensitivity of amplicon hybridization 
without affecting specificity or reproducibility (Wei et al., 2004, Lodes et al., 2007).  In this study 
we attempted for the first time the adaptation of a three-step amplification strategy, adopted from 
Combimatrix chip microarrays, to the suspension microarray format (Lodes et al., 2007).  This 
method was compared to asymmetrical amplification using a higher ratio of labelled primer.  
Although both amplification strategies performed similarly with respect to sensitivity, we opted to 
use the Combimatrix strategy as it produced a slightly stronger signal and reduced the amount of 
expensive, labelled primer required.  This decreased both the cost and the potential for probe/primer 
interaction.  This is the first reported use of this amplification strategy in association with a 
suspension microarray and would allow samples that test positive on the suspension microarray to 
then be used directly on genotyping chip microarrays, such as the Combimatrix. 
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To optimise the suspension microarray we also investigated the concentrations of probes and 
reagents, as some studies have shown these can significantly affect results.  According to 
manufacturer recommendations we titrated the amount of probe coupled from 0.2 to 0.4nmol per 
coupling reaction.  We found the optimal amount of probe for each bead coupling reaction was 
0.4nmol for the BFV probe and 0.2nmol for the other alphavirus probes (RRV, CHIK, and SINV).  
This concurred with a previous study that showed a significant improvement of up to 75% by 
increasing the concentration of probe used for bead coupling for some probes; but noted conversely 
too much probe can result in overconjugation of the bead and steric hindrance preventing 
hybridization (Diaz & Fell, 2004).  Another reagent which was investigated was TMAC buffer, 
which is used to help stabilise AT and CG base pair stability and minimise the differences in 
melting temperature between probes (Das et al., 2006, Wilson et al., 2005).  One study found that a 
3 or 4M TMAC solution enhanced results (Diaz & Fell, 2004). However, most studies use a 1.5M 
TMAC solution; and we also found this concentration optimal on comparison with higher 
concentrations.  Likewise we followed the manufacturers’ instructions and titrated the MgSO4 
concentration to optimise PCR and found a concentration of 2mM yielded the best results.  We also 
titrated the conjugate and found a dilution of 1:100 maximised the sample to background signal 
ratio and also minimised expense.  Thus we were able to effectively use titration to determine the 
important parameters for the suspension microarray. 
 
Another key point of difference between methods used in previously developed suspension 
microarrays is the inclusion of a wash step in the protocol and the way the data is anlysed.  Some 
studies have found that it is necessary to include a wash step to reduce non-specific background 
signal (Wilson et al., 2005).  Others have eliminated the wash steps recommended by the 
manufacturer (Deregt et al., 2006b).  We investigated two different wash methods to determine the 
best, and compared it to a no-wash method.  We found the elimination of the wash step from the 
protocol was advantageous for a number of reasons including the production of a higher signal, 
reduced risk of contamination and a reduction in labour which would also lead to cost savings. 
Deregt et al. (Deregt et al., 2006b) also reported removal of the wash step due to problems 
encountered with the filter plate leaking.  With respect to data analysis, we adopted the widely used 
definition of a positive sample as one with a signal twice that of the background signal.  The 
reasons for this decision are discussed further in Chapter 3. 
 
Finally, a variety of internal controls can be used in a suspension microarray.  In this microarray, we 
decided to incorporate a synthetic positive control as this eliminates the potential for false positives. 
This was a novel concept at the time the study commenced; however, more recently another study 
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has also reported the use of a synthetic probe (Ros-Garcia et al., 2012).  Although the methods are 
not identical, the use of a synthetic control serves the same purpose of acting as an amplification 
control, to confirm effective PCR, avoid false negatives and eliminate the need to test products by 
gel electrophoresis.   The synthetic control also acts as a positive control for the reagents of the 
suspension microarray, and the signal produced should be consistent between runs.  If the synthetic 
control failed, the sample should be re-run to determine the nature of the problem.  The synthetic 
control could be spiked into each sample; but we opted instead to run a synthetic control from each 
amplification experiment in an individual well.  Although this approach does not control for the 
difference in efficiency or the presence of inhibitors in the samples, the utilisation of a synthetic control 
in an individual well reduces labour and eliminates the possibility of contamination due to positive 
control material. Negative controls were also incorporated in each run.  These included a TE buffer 
blank; as well as the negative amplification control which used water blank as template. These 
controls ensured freedom from contamination of either the reagents or PCR. 
2.4.3 Specificity, sensitivity and validation 
The suspension microarray proved specific, with the alphavirus probes for BFV, CHIKV, RRV and 
SINV showing no cross-reactivity when tested against the panel of alphaviruses.  During 
preliminary validation, ninety-one percent of the samples were detected with just one round of 
amplification, while 100% of the samples were detected with two rounds of amplification.  The 
signal for the BFV probe increased almost five-fold following two rounds of amplification.  This 
may suggest less efficient amplification of BFV by the primers or a low viral load in the sample.  
This would appear to be confirmed by the fact that no band was visible on gel electrophoresis.  As 
the signal improved after two-rounds of amplification, a probe mismatch or steric hindrance to 
binding are less likely explanations.  Similar results were also seen for the CHIKV strain 
Malaysia08, which was initially undetected following one round of amplification.  
 
These results, given the high level of specificity, were considered satisfactory to warrant 
continuation with the next phase of validation, as it is not uncommon for a broad-ranging assay 
targeting multiple pathogens to have sensitivities that vary considerably between species.  For 
example, a Sybr-Green RT-PCR developed for the detection of  flaviviruses had a limit of detection 
that varied from 2  to 20,500 copies/reaction depending upon the virus tested (Moureau et al., 
2007); while a suspension microarray for pathogen screening in meningitis had a limit of detection 
from 23 to 5,998 genomes/mL (Boving et al., 2009).  Both these assays were considered to have 
potential diagnostic application and showed the ability to detect a variety of samples during 
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validation. Although the alphavirus suspension microarray also showed similar variability in 
sensitivity between the alphavirus species, it is expected that the sensitivity will still be adequate to 
be of diagnostic value, especially given that alphaviruses can reach higher titres in mosquitoes than 
flaviviruses (Nasci and Mitchell, 1996).  It is anticipated that even though the sensitivity is lower 
than what may be achieved with some uniplex real-time techniques, it may be adequate to improve 
surveillance for these viruses overall by increasing the frequency for which these viruses are 
included in the diagnostic work-up.  However, further validation will be required to confirm this.      
 
The ability to multiplex probes with minimal loss of sensitivity is one of the key advantages of 
suspension microarrays.  We compared the sensitivity of the alphavirus suspension microarray 
when the same samples were tested in either a 1-plex or 4-plex assay.  Although the signal was 
slightly higher in the uniplex suspension microarray, the limit of detection was the same when the 
probes were multiplexed. Therefore, it was possible to have the advantages of a multiplex 
suspension microarray without adversely affecting results.  This is in agreement with other 
published studies (Diaz & Fell, 2004, Diaz et al., 2006, Kuriakose et al., 2012). 
 
As discussed previously, there has been great variation in the literature regarding the amplification 
method adopted for suspension microarrays.  Viruses from the validation panel were tested to 
determine their limit of sensitivity using several amplification strategies to generate single-stranded 
DNA, including a novel three-step strategy that has previously only been used for chip microarrays.  
In the initial evaluation, this strategy was found to produce higher signal than the strategy using a 
higher reverse primer ratio. This was investigated further to determine whether the new 
amplification strategy improved the sensitivity of the alphavirus suspension microarray.  Although 
the limit of detection was the same for all amplification strategies tested, the highest signal was 
produced by using the modified primer M13-cM3W with the three stage PCR reaction for the 
second round of amplification. This strategy was used for all further test validation.  The strategy 
utilised the modified reverse primer, M13-cM3W, which had a higher melting temperature than the 
forward primer, so that a higher hybridisation temperature during the third stage of the PCR 
reaction favoured the production of single-stranded, biotinylated DNA. As discussed previously, 
this method has the key advantage of reduced costs and the potential to allow a positive sample to 
then be tested directly on chip-array for further genotyping or phylogenetic studies.  To our 
knowledge, this is the first time that this protocol has been used in association with suspension 
microarrays, but we believe it has many advantages and adopted it for use in our assay. 
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Comparison of the alphavirus suspension microarray with the current molecular assays in use in our 
laboratory, gel electrophoresis and TaqMan assay, was critical to determine its usefulness. A ten-
fold dilution panel of cell culture derived virus samples were tested in parallel on all three assays. 
The suspension microarray was found to be more sensitive than one round of PCR followed by gel 
electrophoresis for all samples.  When compared with the TaqMan assays, the alphavirus 
suspension microarray was as sensitive for the detection of RRV and SINV, but not as sensitive as 
the TaqMan for the detection of BFV and CHIKV.  However, it is to be noted that the suspension 
microarray was multiplex while the TaqMan assays were run individually.  Although it is possible 
to multiplex TaqMan assays for up to 4 targets, this is known to cause a loss of sensitivity.  
Therefore, these results were considered promising as the sensitivity was the same for half of the 
panel, and the advantages of multiplexing can outweigh loss of sensitivity in some diagnostic 
situations. For example, the assay may be a useful tool for mosquito surveillance where running a 
multiplex test at a lower cost may enable improved capabilities to screen larger numbers of 
mosquitoes with limited funding. This would offer a better surveillance capability. 
 
The focus of the studies on the spiked mosquito pools was to demonstrate proof of concept, and 
future studies will be required to determine the detection limit of the assay for this purpose. There 
are several options to achieve this and enable comparison with the current gold standard tests.   
Comparison of the suspension microarray with the gold standard plaque forming or TCID50 assays 
for live virus detection or TaqMan for RNA detection could be conducted in the same manner to the 
other sensitivity studies described in this thesis.  A spiked pool of mosquitoes could be generated by 
including one virus-positive mosquito in a pool of known size.  Serial dilutions could then be 
generated and the aliquots tested by plaque forming assay, suspension microarray and TaqMan.  
Alternatively, positive mosquito pools could be created by using serial dilutions of stock virus in 
the medium used to grind the mosquitoes, as has been described previously (Sutherland and Nasci, 
2007);  or serial dilutions of RNA extracted from one virus-positive mosquito could be added to 
mosquito pools, as described by Grubaugh et al. (Grubaugh et al., 2013).  Serially diluted in vitro 
RNA transcript product has also been used to examine the effect of pooling on assay sensitivity in 
serum and blood swab samples (Rovira et al., 2007), and could be adopted for mosquito pools.  All 
these studies have used the aliquots of known viral concentration from the serial dilution series to 
generate standard curves by TaqMan, which can be used to extrapolate the viral concentration of 
pooled samples.  However, there are many factors that can influence detection limits in mosquito 
pools, including virus strain, mosquito species and their vectorial capacity for the virus (Nasci and 
Mitchell, 1996), the probability that a single aliquot taken from a pooled sample will contain virions 
(Vitek et al., 2009) and also degradation of the sample due to environmental exposure prior to 
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collection and subsequent transport and handling procedures.  Nonetheless, the use of pooled 
mosquito specimens is a widely adopted and successful method of arbovirus surveillance and pools 
of 50 to 100 mosquitoes are commonly utilised (Chisenhall et al., 2007, White, 2001).  
 
Finally, of critical concern with any diagnostic assay is its repeatability and reproducibility.  A key 
advantage of the suspension microarray technology is that the reported signal for any sample is 
based on the analysis of 100 beads, making it statistically robust.  During validation, all samples 
were run in triplicate on the suspension microarray and the standard error between results was 
determined.  All samples consistently returned the same diagnostic result and the standard error was 
low.  This is similar to previous studies, which have reported the suspension microarray to have 
excellent repeatability and reproducibility (Schmitt et al., 2006, Kuriakose et al., 2012).  
Reproducibility was evaluated by running the samples from the mosquito pools in triplicate, on the 
assay twice on different days. Again, the results from both runs produced consistent results. 
Although we have not had the opportunity to test this reproducibility between laboratories, this 
would be the next step in evaluation. However, the ease of the laboratory protocol and the use of a 
median signal, based on analysis of 100 beads, all contribute to a robust assay with advantages with 
respect to statistical analysis over a chip microarray (Diaz et al., 2006). 
2.4.4 Application of the alphavirus suspension microarray to mosquito 
surveillance  
One of the current areas identified for improvement in diagnostic services is the provision of a low-
cost, quick diagnostic test for mosquito screening.  The alphavirus suspension microarray was 
evaluated for this purpose.  We found the multiplex suspension microarray capable of detecting 
94% of individual virus-positive mosquitoes compared to the TaqMan assays; with 100% 
specificity.  The BFV probe was the least sensitive and may require refinement or redesign upon 
further validation.  However, the sensitivity of the suspension microarray for individual CHIKV and 
RRV positive mosquitoes was 100% compared to the TaqMan assays and these two viruses are 
arguably the most important clinically. 
 
This study is the first we are aware of to investigate the ability of suspension microarray technology 
to screen mosquito pools for arboviruses.  However, although the preliminary experiments on 
individual virus-positive mosquitoes were promising; the suspension microarray was unable to 
detect mosquito pools spiked with a single CHIKV-positive mosquito body in the initial experiment 
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involving three pools.   To investigate further, an alternative extraction technique routinely used in 
our laboratory for the extraction of mosquitoes was adopted.  This extraction method utilised Trizol 
extraction and the RNeasy mini-kit, and is widely used in the literature for the extraction of 
mosquito samples and pools (Eshoo et al., 2007, Calzolari et al., 2012, Pinto et al., 2013). During 
sample homogenisation, Trizol maintains the integrity of RNA, while disrupting cells and 
dissolving cell components; producing both a high quality and yield of RNA (Chomcynski and 
Sacchi, 1987). Trizol extraction of mosquito samples prior to analysis by TaqMan became a routine 
procedure during some experiments conducted in the QHFSS laboratory during the course of this 
project (Moreira et al., 2009). A review of the literature suggested it was a preferred extraction 
method to optimise the yield of viral RNA from the sample. An additional 6 pools spiked with a 
single virus-infected mosquito body were extracted with this technique and tested in parallel on 
both assays.  Following Trizol extraction, there was concurrence between the TaqMan and 
suspension microarray assays, with four pools, including one co-infected with both RRV and 
CHIKV, positive on both assays.   
 
Many factors affect the ability to detect virus-positive mosquito pools (Vitek et al., 2009).  It is 
possible that factors such as extraction method, viral load of the sample, sampling error or storage 
of the CHIKV positive mosquitoes at -20°C rather than -80°C for the previous 12 months 
contributed to an inability of the assays to detect the virus in two of the spiked pools.  Further 
studies on the sensitivity of the assays for detection of alphavirus-positive mosquito pools, as 
discussed in Section 2.4.3, will be required to investigate these issues. However, additional studies 
using flavivirus-positive mosquito pools were conducted and these also showed that the suspension 
microarray was capable of detecting virus in mosquito pools spiked with a single virus-infected 
mosquito.  Although this only represents a small sample size and further validation, preferably run 
in parallel with routine processing of field samples is required, it does suggest that the new 
suspension microarray has potential for use in the screening of mosquito pools for surveillance 
purposes and that further research and development is warranted. 
 
One of the most important findings with the increased use of multiplex suspension microarrays has 
been the reporting of concurrent infections.  Frequently, laboratory analysis stops with the detection 
of the first relevant pathogen detected in the samples. However, dual or co-infections have been 
regularly reported with the use of suspension microarrays, allowing a better understanding of 
clinical disease presentations (Brunstein & Thomas, 2006, Page et al., 2006, Mahony et al., 2007, 
Bandyopadhyay et al., 2007, Wallace et al., 2005).  The alphavirus suspension microarray was 
capable of accurately detecting a mosquito pool spiked with two different alphaviruses, CHIKV and 
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RRV. This capacity is important as it is possible for alphaviruses to circulate concurrently, even in 
an outbreak situation.  The result again showed concordance with the TaqMan assay; however, 
demonstrated the advantages of a multiplex assay.  It is possible that testing in our laboratory in a 
routine situation would have ceased with the detection of one or other virus due to cost and time 
constraints. Blood cultures have recently been proven to be inefficient in the detection of 
polymicrobial bacteremia (Lin et al., 2008), and the same may apply for the culture of viruses.  Two 
rounds of amplification did produce a stronger signal in the suspension microarray, but one round 
was sufficient to detect both RRV and CHIKV in the mosquito pool of 100.  This result needs 
further replication, but as a proof of concept, demonstrates the advantages with respect to time and 
labour of using a multiplex assay compared to uniplex assays for surveillance.  This ability to detect 
concurrent infections could be further extended by the inclusion of additional probes in the panel 
for the detection of other arboviruses. 
 
The alphavirus suspension microarray may also prove compatible with new and emerging 
diagnostic tools.  Recent developments in mosquito-based arbovirus surveillance have shown sugar-
baited nucleic preservation acid cards to be a viable alternative for virus detection, rather than 
mosquito pools (Lothrop et al., 2012, van den Hurk et al., 2012).  This new method may also prove 
compatible with suspension microarray technology, and the use of the assay to detect virus in sugar-
baited nucleic preservation acid could be investigated as a means to further reduce the costs 
associated with mosquito-based surveillance. 
2.5 Conclusion 
A multiplex, suspension microarray for the detection of the alphaviruses BFV, RRV, CHIK, and 
SINV was designed and evaluated. The assay uses a novel amplification strategy and synthetic 
control to other previously published suspension microarrays.  This study is the first to explore the 
utility of suspension microarray technology for mosquito surveillance.  The assay shows promise to 
be further utilised for the surveillance of viruses in mosquitoes; and should also be evaluated for 
clinical use. 
 
Future work could extend to the expansion of the panel to include the exotic alphaviruses Western 
equine encephalomyelitis virus (WEEV), Eastern equine encephalomyelitis virus (EEEV) and 
Venezuelan equine encephalomyelitis (VEEV) virus. Alternatively, an equine panel of viruses 
could be developed for testing horses that could include the alphaviruses RRV, GETV, WEEV, 
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EEEV, VEEV; the flaviviruses, Kunjin and Murray Valley Encephalitis viruses and possibly the 
paramyxovirus Hendra virus. 
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Chapter 3: Development of Suspension 
Microarrays for the Diagnosis of 
Mosquito-borne Flavivirus Encephalitis 
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3.1 Introduction 
Encephalitis is a life-threatening condition which can cause mild or severe neurological sequelae 
and may result in death of the patient.  The cause of encephalitis is frequently not identified but it 
can be caused by a number of different viruses, none of which can be distinguished clinically.  
Flaviviruses such as Japanese encephalitis virus (JEV), Murray Valley encephalitis (MVEV) and 
the Kunjin strain of West Nile virus (KUNV) are among the most important causes of viral 
encephalitis in the Australasian region. 
 
Currently, JEV and strains of WNV other than KUNV are exotic to Australia, although there has 
been an increase in the activity and territory of both these viruses in the past decade.  JEV is 
widespread throughout South East Asia where there is an estimated 30,000-50,000 cases/year and 
10,000 deaths documented annually (Solomon, 2003). WNV has undergone an explosive expansion 
in range with a concurrent increase in morbidity and mortality.  In 2002 and 2003 the virus was 
responsible for two of the largest arboviral epidemics ever observed and has now become endemic 
in large areas of the Western Hemisphere (Ayers et al., 2006).  KUNV is a strain of WNV and has 
been isolated from cases of encephalitis in Western Australia and the Northern Territory (Ayers et 
al., 2006, Gray et al., 2011).  The fact that several species of mosquitoes in Australia have been 
shown to be competent vectors of WNV, and may share the same hosts as KUNV, means that there 
is also a risk that WNV could become established if introduced into urban areas of Australia (Jansen 
et al., 2008).  If this happens it is likely to result in higher morbidity and mortality than the current 
circulating KUNV, as the WNV NY99 strain has been associated with large epidemics of 
encephalitis in both Europe and North America with a case rate of 5-15% mortality (Solomon, 
2004).  Therefore, diagnostic tests capable of detecting and distinguishing the exotic viruses, along 
with the endemic MVEV and KUNV; are important from a public health perspective. 
 
Both MVEV and KUNV are known to cause encephalitis in Australia and can result in mixed 
outbreaks (Hall et al., 2002).  Murray valley encephalitis is particularly serious, with a case fatality 
rate of 20-30% and severe neurological sequelae in 50% of survivors (Burrow et al., 1998, Gray et 
al., 2011). However, the incidence of non-encephalitic illness due to both MVEV and KUNV is 
thought to be under-estimated due to a failure of sample submission (Gray et al., 2011, Solomon, 
2004).  Other factors, such as the shared geographical distribution and ensuing issues with cross-
reactivity in diagnostic tests means the clinical significance of KUNV is still incompletely 
understood.   Expanding current surveillance programs to routinely incorporate these viruses would 
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expand our understanding of the geographic range, concurrent activity and clinical significance of 
these viruses.   
 
As there is no specific treatment for encephalitic disease, prevention remains the most important 
strategy for averting disease.  Surveillance plays a critical component of this and allows warnings of 
increased risk to be issued to communities (Broom et al., 2001).  However, in economic terms the 
cost of surveillance systems must be weighed against the cost of preventing human disease or 
allowing the establishment of exotic viruses. Development of PCR based assays for the detection of 
arboviruses in pools of mosquitoes was identified as a key priority for more timely and cost 
effective surveillance (Spencer et al., 2001).  Multiplex tests offer the capacity to test a sample for 
several different pathogens simultaneously, decreasing costs associated with labour and reagents.  
This study aimed to develop a multiplexed diagnostic test capable of differentially diagnosing these 
viruses.   
 
Due to the public health importance of these viruses, active surveillance and laboratory testing are 
increasingly important. Diagnostic tests for these viruses include virus isolation, serology, reverse 
transcription polymerse chain reaction (RT-PCR), real-time PCR and chip microarrays. The 
limitations of these methods include turn-around time, cost, cross-reactivity, multiplexing 
capabilities and sensitivity.  In particular, the TaqMan real-time PCR is reported to be highly 
sensitive and specific but the limit of its multiplexing capabilities is four agents and multiplexing  
may result in a clinical loss of sensitivity (Lanciotti, 2003, Wilson et al., 2005, Mothershed & 
Whitney, 2006). The cost is also prohibitive in many laboratories and the assays have not been 
widely adopted in reference laboratories world-wide (Swami et al., 2008, Domingo et al., 2011). 
Alternatively suspension microarrays have been shown to be cost-effective and sensitive when 
multiplexed.  TaqMan real-time PCR tests have been successfully converted to suspension 
microarrays (Wilson et al., 2005).  The goal of this paper was to determine whether previously 
published and validated assays for the JEV, KUNV, MVEV & WNV could be adapted for use in a 
suspension microarray. 
 
Previous studies have developed molecular diagnostic tests capable of targeting multiple 
flaviviruses that may cause encephalitis (Pyke et al., 2004, Ayers et al., 2006, Boriskin et al., 2004).    
These molecular tests can generally produce a result in a much shorter time frame than the gold-
standard test, virus isolation. However, a suspension microarray, molecular-based approach has not 
previously been described.  This technology has been used for the detection of several different 
viral pathogen panels and offers several advantages (Dias et al., 2005, Deregt et al., 2006b).    
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Unlike real-time PCR, multiplexing is not reported to reduce the sensitivity of the assay and it is 
possible to multiplex for up to 100 different probes.  The robustness of the suspension microarray 
can also be increased by the addition of more than one probe for each virus.  This reduces possible 
issues due to strain variation and mismatches, a common cause of false negative results in 
molecular assays and potential downfall of highly specific TaqMan assays.  In comparison to chip 
microarray technology, however, the cost and expertise required for suspension microarrays are 
substantially lower (Wilson et al., 2005). Additionally, while TaqMan RT-PCR has proved to be 
more sensitive than traditional RT-PCR, it is not economic in developing countries and needs a 
special thermocycler (Swami et al., 2008). For these reasons, a suspension microarray approach has 
been selected for the development and evaluation in the detection of encephalitic viruses of concern 
in the Australasian region. 
 
3.2 Materials and Methods 
3.2.1 Viruses 
The virus strains used for the preliminary development of the encephalitic microsphere microarray 
are listed in Table 3.1. All viruses were propagated in porcine stable equine kidney (PSEK) cell 
lines. The examined strains were obtained from Queensland Health Forensic and Scientific Services 
(QHFSS), Brisbane, Australia and the University of Queensland, Brisbane, Australia.  The 
exception was the NY-99 (4132) strain of WNV, originally isolated from the brain of an American 
crow during the 1999 New York outbreak, which was obtained from the Division of Vector-Borne 
Infectious Diseases, Centers for Disease Control, Fort Collins, USA. 
 
3.2.2 Virus positive mosquitoes 
Virus positive mosquitoes from published vector-competence studies were used to validate the 
suspension microarray and the methods used to infect the viruses have been previously described 
(Johnson, 2009, Jansen et al., 2008).  All experiments were conducted in a physical containment 
level 3 (PC3) insectary located at QHFSS.  These samples included Culex gelidus infected with JEV 
strain TS00 or KUNV strain 2002-1412; and Culex annulirostris infected with the NY-99 (4132) 
strain of WNV.   Briefly, mosquitoes were fed on stock virus diluted in washed, defibrinated sheep 
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blood and 1% sucrose via either pledgets or an artificial membrane apparatus.  Following feeding, 
mosquitoes were briefly anaesthetised with CO2 gas and those which had blood-fed were selected 
and placed in an environmental growth chamber.  Mosquitoes were maintained on 10% sucrose 
solution post-infection at 28°C and 75% relative humidity.  The incubation period varied from 11 to 
15 days, according to the virus, before the mosquitoes were killed with CO2 gas.  Individual 
mosquitoes were placed in separate tubes containing 1mL growth media (GM) containing 3% FBS 
and three sterile glass beads.  The samples were stored at -80°C.   
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Table 3.1: Virus strains used for development of the encephalitic suspension microarray 
Virus Strain Year, Location 
 
 
 
 
 
 
  
JEV M96  
Unknown 
JEV PNG6544 
1998, Papua New Guinea 
JEV FU1028 
2000, Torres Strait 
JEV TS6516 
Unknown 
JEV SA14 
1960, China 
JEV Mabuig 2576 
1998, Torres Strait 
JEV BI146 
2001, Badu Island 
JEV Nakayama  
1935, Japan 
MVEV MRM66 
1959, Mitchell River Mission, Australia 
MVEV MV02  
2002, unknown 
MVEV 341/2001 
2001, Mt Isa, Australia 
MVEV 326/2001 
2001, Mt Isa, Australia 
MVEV OR156 
1973, Western Australia 
MVEV MVEV15109 
1972, Mitchell River Mission, Australia 
MVEV MVEV16219 
1974, Charleville, Australia 
MVEV MK6884 
1966, Papua New Guinea 
MVEV PNG156 
1956, Papua New Guinea 
KUNV Sarawak 
1966,  Borneo 
KUNV CX288 
1982, Kimberley, Australia 
KUNV HU6744 
1991, New South Wales, Australia 
KUNV K1738 
1989, Ord River, Australia 
KUNV MRM16 
1960, Mitchell River Mission, Australia 
KUNV Boort 
1984, Victoria, Australia 
WNV Wengler (B956) 
1938, Uganda 
WNV Koutango  
1968, Senegal 
WNV NY99 
1999, United States America 
WNV G22886 
1958, India 
WNV MgAr978 
Unknown 
WNV Sarafend  
1974, Israel 
 
 
 76 
3.2.3 RNA extraction 
Viral RNA was extracted from cell culture using the QIAmp® Viral RNA Mini kit (Qiagen, 
Victoria, Australia) according to manufacturer’s instructions. The extracted RNA was diluted 10-
fold in distilled water and stored at -80°C.  Mosquitoes used to validate the suspension microarray 
assay were processed and the RNA extracted as detailed in Chapter 2. The viral RNA was stored at 
-80
o
C. 
3.2.4 Polymerase Chain Reaction (PCR) 
3.2.4.1 Symmetrical PCR 
For RT-PCR a one-step kit SuperScript III with Platinum® Taq (Invitrogen, Victoria, Australia) 
was used according to manufacturer’s instructions.  A 4µL volume of extracted RNA was added to 
each 50µL reaction. Amplification was carried out using previously described universal primers 
EMF and VD8 (Pierre et al., 1994).  Briefly, reverse transcription was carried out at 50°C for 30 
minutes followed by denaturation at 94°C for 2 minutes. The reactions underwent 40 cycles as 
follows: 94°C for 15 seconds, 55°C for 30 seconds and 68°C for 1 minute, with a final extension 
step at 68°C for 5 minutes. 
3.2.4.2 Asymmetrical PCR 
Two different methods were employed to generate asymmetrical PCR product. The first method 
involved including the reverse primer in a concentration eight times greater than the forward 
primer.  In the second method, the reverse primer VD8 was modified (M13-VD8) to increase the 
melting temperature to 65°C and a three stage RT-PCR reaction employed. The variation of the 
forward and reverse primers’ melting temperature allowed additional rounds of amplification to 
occur at a higher temperature, favouring reverse primer extension.   
 
The amplification method varied according to whether one or two rounds of amplification were 
used.  If only one round of amplification was required then the biotinylated, modified reverse 
primer M13-VD8 was used.  The following protocol of cycling times and temperatures was 
employed for the 3 stage RT-PCR reaction: 1 cycle of 50°C for 30 minutes, 1 cycle of 94°C for 2 
minutes; 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds and 68°C for 1 minute; 30 cycles of 
94°C for 30 seconds and 68°C for 1 minute; and finally one cycle of 72°C for 5 minutes. 
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When two rounds of amplification were required, the first round used the primers and method 
described by Pierre et al. (1994), with minor adjustments to the cycling conditions. The following 
protocol of cycling times and temperatures was used: 1 cycle of 50°C for 30 minutes; 1 cycle of 
94°C for 2 minutes; 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds and 68°C for 1 minute; 
and finally one cycle of 68°C for 5 minutes.  For the second round of amplification, 4µL of first 
round product were added to a 50µL reaction containing the biotinylated, modified reverse primer 
m13-VD8.  The three-stage RT-PCR reaction for the second round of amplification used the 
following protocol: 1 cycle of 94°C for 2 minutes; 40 cycles of 94°C for 15 seconds, 55°C for 30 
seconds and 68°C for 1 minute; 30 cycles of 94°C for 30 seconds and 68°C for 1 minute; and 
finally one cycle of 72°C for 5 minutes.  
 
3.2.4.3  Amplification controls, including gel electrophoresis 
Positive and negative controls were included for every amplification experiment.  The positive 
amplification control used synthetic RNA as the template, following minor modifications of the 
method described by Smith et al., (2006) (see Figure 2.2).  The inclusion of synthetic controls 
reduces both the potential for cross-contamination to occur, as well as the health and safety risks 
associated with handling live virus (Smith et al., 2006).    
 
Briefly, for the preparation of synthetic controls, first round primer pairs were chosen using the 
primer design software Primer Express™ Version 2.0.0 (Perkin-Elmer, Applied Biosystems, USA) 
to produce a product of approximately 702 bp in length from pUC18 DNA, a product approximately 
the same size as the amplicons generated for the suspension microarray. The first round primers 
were designed so that the ApaLI containing multiple cloning site of the plasmid would be located 
approximately in the middle of the resulting amplicon to allow later digestion of the product by 
ApaLI digestion. The primers were designed to incorporate the addition of the forward primer 
sequence of the EMF to the 5′ end of a pUC18 specific sequence (5′1869-
GCCGGGAAGCTAGAGTAAGRTAGTTC 
1894
-3′) to produce a primer 47 bp in length.   The VD8 
reverse primer sequence was added to the 5’ end of a pUC18 specific sequence (5’-
2533
TCATGAGCGGATACATATTTGAATG
2558
-3’) in the order 5’-[VD8]-[pUC18 (rev) 
sequence]-3’ to produce a primer of 45 bp in length.  Finally, a probe with similar design 
parameters to those used for the suspension microarray was designed that was complementary to the 
amplified region of pUC18.  This 22bp probe was called Flavi-Synthetic Probe 
AGTTGCTCTTGCCCGGCGTCAA. The pUC18 plasmid used in this study was purchased from 
New England Biolabs, USA.  
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The negative amplification control used the negative extraction control as the sample template.  All 
first round amplified products were separated on a 1.5% agarose gel at 90 volts for 45 minutes and 
viewed by UV transillumination to confirm amplification of positive samples, and lack of 
contamination in negative controls.  The second round amplified products could not be viewed in 
this manner as single-stranded DNA is not visible by this method (Spiro et al., 2000, Deregt et al., 
2006a). 
3.2.5 Sequencing 
RNA was extracted and subjected to RT-PCR analysis using the protocol and primers discussed 
above.  Amplified DNA products were sequenced using Applied Biosystems Big Dye Terminator 
sequencing reagents (Applied Biosystems, Foster City, CA) and an Applied Biosystems Prism 
3130x1 Genetic Analyser (Griffith University Sequencing Facility, Brisbane, Australia).  Sequences 
were then analysed using ChromasPro (Technelysium Pty Ltd, Tewantin, Australia).  
3.2.6 Oligonucleotide probe design 
Probes for JEV, KUNV and WNV previously developed for TaqMan assays met the above 
requirements, targeted the amplified region and were included in the microsphere microarray (Pyke 
et al., 2004, Lanciotti et al., 2000).  Additional probes for the detection of ALFV and MVEV were 
designed using the program Primer Express™ 2.0 (Perkin-Elmer, Applied Biosystems, USA).  The 
target region for the probe was based on the NS5/3’UTR region amplified by the universal primers 
EMF & VD8 (Pierre et al., 1994). The GenBank accession numbers used for probe design were 
AY898809 (ALFV) and AF161266 (MVEV). Probes with a similar length (20-27 nucleotides), GC 
content (40-70%) and melting temperature were selected.  Probes that bound to the middle or 3’end 
of the amplicon were preferentially selected where possible. Probes were excluded that formed 
hairpins or strong secondary structures, or displayed a run of more than three Gs or Cs at the 5’ or 
3’ end. Finally, a NCBI Blast (Altschul et al., 1990) was conducted with the candidate probes to 
ensure they matched as many specific virus strains as possible and showed no indication of cross-
reactivity with other alphaviruses, microorganisms or contaminants.  Additionally, a synthetic 
control probe was designed in a method previously described by Smith, et al., (2006).  These probes 
are listed below in Table 3.2. 
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Table 3.2: Nucleotide sequences of primers and probes used for the encephalitic suspension 
microarray  
Primer or Probe Sequence Size 
EMF
a 
TGGATGACSACKGARGATATG 21 
VD8
a 
GGGTCTCCTCTAACCTCTAG-Biotin 20 
ALFV2 probe CGTCTCGGAATAGGAGTCCCTGCCAAT 27 
JEV TI
b 
probe CGGAACGCGATCCAGGGCAA 20 
KUNV
b
 probe CGATGTTCCATACTCTGGCAAACG  24 
MVEV
 
probe CGCCGCCATCAACCAAGTGAGG 22 
MVEV2 probe TGGAGATGAAGCCCGTGTCAGAT 23 
WNV
c 
probe TCTGCGGAGAGTGCAGTCTGCGAT 24 
Flavi-Synthetic Control probe AGTTGCTCTTGCCCGGCGTCAA 23 
a The EMF and VD8 primers have previously been described by Pierre et al., (1994) 
b 
The JEV TI and KUNV probes have previously been described by Pyke et al.,(2004) 
c 
The WNV probe was previously described by Lanciotti et al., (2000) 
3.2.7 Oligonucleotide probe bead preparation  
Bead coupling of the probes to carboxylated beads was performed according to the manufacturer’s 
guidelines as outlined in Chapter 2. Coupled microspheres are then suspended in 50µL of TE buffer 
(10mM Tris-HCl, 1mM ethylenediamine tetraacetic acid, pH 8.0), enumerated using a 
haemocytometer and stored in the dark at 4°C until use.  To confirm successful bead coupling and 
consistency of results, the same panel of samples were used to validate all coupling reactions, to 
ensure there was no great variation in signal between batches.   
3.2.8 Multiplex encephalitic suspension microarry 
Hybridization of the probes and PCR product was performed according to the manufacturer’s 
guidelines discussed in Chapter 2 A schematic overview is illustrated in Figure 3.1.  The median 
fluorescent intensity (MFI) values of each beadset were calculated by the BioPlex xMap. Each 
sample was analysed in either duplicate or triplicate and a blank and negative control were included 
in each assay. The sample-to-background (S/B) ratio was calculated for each sample by dividing the 
mean MFI of the sample by the mean background fluorescent intensity (BFI) of the negative 
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controls of that run, using a modified protocol from Das et al., (2006). A positive sample was 
defined as a sample with a MFI at least twice the BFI for that bead-probe set.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Overview of the encephalitic suspension microarray 
3.2.9 Analysis of hybridisation results  
The BioPlex xMap system calculated the median fluorescent intensity (MFI) values of each beadset. 
For each beadset in a well, an MFI value was calculated from the signal of at least 100 beads. Raw 
data was exported from the Bio-Plex™ Manager Software 4.0 to Microsoft Excel for analysis. The 
sample-to-background (S/B) ratio was calculated for each sample by dividing the mean MFI of the 
sample by the mean background fluorescent intensity (BFI) of the negative controls of that run, 
using a modified, published protocol (Das et al., 2006). A positive sample was defined as a sample 
with a MFI at least twice the BFI for that bead-probe set, in accordance with previously published 
protocols in the literature  (Lin et al., 2008, Das et al., 2006, Huang et al., 2008, Wilson et al., 2005, 
Kuriakose et al., 2012).   
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3.2.10 TaqMan RT-PCR 
Virus samples were tested in triplicate on the TaqMan RT-PCR assay, following the method 
detailed by Pyke, et al. (Pyke et al., 2004) and Lanciotti et al. (Lanciotti et al., 2000).  Probe and 
primer pairs used are listed Table 3.3.  Amplification and real time detection were performed with 
the ABI Prism 770 sequence detection system (PE Applied Biosystems, USA).  A negative result 
was considered to be a Ct value of 40 or more cycles.  Probe and primer controls and negative 
controls were also included. 
 
In brief, amplification and detection of the flavivirus RNA was conducted in a single tube one-step 
RT-PCR in a final volume of 20µL. Amplification and real time detection were performed with the 
ABI Prism 770 sequence detection system (PE Applied Biosystems, USA).  The reaction mix was 
prepared using the Superscript III Platinum one-step qRT-PCR system (Invitrogen, Carlsbad, CA) 
and contained 0.4 µL Superscript™ III RT/Platinum® Taq mix, 9.5 µL of 2x Reaction Mix, 370nM 
primers, 180nM dual labelled probe, 47nM ROX Reference Dye, and 5 µL of extracted viral RNA 
or diluted synthetic control. The cycling conditions were as recommended by the manufacturer 
(Fast Mode, PE Applied Biosystems, Foster City, CA) and consisted of one cycle at 50°C for 5 
minutes, one cycle at 95°C for 10 minutes and 40 cycles at 95°C for 3 s and 60°C for 30 s. The 
threshold cycle number (Ct) was determined for each sample.  All oligonucleotides and probes were 
synthesized by GeneWorks Pty. Ltd. (Adelaide, Australia). 
 
Negative controls, and probe and primer controls, were also included. Negative RNA template 
controls included the negative extraction control and RNase-free water.  A negative result was 
considered to be a Ct value of 40 or more cycles.  In addition, separate synthetic primer and probe 
positive controls were developed following minor modifications of the method described by Smith 
et al. (2006). These provided specific, nonviral reagents that eliminated potential contamination by 
viral RNA controls. Briefly, two high-performance liquid chromatography–purified 
oligonucleotides with complementary forward and reverse sequences were designed for each primer 
and probe control. The primer and probe synthetic controls were prepared individually to produce 
double-stranded DNA that could be used directly in the TaqMan RT-PCR. Each forward primer and 
its complementary reverse were diluted to 200µM, combined, and then annealed following a 
process of denaturation at 94°C for 1 min and hybridization at room temperature for 10 minutes. 
The optimal working dilution was then determined by titration and incorporated into the standard 
protocol.  The primer and probe control oligonucleotides were synthesized by GeneWorks Pty. Ltd. 
(Adelaide, Australia). 
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Table 3.3: TaqMan primers and probes used for the detection of encephalitic flaviviruses 
Virus Oligonucleotide Sequence 5’-3’ 
JEV
a
 Forward primer 
10224
ATCTGGTGYGGYAGTCTCA
10242
 
 Reverse primer 
10286
CGCGTAGATGTTCTCAGCCC
102673
 
 Probe FAM-
10244
CGGAACGCGATCCAGGGCAA
10263
-TAMRA 
KUNV
a 
Forward primer 
10155
AACCCCAGTGGAGAAGTGGA
10174
 
 Reverse primer 
10225
TCAGGCTGCCACACCAAA
10208
 
 Probe FAM
10176
CGATGTTCCATACTCTGGCAAACG
10199
-TAMRA 
MVEV
a 
Forward primer 
10230
ATCTGGTGYGGAAGYCTCA
10248
 
 Reverse primer 
10291
CGCGTAGATGTTCTCAGCCC
10273
 
 Probe FAM
10272
ATGTTGCCCTGGTCCTGGTCCCT
10250
-TAMRA 
WNV
b 
Forward primer 
10,668
 CAGACCACGCTACGGCG 
10,684
 
 Reverse primer 
10,770
 CTAGGGCCGCGTGGG
10,756
 
 Probe FAM
10,691
TCTGCGGAGAGTGCAGTCTGCGAT
10,714
TAMRA 
a
JEV, KUNV, MVEV and Synthetic control described by Pyke et al., (2004) 
b
WNV described by Lanciotti et al., (2000)  
3.2.11 Specificity and sensitivity studies, including plaque forming 
assays 
To investigate specificity, each virus-specific probe was tested against a preliminary panel of 13 
flaviviruses (data not shown). For further validation and to determine whether any undesirable 
cross-reactivity was observed, each probe was tested against the panel of 30 flaviviruses detailed in 
Table 3.1. 
 
To compare the sensitivity of the encephalitic suspension microarray and TaqMan assays, virus was 
titrated using a plaque reduction neutralisation assay, as previously described (Pyke et al., 2004). 
Briefly, ten-fold dilutions of JEV (BI), KUNV (MRM16), MVEV (MRM66) and WNV (Sarafend 
and NY99) were cultured on confluent monolayers of PSEK cells.  After two hours of incubation at 
37°C, a 1.5% carboxy methyl cellulose overlay was added. The cells were incubated for 3 days at 
37°C and then stained to determine the plaque forming units per millilitre (PFU/mL). Four 
replicates of each virus were performed and the mean determined.  Aliquots of 140µL from each 
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dilution were taken and extracted as described previously.  The extracts were then tested in 
triplicate using both the TaqMan and suspension microarray to determine the detection limit of each 
test.  Two different amplification methods to generate asymmetrical PCR product were also 
compared on the suspension microarray, to determine whether this was a means to improve the 
detection limit.  Additionally, mosquito-positive infected mosquitoes were tested to determine the 
sensitivity of the assay for mosquito-surveillance purposes. 
3.3 Results 
3.3.1 Probe design 
The four TaqMan probes routinely used in uniplex assays for the detection of JEV, KUNV, MVEV 
and WNV were evaluated for use in the suspension microarray.  The screening process involved 
testing each probe against positive and negative samples in both uniplex and multiplex assay. 
Suitable probes had a high sample to background ratio and low cross-reactivity. The TaqMan 
probes adapted well to the suspension microarray format, despite the fact that different primers to 
those previously published were used for amplification.  The JEV, KUNV and WNV probes passed 
preliminary validation, but the MVEV probe was not able to detect positive cell-culture samples.  
Sequencing confirmed this was not due to probe mismatches and steric hinderence was considered 
the most likely cause.  Therefore, a new MVEV probe was designed. An early validation study 
indicated that the new MVEV probe did not pick up MRM66 or PNG156 (data not shown); 
therefore a second probe MVEV2 was designed to allow more robust detection of MVEV.  
Additionally, the JEV probe had a weaker signal than the other probes.  Variation in the strength of 
the signal produced by individual probes is common and has been reported previously.  A second 
JEV probe was designed, in an attempt to overcome this issue.  However, this probe produced a 
high background signal.  Therefore, as the first JEV probe passed validation of the assay with 
respect to specificity, it was included in the assay.  Interpretation of results was made with this 
knowledge in mind.  
 
The inclusion of a universal probe, to act as a positive control is highly desirable.  Several attempts 
to design such a probe were made, including using the sequence of the primers EMF and VD8.  An 
alternative approach attempted was to use the program ClustalX (Thompson, et al., 1997) to 
identify regions of consensus using sequence alignments available on GenBank. However, areas of 
consensus did not necessarily match the ideal design parameters required of the probes for this 
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assay.  Two potential areas of consensus were targeted as the focus of a probe, but both failed 
validation as they produced a high background signal in the presence of a negative sample.   
 
A synthetic control probe was also designed, as described in the previous chapter.  The probes 
which passed screening and were included in the suspension microarray are listed in Table 3.2. 
Internal controls are also essential.  Synthetic controls to ensure amplification was successful and 
genus-specific probes were also designed and screened. At the time of protocol development, there 
was no example of a synthetic control used for inclusion.  A recent study in 2012 has detailed a 
similar method, showing its usefulness and validity (Ros-Garcia et al., 2012). 
3.3.2 Optimisation of encephalitic suspension microarray 
Factors were investigated that would optimise generation, hybridisation and detection of 
biotinylated, PCR product.   
 
3.3.2.1 Optimisation of PCR amplification 
Preliminary validation of the encephalitic suspension microarray examined both symmetrical and 
asymmetrical PCR. Symmetric PCR generated double stranded PCR product, while asymmetric 
PCR favoured the production of single stranded PCR product.   The experiments were replicated 
using several flaviviruses (JEV, KUNV, STRATV and YFV) and the results were consistent with 
those of the alphavirus suspension microarray.  The KUNV results are detailed below for 
demonstration (Figure 3.2), while the results for the other flaviviruses can be found detailed in 
Appendix 1. 
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Figure 3.2: Comparison of the S/B (sample-to-background) ratios produced by the KUNV 
probe following hybridisation with KUNV products from either symmetrical (Sym) or 
asymmetrical
+ 
(Asym) PCR.  
(
+
) The asymmetrical PCR product was produced using a forward to reverse primer ratio of 1:4 
 
We found that asymmetrical PCR products generated much higher MFIs than the symmetrical PCR 
product.  Symmetrical PCR generates double stranded PCR product, which can self-reanneal during 
hybridisation.  This resulted in a lower signal.  In comparison, asymmetrical PCR generates single 
stranded PCR product that is then available to hybridise to the probe.  This resulted in a higher 
fluorescent signal as there is increased product bound to the probe.  Therefore, an asymmetrical 
amplification strategy was examined for the encephalitic flavivirus suspension microarray, to 
determine the optimal ratio of forward to reverse primers.  This was investigated in combination 
with the MgS04 concentration in a checkerboard titration for several flaviviruses (data not shown) 
and an amplification strategy using the reverse primer at 8 times the concentration of the forward 
was adopted at an MgSO4 of 2mM was adopted for the experiments that relied on the primer ratio to 
generate asymmetric PCR product.   
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3.3.2.2 Optimisation of probe conditions 
The optimal amount of probe to conjugate to the microspheres was determined by titration. As 
recommended by the manufacturers, a range of concentrations from 0.2 to 0.4 nmol, were tested to 
determine the best concentration for each probe. The signal performance for the KUNV probe was 
optimal at 0.3nmol (Figure 3.3); however, this value was determined for each probe individually. 
 
Figure 3.3:  Effect of varying the amount of KUNV probe coupled to the microspheres per 
reaction, on the S/B (sample-to-background) ratio generated after hybridisation with KUNV 
PCR product 
 
3.3.2.3 Optimisation of hybridisation and detection of PCR product 
The hybridisation conditions of the suspension microarray were optimised after evaluating 
hybridisation temperatures and TMAC concentration.  In brief, a range of hybridisation 
temperatures (56-62°C) were investigated before selecting 56°C as the optimal hybridization 
temperature (data not shown). A range of TMAC concentrations (1.5M to 3M TMAC) were also 
investigated before 1.5M was selected (data not shown).  TMAC solution is known to have an 
influence in overcoming differences in melting temperatures between probes (Honore et al., 1993). 
Finally, the conjugate dilution was also titrated to determine the most suitable dilution (results not 
shown). These experiments were conducted in parallel with the optimisation of the alphavirus assay 
and optimal conditions were selected based on those which concurred between the two assays.  This 
was to allow the potential for further multiplexing of the flavivirus and alphavirus assays at a later 
date. 
 87 
 
3.3.2.4 Minimisation of background signal 
The value of a wash step to reduce the background signal generated in the negative control samples 
was investigated.  Using the centrifuge method recommended by Bio-Plex, the 96-well plate was 
centrifuged at >2, 250 x g for 3 minutes immediately after hybridisation, to pellet the microspheres.  
The supernatant was removed using a multi-channel pipette. This was compared with a no-wash 
protocol, to determine whether a wash step had a positive effect upon the sample signal.  The no-
wash protocol involved the addition of the conjugate directly into 96 well plate after hybridisation.  
The concentration of the conjugate was adjusted to ensure the same amount of streptavidin-RPE 
was used for each protocol.   The samples were run in duplicate and the results were consistent with 
those obtained during development of the alphavirus suspension microarray. 
 
The results indicated that the inclusion of a wash step in the method for the flavivirus suspension 
array did not increase the strength of the sample to background ratio for a positive sample (Figure 
3.4). Additionally, the potential for sample contamination or laboratory error to occur was increased 
by the inclusion of such a step.  Therefore, it was decided that further investigation was not 
warranted and a no-wash protocol was adopted for the encephalitic suspension microarray. 
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Figure 3.4: Comparison of the S/B (sample-to-background) ratios obtained when an 
additional wash step was either included or not to minimise the background signal.  Each 
column represents the mean S/B ratio of the probe ± standard error 
3.3.3 Specificity of probes in the encephalitic suspension microarray  
For initial validation, the probes were tested against the panel of flaviviruses listed in Table 4.1.  
There was no cross-reactivity observed between viruses, with the exception of the KUNV and 
MVEV probes, which showed weak cross-reactivity with WNV and SEPV respectively (Fischer et 
al., 2008).   
 
Further validation of the encephalitic suspension microarray involved the testing of a panel of 30 
strains of encephalitic flaviviruses (Table 3.1). The virus-specific probes were first tested in uniplex 
assays before the pooling of the five beads in a multiplex assay.  The results (MFI) were similar in 
both the uniplex and multiplex assays (data not shown). The specificity of the encephalitic panel 
was 93%, with 28 of the 30 viruses detected (Table 3.4). 
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Table 3.4: Specificity of the encephalitic suspension microarray  
Virus Strain Mean S/B ratio of probe (SE) 
  JEV MVEV MVEV2 KUNV WNV 
JEV M96  4.4 (0.1) - - - - 
JEV PNG6544 5.9 (0.4) - - - - 
JEV FU1028 6.0 (0.1) - - - - 
JEV TS6516 7.6 (1.2) - - - - 
JEV SA14 - - - - - 
JEV Mabuig 2576 5.1 (0.4) - - - - 
JEV BI146 5.3 (0.1) - - - - 
JEV Nakayama  13 - - - - 
MVEV MRM66 - - 34.1 (0.5) - - 
MVEV MV02  - 16.8 (0.5) 30.1 (1.2) - - 
MVEV 341/2001 - 21.9 (0.9) 30.7 (0.9) - - 
MVEV 326/2001 - 24.9 (0.6) 30.6 (0.4) - - 
MVEV OR156 - 24.6 (0.2) 30.0 (0.6) - - 
MVEV MVEV15109 - 5.6 (0.4) 29.6 (1.5) - - 
MVEV MVEV16219 - 17.6 (0.8) 29.6 (1.7) - - 
MVEV MK6884 - 17.6 (0.5) 32.6 (0.8) - - 
MVEV PNG156 - - 30.3 (1.6) - - 
KUNV Sarawak - - - - 9.7 (1.7) 
KUNV CX288 - - - 17.2 (2.3) 12.9 (1.6) 
KUNV HU6744 - - - 15.5 (1.2) 10.6 (1.5) 
KUNV K1738 - - - 8.2 (1) 6.1 (0.9) 
KUNV MRM16 - - - 31.9 (2.8) 14.1 (1.0) 
KUNV Boort - - - 36.3 (1.6) 21.1 (6.3) 
WNV Wengler (B956) - - - 3.3 (0.2) 10.2 (0) 
WNV Koutango  - - - - - 
WNV NY99 - - - - 13.3 (0.8) 
WNV G22886 - - - - 11.3 (0.4) 
WNV MgAr978 - - - - 14.5 (0.3) 
WNV Sarafend  - - - - 13.2 (0.5) 
 
(-) indicates S/B (sample-to-background) ratio <2. Samples were run in triplicate and the S/B ratio 
of each replicate was calculated by dividing the MFI of the sample by the MFI of the negative 
control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard error) 
 
 
Preliminary studies had indicated that the MVEV probe did not detect MRM66 or PNG156 despite 
evidence on gel electrophoresis that these virus strains have been successfully amplified.  Therefore 
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a second probe MVEV2 was included in the assay.  Using the two probes, all validation stains of 
MVEV were detected.   
 
However, there were two virus strains that could not be detected by their respective virus-specific 
probes, JEV SA14 and WNV Koutango.  Gel electrophoresis confirmed successful amplification of 
both strains and the samples were submitted for sequencing. The sequences showed high correlation 
with GenBank submissions SA-14 (M55506) and Koutango virus (L48980) respectively.  However, 
there was only 80% alignment between the Koutango strain and the WNV probe, with four 
mismatches; and one mismatch between the JEV probe and the SA strain.  These mismatches were 
sufficient to prevent the suspension microarray from detecting these strains.   
 
3.3.4 Sensitivity of the encephalitic suspension microarray 
The suspension microarray was evaluated to determine the effect on sensitivity when the assay was 
multiplexed and different amplification strategies were used.  The detection limit of the assay for 
each reference strain of virus was then determined and compared with two current diagnostic tests, 
the TaqMan assay and gel electrophoresis. 
   
3.3.4.1 Multiplex encephalitic suspension microarray 
To determine the effect of multiplexing the five encephalitic probes in the suspension microarray, 
the signal generated in response to a PCR product was compared when the probes were either 
pooled together in a 5-plex assay (5 probes included), or uniplex for the target PCR of interest.  The 
assays were run in parallel, using a 10-fold dilution series to determine the limit of detection. All 
samples were run in triplicate and each reference virus from the validation panel was tested. For 
example, Figure 3.5 demonstrates the sample-to-background ratio produced when the same MVEV-
positive sample was run in parallel on a uniplex or five-plex assay.     
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Figure 3.5: Comparison of the S/B (sample-to-background) ratios of the uniplex and multiplex 
MVEV probe for detection of 10-fold serial dilutions of MVEV strain MRM66 cell culture.    
The experiment was run in triplicate and each column represents the mean S/B ratio of the 
probe ± standard error 
The detection limit for MVEV in both the uniplex and multiplex suspension microarray was at a 
virus dilution of 10
-6
.  There was a steady increase in signal as the amount of amplification product 
increased above the limit of detection. For all probes, the detection limit in both the uniplex and 
multiplex suspension microarray was the same; although the sample to background MFI ratio was 
consistently higher in the uniplex assay (Figure 3.5).  However, the advantages of multiplexing the 
assay far outweigh those of the slight increase in MFI and all tests for validation were conducted in 
multiplex format.  An example of the results of a five-plex assay can be seen below in Figure 3.6. 
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Figure 3.6: Comparison of the S/B (sample-to-background) ratios of the five probes in the 
multiplex encephalitic suspension microarray after hybridisation with 10-fold serial dilutions 
of MVEV strain MRM66 cell culture.    The experiment was run in triplicate and each column 
represents the mean S/B ratio of the probe ± standard error 
 
3.3.4.2 Amplification strategy 
All viruses from the validation panel were tested to determine their limit of sensitivity using the two 
key amplification techniques, the Combimatrix 3-stage amplification strategy using the modified 
primer M13-VD8 and asymmetrical amplification using reverse primer at a concentration 8 times 
higher than the forward.    The limits of detection were similar on both assays, but the M13-VD8 
primer and three-stage amplification produced a stronger sample-to-background ratio in general 
(Figure 3.7 a and b). 
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Figure 3.7a and b: Comparison of the S/B (sample-to-background) ratios of the encephalitic 
suspension microarray when two different strategies were used for amplification of 10-fold 
serial dilutions of MVEV (MRM66) and WNV (Sarafend) cell culture. The experiment was 
run in triplicate and each column represents the mean S/B ratio of the probe ± standard error 
The difficulty of validating a multiplex assay to optimal conditions for all viruses is widely 
acknowledged.  However, the three-stage M13-VD8 strategy was adopted for empirical reasons, 
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which will be discussed further in the results section. This method was used for all further test 
validations. 
 
3.3.4.3 Comparison of the encephalitic suspension microarray and TaqMan assay 
 
The TaqMan and the multiplex encephalitic suspension microarray were run in parallel to compare 
the detection limits of both tests (Table 3.5).  TaqMan is considered the current gold standard 
molecular diagnostic test for flaviviruses and is the routine diagnostic test used in our laboratory.  
Gel electrophoresis was also performed on the first round product, to confirm amplification had 
occurred.  This test is also routinely used in the QHFSS laboratory. 
  
Table 3.5: Comparison of the detection limits of three diagnostic tests for the detection of 
encephalitic flaviviruses 
Virus Strain Detection Limit (PFU/mL) 
  Suspension microarray TaqMan Gel  
JEV BI146 200 0.25 2 
MVEV MRM66 0.154 1.9 1.54 
KUNV MRM16 0.17 0.02 0.17 
WNV NY99 0.93 116 0.09 
WNV Sarafend 1.05 ND* 1.05 
 
*Not detected 
 
The JEV, KUNV and WNV probes utilised in the TaqMan RT-PCR have previously been validated 
(Pyke, 2004; Lanciotti, 2003). This allowed the opportunity to compare the performance of these 
probes in both the suspension microarray and TaqMan format.  
 
No one assay consistently performed better than the others. The TaqMan assay was the most 
sensitive of the assays for the detection of JEV and KUNV, while the suspension microarray was 
more sensitive for the detection of the MVEV and WNV.  The TaqMan result for the WNV NY99 
strain was less sensitive than previously published.  However, as the same virus aliquots were used 
for both tests and the TaqMan probe and primer controls indicated no issue with the assay, the 
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comparison is valid for the test as run in our laboratory.  It may be that our reagents or probes vary 
to those originally published or have degraded over time.  This will be investigated further but was 
beyond the scope of this study. 
 
3.3.5 Detection of virus in mosquitoes 
The multiplexed encephalitic suspension microarray has proven capable of detecting either 
individual virus-infected mosquitoes or pools of 1/100 virus-infected mosquitoes.  The sensitivity of 
the assay was sufficient that only one round of asymmetric PCR was required to detect the 
individual virus-infected mosquitoes.  The ability of the suspension microarray to detect an infected 
mosquito in a pool of 100 was also tested, and is similar to the requirements of a diagnostic test 
used for mosquito surveillance. 
 
3.3.5.1 Detection of individual virus-infected mosquitoes 
Initially, the suspension microarray was tested to ensure it was capable of detecting a single, virus-
positive mosquito.  To validate the assay, twelve individual virus-exposed mosquitoes were tested 
in parallel on both the encephalitic suspension microarray and the TaqMan assay.  The suspension 
microarray detected positive mosquitoes for the flaviviruses JEV, KUNV and WNV. MVEV virus 
positive mosquitoes were not available for testing.  The results are presented in Table 3.6. 
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Table 3.6: Detection of individual flavivirus-positive mosquitoes with the encephalitic 
suspension microarray 
Mosquito Sample Mean S/B ratio of probe (SE) 
 JEV KUNV MVEV MVEV2 WNV 
JEV 146789 18 (0.3) 1 (0.1) 4 (0.1) 3 (0.1) 1 (0.1) 
JEV 146790 18 (0.1) 1 (0) 4 (0.1) 3 (0.1) 1 (0.1) 
JEV 146791 18 (0.3) 1 (0.1) 4 (0.1) 3 (0.1) 1 (0) 
JEV 146792 18 (0.2) 1 (0) 4 (0) 3 (0.1) 1 (0.1) 
KUNV 147168 1 (0.2) 24 (1.1) 6 (1.3) 3 (1.1) 12 (1.8) 
KUNV 147184 1 (0) 26 (1.6)  5 (0.5) 3 (0.2) 12 (1.1) 
KUNV 147185 1 (0.1) 25 (1.6) 4 (0.5) 3 (0.3) 11 (0.3) 
KUNV 147167 1 (0) 26 (2.1) 6 (0.5) 3 (0.1) 13 (0.3) 
WNV 149379 1 (0) 1 (0) 1 (0.1) 3 (0.1) 25 (0.9) 
WNV 149377 1 (0) 1 (0) 1 (0) 3 (0.1) 22 (0.9) 
WNV 149380 1 (0) 1 (0) 1(0) 3 (0.1) 23 (0.9) 
WNV 149373 1 (0) 1 (0) 1 (0) 3 (0.1) 26 (0.9) 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was 
calculated by dividing the MFI of the sample by the MFI of the negative control.  The mean of these 
replicate values is the mean S/B ratio of the probe (±standard error) 
 
The sensitivity of the encephalitic suspension microarray compared to the TaqMan assay was 
100%.  Some cross-reactivity was observed, most notably between the WNV probe and the KUNV 
infected mosquitoes. However, if cross-reactivity was seen, the probe with the highest sample-to-
background ratio always correctly identified the virus in each sample (Table 3.6). This cross-
reactivity was not unexpected as KUNV is classified as a strain of WNV (Simmonds et al., 2012). 
Other suspension microarray studies have also noted cross-reactivity in some probes (Page & 
Kurtzman, 2005, Brunstein et al., 2006, Deak et al., 2010).  In these studies, the sample was 
identified as the virus targeted by the probe with the strongest signal and this approach was adopted 
for the encephalitic suspension microarray. 
 
3.3.5.2 Detection of virus infected mosquitoes in mosquito pools 
Mosquitoes suspected to be virus positive were confirmed to be so by removal of the head and 
testing on TaqMan.  If the mosquito was positive, it was then spiked into a pool of 99 mosquitoes, 
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extracted and tested in parallel on both the encephalitic suspension microarray and the TaqMan 
assay.    A total of five pools were available for validation and all were detected on the suspension 
microarray (Table 3.7).   
 
Table 3.7: Detection of encephalitic flavivirus-positive mosquito pools following Trizol 
extraction 
Mosquito Sample Mean S/B ratio of probe (SE) 
 JEV KUNV MVEV MVEV2 WNV 
JEV Mozzie Pool 14 (1) 1 (0.1) 2 (0.1) 1 (0) 1 (0.1) 
KUNV Mozzie Pool 1 (0.1) 28 (2)  10 (0.7) 1 (0.1) 15 (0.7) 
WNV Mozzie Pool 1 1 (0.1) 1 (0.1) 1 (0.1) 1 (0) 18 (1) 
WNV Mozzie Pool 2  1 (0.1) 1 (0.1) 1 (0.1) 1 (0.1) 31 (0.9) 
WNV Mozzie Pool 3 1 (0.1) 1 (0) 1 (0.1) 1 (0.1) 26 (0.6) 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was 
calculated by dividing the MFI of the sample by the MFI of the negative control.  The mean of these 
replicate values is the mean S/B ratio of the probe (±standard error) 
 
 
The sensitivity and specificity of the suspension microarray was 100% when compared to the 
TaqMan assay. This represents a small sample size and further validation of the new suspension 
microarray on a much larger number of samples is warranted for use in the screening of mosquito 
pools for surveillance purposes. 
 
3.4 Discussion 
This chapter reports a novel, multiplexed test for the molecular diagnosis of the encephalitic 
flaviviruses JEV, KUNV, MVEV and WNV. Several papers have explored the potential to adapt 
previously validated diagnostic tests to suspension microarray format. However, this is the first 
report we are aware of where both previously validated consensus primers and Taqman RT-PCR 
probes from separate studies have been combined in a suspension microarray. It is also the first 
reported development of a suspension microarray to target the encephalitic flaviviruses of public 
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health concern in the Australiasian region.  The suspension microarray shows potential for use in 
surveillance programmes and the diagnosis of the encephalitic flaviviruses.  
3.4.1  Adaptation of validated molecular assays to suspension 
microarray  
Previous studies have reported varied success in adapting validated diagnostic tests to the 
suspension microarray format. In some cases, the molecular probes used for other diagnostic tests, 
such as spoligotyping or TaqMan RT-PCR have been successfully used (Cowan et al., 2004, Wilson 
et al., 2005). In another study, the probes from a PCR-enzyme immunoassay required modification 
by shortening the length, before they could be successfully included (Das et al., 2006). One study 
found it impossible to use some probes from a validated Reverse Line Blot, as the probes gave very 
low MFI values and showed cross-reactivity (Ros-Garcia et al., 2012).    However, the use of probes 
from previously validated tests has many advantages with respect to time, as validation is often an 
expensive and lengthy process.  Although the use of validated probes from other molecular tests 
will not remove the need for validation if used in a new format, it does add to the robustness of the 
assay if the probes are already known to be sensitive and specific against a wide panel of viruses.  A 
previous study has also reported the successful use of consensus primers for the amplification of 
yeasts targeted by a suspension microarray (Diaz & Fell, 2004).  The advantage of this approach 
was that it eliminated the need to perform a multiplex PCR, which can decrease assay sensitivity 
(Wilson et al., 2005); as well as reducing reagent costs and potentially primer and probe 
interactions. Therefore, we decided to attempt the development of a suspension microarray by 
utilising previously published probes and consensus primers.   
 
We decided to target the NS5-3UTR’ region of the flavivirus genome as it has been shown to be 
highly conserved among mosquito-borne flaviviruses (Lanciotti, 2003).  Additionally, the region 
has been the focus of previous studies to develop universal primers for amplification of flaviviruses 
and probes for use in the molecular assays (Pierre et al., 1994, Maher-Sturgess et al., 2008, 
Figueiredo et al., 1998, Tanaka, 1993, Pyke et al., 2004, Lanciotti, 2000).   A loss of sensitivity can 
be seen in assays using universal primers compared to specific primers, although this is not always 
the case (Domingo et al., 2011, Patel et al., 2013).  However, utilising universal primers has the 
added advantage of the ability to test for multiple viruses in the one geographical region that cause 
very similar clinical signs; and can also to increase the size of the panel by inclusion of related 
viruses in the future.  The alternatives, which include multiplexed PCR reactions or using virus 
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specific primers; would also present issues with respect to loss of sensitivity or undesirable 
specificity respectively. The use of universal primers offered a cost-effect measure to obtain 
epidemiological and surveillance data and proved to have appropriate sensitivity during validation.   
 
We used the previously published consensus primers EMF and VD8, which were developed for the 
detection of mosquito-borne flaviviruses by conventional PCR (Pierre et al., 1994).  The consensus 
primers EMF/VD8 have been in routine use at QHFSS and have shown themselves to have good 
specificity and a lack of cross-reactivity with closely related organisms.  They were selected for the 
suspension microarray as they have been shown to amplify all mosquito-borne flaviviruses of 
interest, including those enzootic in Australia such as STRATV, KOKV and ALFV (Pierre et al., 
1994, Poidinger et al., 1996, Nisbet et al., 2005). They have also continued to show their utility for 
the detection of flaviviruses in clinical and mosquito surveillance samples internationally (Lindahl 
et al., 2013, de Souza et al., 2010).  The use of these primers provides the potential to expand the 
panel for detection of other mosquito-borne flaviviruses of public health importance to Australia, in 
the future. Additionally, they produce an amplicon of approximately 600-800bp in length, a size 
which has been shown to be suitable for use in suspension microarrays (Diaz & Fell, 2004, Page & 
Kurtzman, 2005).  Importantly, the amplicon produced also incorporates the NS5-3’UTR region 
targeted by the chosen TaqMan RT-PCR probes.  As the primers had previously been validated and 
already proven to be useful for the molecular detection of flaviviruses, we decided to use them, 
rather than design our own for the purpose of the suspension microarray.   
 
TaqMan RT-PCR assays routinely used for flavivirus screening in our laboratory utilised probes 
that were complementary to the region amplified by EMF/VD8 (Pyke et al., 2004, Lanciotti et al., 
2000).  This offered the potential to investigate conversion of TaqMan probes for use in the 
suspension microarray and to compare the two technologies with respect to sensitivity and 
specificity.  The JEV, KUNV and WNV virus-specific probes previously designed for use in the 
detection of encephalitic flaviviruses by TaqMan RT-PCR, all successfully coupled and passed 
preliminary validation in the suspension microarray. The length of these probes ranged from 20 to 
24 bases and all had similar melting temperatures. The length of the probes used previously in 
suspension microarrays has not been found to be a critical factor, with probes varying in length 
from 18 to 45 bases used in the one assay (Deregt et al., 2006b); however, several have used probe 
lengths similar to those we have reported (Kuriakose et al., 2012, Diaz & Fell, 2004, Etienne et al., 
2009, Oh et al., 2007).  These probes were eventually multiplexed and validated for use in the 
suspension microarray. 
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The TaqMan MVEV probe did not pass validation in the encephalitic suspension microarray and 
required redesign, despite having a similar length and melting temperature to the other three probes. 
Many factors have been suggested as the cause of poor performance in probes.  As discussed in the 
previous chapter, the location of the probes should ideally not be within 100 bp of the 5’ end, while 
undesirable structural conformation such as hairpins or strong secondary structures can prevent the 
PCR product from binding to the bead (Diaz & Fell, 2004). Previous studies have also avoided runs 
of three or more guanine or cytosines on the ends of probes where possible (Diaz & Fell, 2004, 
Page & Kurtzman, 2005). The use of gel electrophoresis confirmed the successful amplification of 
the MVEV strains in the validation panel, and BLAST alignments confirmed the probe matched the 
amplified region and showed 100% sequence alignment with numerous MVEV strains.  However, 
the MVEV TaqMan probe had 3 Cs at the 5’ prime end and targeted the 5’ end of the amplicon and 
these properties may have contributed to its failure to adapt to the suspension microarray format. 
 
A new MVEV probe was designed, avoiding the probe features considered to be undesirable 
discussed above.   This new probe detected all strains in the validation panel, with the exception of 
MRM66 and PNG156.  This was despite the fact that gel electrophoresis confirmed that all strains 
had successfully amplified.  This suggested that the mismatch was with the MVEV probe. 
Therefore, a second MVEV probe was designed and was found to detect all MVEV strains included 
in the validation panel. We decided to incorporate both new MVEV probes in the panel to improve 
the robustness of the assay.  The advantage of the multiplex format is that multiple probes for the 
same target can be included to act as controls (Diaz & Fell, 2004).  The potential exists to extend 
the panel to include multiple probes for each virus for this purpose. No loss of signal intensity was 
seen on multiplexing the two MVEV probes, suggesting that competition for PCR product was not 
an issue.  Therefore, we report two novel probes for the detection of MVEV. 
 
However, there were two virus strains that could not be detected by their respective virus-specific 
probes, JEV SA14 and WNV Koutango.  Gel electrophoresis confirmed successful amplification of 
both viruses, and the samples were submitted for sequencing.  The sequences showed high 
correlation with GenBank submissions SA-14 (M55506) and Koutango virus (L48980) 
respectively. However, there was only 80% alignment with the actual WNV probe, with four 
mismatches; and 95% alignment between the JEV probe and SA14 with one mismatch located near 
the 3’ end. These mismatches were sufficient to prevent the suspension microarray from detecting 
these strains.  Of note is the fact that the WNV probe was able to detect the Sarafend strain in the 
suspension microarray but not the TaqMan RT-PCR. This probe was a 100% match for the 
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Sarafend strain; however, the TaqMan WNV-specific primers did not match the sequence available 
on GenBank, explaining why it was undetectable. 
3.4.2 Design of a consensus probe 
It was hypothesised that a consensus probe capable of detecting all encephalitic flaviviruses of 
interest could be designed for inclusion in the assay, as the NS5-3UTR’ region of the flavivirus 
genome amplified by EMV/VD8 has been shown to be highly conserved. A consensus probe would 
not only act as a positive internal control, but could potentially detect new strain variations or 
viruses which were not specifically included in the array.  Sequences were taken from GenBank and 
analysed using ClustalX (Thompson, et al., 1997) software to locate regions of high conservation 
amongst the four viruses targeted by this suspension microarray. Although regions of consensus 
were identified, they did not conform to the parameters needed for a probe in the encephalitic 
suspension microarray, even when redundancies were included.  Several targets for probes were 
selected but unfortunately did not pass preliminary validation. We also unsuccessfully attempted to 
use the sequence from the universal primer EMF as a probe.  The same result was found when 
attempting to use the universal primer as a probe in the alphavirus assay. It could be hypothesised 
that the sequence is too closely aligned to the very end of the amplicon, making hybridisation 
difficult. Therefore, this assay only has the ability to detect viruses for which it is specified and does 
not have the capability to act as a broad screening tool as anticipated. 
3.4.3 Internal controls 
A variety of internal controls can be used in a suspension microarray.  In this microarray, we 
decided to incorporate a synthetic positive control as this eliminates the potential for false positives.  
The synthetic control acts as a positive control for amplification and for the reagents of the 
suspension microarray.  If the synthetic control failed, the sample should be re-run to determine the 
nature of the problem.  The synthetic control could be spiked into each sample; however, we opted 
instead to run a synthetic control from each amplification experiment in an individual well to reduce 
labour.  Two negative controls were incorporated in each run as well; with either TE buffer or the 
negative extraction control added instead of the sample.  These negative controls acted as a 
safeguard to ensure the amplification reaction and microarray reagents were free from 
contamination.  
 102 
3.4.4 Variability in signal intensity and sensitivity of probes 
Design of probes for suspension microarrays has largely been reported to be by trial and error and 
the intensity of the signal produced by individual probes is known to vary widely (Diaz & Fell, 
2004, Ros-Garcia et al., 2012, Wilson et al., 2005). The cause of this is not known, however, there 
are several possible explanations. The efficiency of PCR could have some impact as there could be 
less template available to hybridise to the probe, compared to other target sequences and probes 
(Das et al., 2006).  Also signal intensity may be in influenced by the secondary structure of the 
probe or target, or weak hybridisation of the product to the probe (Dunbar, 2006, Boving et al., 
2009).  The sample-to-background ratio for the JEV probe was consistently lower than for the other 
probes.  Attempts were made to redesign this probe but no alternative proved more suitable. 
However, although the signal was comparatively low, at approximately five times that of the 
negative background MFI, positive samples were still identified with acceptable sensitivity and we 
acknowledge that this individual probe had a comparatively lower signal than other probes in the 
assay.  Variation in signal intensity between individual probes is a known feature of suspension 
microarrays, but does not adversely affect their usefulness.  
 
Variations in the sensitivity of species-specific probes are also common in multiplex assays (Boving 
et al., 2009). In addition to the variability in signal intensity of individual probes, it is very difficult 
to optimise an assay for multiple targets and compromise is invariably required. One study has 
found that the suspension microarray format can provide semi-quantitative information as the MFI 
reading correlates to the number of DNA copies in the sample (Dumonceaux, 2009). Like these 
researchers, we also found the MFI for an individual probe had a consistent signal at high input 
copy numbers, indicating saturation of the probe.  We also found that at the lower copy numbers, 
the correlation between MFI and copies of target was reasonably linear.  However, we do not feel 
our assay could be used in a semi-quantitative manner as the signal for individual probes may also 
be influenced by the particular strain of virus, with some strains returning higher MFI than others of 
the same virus. This could possibly be explained due to variations in the amount of template in each 
sample, as not all samples were quantified.  However, we did see variation in several of the viruses 
that we did quantify, such as the Sarafend and NY99 strains of WNV.  Therefore, we feel this 
suspension assay cannot be used semi-quantitatively.  However, despite the variations in sensitivity 
seen between the species-specific probes, we feel this assay has adequate sensitivity to use as a 
screening tool.   
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3.4.5 Protocol optimisation  
As discussed in the previous chapter, a wide variety of amplification strategies can be used in 
association with suspension microarrays.  Similar to the alphavirus suspension microarray, and in 
agreement with some previous studies, we found that asymmetric PCR using a higher reverse to 
forward primer ratio performed better than symmetrical PCR.  We also decided to compare this 
asymmetrical amplification strategy with the novel strategy adopted from the Combimatrix chip 
microarrays, which was found to be useful with the alphavirus suspension microarray (Lodes et al., 
2007).  Although both amplification strategies performed similarly with respect to the sensitivity, 
we opted to use the Combimatrix strategy as it produced a slightly stronger signal and reduced the 
amount of reverse primer required.  It also provided the opportunity to develop a microarray chip 
and suspension microarray that could utilise the same PCR reaction product.  This is the first 
reported use of this amplification strategy in association with suspension microarrays but by 
adopting identical PCR conditions for the alphavirus and encephalitic suspension microarray, there 
is potential for the PCR to be multiplexed at a later date.  
 
Similarly, the same process of protocol optimisation discussed in the previous chapter was 
investigated for the encephalitic suspension microarray.  The optimal concentration of probe for 
coupling was determined individually for each probe and was again found to be important in 
optimising signal intensity.  Identical protocols were optimal for both the alphavirus and 
encephalitic suspension microarray, with respect to hybridisation conditions, minimising 
background signal and signal optimisation, as detailed in the results section of this chapter. 
Therefore, the alphavirus and encephalitic suspension microarrays have the potential to be 
multiplexed further to enable both PCR and the suspension microarray of both assays to be run 
concurrently together. 
 
Finally, studies were conducted to ensure the optimised uniplex assay produced similar results in 
multiplexed format.  Multiplexed suspension microarray do not generally show a loss of sensitivity 
compared to the uniplex suspension microarray (Diaz & Fell, 2004, Diaz et al., 2006, Kuriakose et 
al., 2012).  This is in contrast to many other molecular diagnostic tests where loss of sensitivity, or 
limited multiplexing capabilities are observed (Wilson et al., 2005).  In the encephalitic flavivirus 
suspension microarray described here, samples were tested in parallel in either a uniplex or five-
plex assay and the MFIs of the probes were similar in both formats.  All validation experiments 
were therefore conducted using the multiplex format. 
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3.4.6 Specificity, sensitivity and validation 
Validation of the encephalitic suspension assay showed considerable robustness in the detection of 
different virus strains, with 93% of the 30 strains of encephalitic flaviviruses detected. However, all 
molecular tests are vulnerable to false negative results if significant strain variation or mutation 
occurs.   Two strains of MVEV could not be detected by the first MVEV probe designed for this 
project, due to sequence mismatch.  Significant sequence variation between MVEV strains from 
Australia PNG, and the eastern Indonesian archipelago has been reported (Poidinger et al., 1996). 
However, the five-plex assay utilising both MVEV and MVEV2 probes showed an ability to detect 
all these strains. Two viruses remained undetected despite evidence of amplification on gel 
electrophoresis. The WNV Koutango strain was not detected by the suspension microarray, but was 
originally defined as a separate virus, rather than a strain of WNV, and is considered a more distant 
member of the subgroup (Poidinger et al., 1996).  If required a specific probe for this virus could be 
incorporated into the suspension assay in the future. Sequencing confirmed a single nucleotide 
difference between the JEV probe and the SA-14 strain, as discussed above.  However, BLAST 
alignments continue to show excellent homology between newly added sequences in GenBank and 
the probes selected for this assay and therefore, the issue was not considered to be a significant 
impediment. A probe specific for SA-14 could be designed for incorporation in the microarray if 
desired to overcome this issue.   
 
The absence of cross-reactivity is usually a desired feature in a diagnostic assay.  In the encephalitic 
suspension microarray cross-reactivity was observed as the WNV probe produced a positive signal 
with both KUNV and WNV positive samples. However, as the KUNV probe was specific and did 
not show cross-reactivity with WNV samples, a specific diagnosis could still be reached.  
Additionally, the sample-to-background ratio for the KUNV probe was consistently higher with the 
KUNV positive samples than the WNV positive samples.  This cross-reactivity was not unexpected 
as the two viruses are closely related, with KUNV virus classified as a sub-type of WNV (Gaunt et 
al., 2001, Mann et al., 2013). The cross-reactivity can be advantageous.  The KUNV strain Sarawak 
was not detected by the KUNV specific probe, but was detected by the WNV probe, demonstrating 
the advantage of a multiplexed assay.  Although cross-reactivity is not ideal, it can prevent the issue 
of false-negative results.  The Sarawak strain, although unambiguously classified as a strain of 
KUNV on cross-neutralisation tests, shows slightly greater homology and similar deletions to WNV 
in this region (Poidinger et al., 1996).  It has been suggested that the Sarawak strain may be a link 
between WNV and Australian KUNV species, and as such it is not surprising that the WNV probe 
performed best for detection of this strain.  Therefore, the cross-reactivity seen in the encephalitic 
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suspension microarray was due to the close relationship between WNV and KUNV, but had the 
advantage of preventing false negative results.  
 
The encephalitic suspension microarray was also compared to the current molecular assay in use in 
our laboratory, gel electrophoresis and the TaqMan assay.  No one assay consistently performed 
better than the others. The TaqMan assay was the most sensitive of the assays for the detection of 
JEV and KUNV, while the suspension microarray was more sensitive for the detection of the 
MVEV and WNV.  The TaqMan result obtained for the WNV NY99 strain was less sensitive than 
previously published.  However, as the same virus aliquots were used for both tests and the TaqMan 
probe and primer controls indicated no problems with the assay, the comparison was considered 
valid.   
 
The results of the sensitivity study validated the utility of the encephalitic suspension microarray for 
diagnostic use, but cannot provide a definitive comparison between the three assays.  As observed 
previously, the suspension microarray was multiplex while the TaqMan assays were run 
individually, which may have improved their sensitivity. Additionally, the limit of detection may 
also be influenced by virus strain, as was highlighted by the Sarafend strain of WNV.  This strain 
was not detectable on the TaqMan assay.  Further investigation revealed that the probe had 100% 
homology to the sequence published on GenBank; there were however, mismatches in the TaqMan 
primers.  Likewise, the detection limit for the JEV strain BI146 was 3-fold less sensitive than the 
TaqMan assay.  It cannot be assumed the same level of sensitivity would apply to all strains of JEV 
though, and further investigation would be warranted in the future.  This issue again highlights the 
difficulties associated with the validation of a multiplex assay, as the tasks of optimising and 
validating for each virus become increasing difficult.  However, one key advantage of the 
suspension microarray is the flexibility to include additional probes as required, as was observed 
with the MVEV probe.  A similar approach could be adopted for JEV, with a probe designed 
specifically for strain BI146 included if improved sensitivity was needed.  Therefore, the 
suspension microarray offers key advantages with respect to multiplexing and flexibility compared 
to the current gold standard, and the sensitivity of the assay was considered acceptable for screening 
purposes. 
3.4.7 Data analysis 
The definition of a positive signal on a suspension microarray varies greatly in the literature and no 
one method has been universally employed.  However, the majority of studies have defined a 
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positive signal as an MFI at least twice that of the background signal (Lin et al., 2008, Das et al., 
2006, Huang et al., 2008, Wilson et al., 2005, Kuriakose et al., 2012).  We also defined a positive 
signal as an MFI at least twice that of the background signal as discussed previously; although other 
studies have used a cut-off of 1.5 times the background signal (Deregt et al., 2006b, 
Bandyopadhyay et al., 2007).  As with all diagnostic assays, the use of a lower cut-off value has the 
potential to either increase the number of false positives or decrease the number of false negatives.  
From our experience with the technology, there was no justification to adopt an alternative or lower 
cut-off than that supported by the majority of studies.    
3.4.8 Testing of mosquito pools 
For arbovirus surveillance, mosquito trapping and submission for molecular testing is becoming 
increasingly popular for implementing public health strategies. It has been found to be the most 
sensitive surveillance method for the determination of WNV activity and human risk in several 
countries (Brownstein et al., 2004, Chevalier et al., 2011, Angelini et al., 2010). Although other 
surveillance systems, such as horse or wild bird surveillance have been used effectively during 
targeted exotic incursions, they become less effective in endemic situations.  Meanwhile, the 
presence of infected mosquitoes, as the route of infection for humans, indicates direct human risk.   
Therefore, mosquito surveillance has become widely used and provides information on which 
public health guidance can be provided.  Mosquito surveillance has also proven to be very useful 
when combined with RT-PCR, to screen for new viruses and co-infections which may otherwise 
have been undetected (Vazquez et al., 2012, Lee et al., 2013, Cook et al., 2009). 
 
Mosquito-based surveillance techniques frequently process trapped mosquitoes in pools of 50 to 
100 in size, to reduce labour and reagent costs. The suspension microarray was sensitive enough to 
detect pools spiked with one positive JEV, KUN or WNV mosquito in a hundred mosquitoes.  The 
extraction method was important in the success of the detection in large pools of mosquitoes. The 
Qiagen mini-kit method was appropriate for detection of individual mosquitoes but led to false 
negative results with the pool of mosquitoes.  This may be due to the RNase activity of the 
mosquito pools.  Adopting a phage-gel extraction method and utilising RNase inhibitors allowed us 
to overcome this problem and enabled us to demonstrate the utility of the encephalitic suspension 
microarray for screening pools of mosquitoes.   
 
The specificity of the encephalitic suspension microarray compared to the TaqMan assay was 
100%.  There was some cross-reactivity observed with the suspension microarray as the WNV 
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probe produced a signal with the KUNV infected mosquitoes; however, the specific virus of interest 
was correctly determined as the highest MFI value was associated with the relevant virus-specific 
probe.  Although this only represents a small sample size and will require validation on a much 
larger number of samples, it does suggest that the new suspension microarray has potential for use 
in the screening of mosquito pools for surveillance purposes and that further development is 
warranted. The lower cost and reduced labour requirements compared to the TaqMan assay makes 
the multiplexed encephalitic suspension microarray particularly appropriate for mosquito based 
surveillance. 
 
3.4.9 Clinical diagnosis 
The successful detection of viral infections by molecular methods depends to a large extent on the 
submission of appropriate samples during the acute stage of infection.  However, molecular 
methods are important for early virus detection, when serological results may be negative and 
results from cell culture are still pending.  Molecular methods have proven to be useful in the 
detection of acute encephalitis in CSF samples (Swami et al., 2008). Success in the detection of 
viral RNA in serum samples tends to be low, possibly due to the transient and low viraemia state 
frequently observed in arboviral infections (Swami et al., 2008).  However, early diagnosis during 
the acute phase is critical as it allows rapid public health control measures and the most appropriate 
medical treatments to be implemented.  The detection levels of the suspension microarray would 
indicate that the assay could be utilised for these purposes, adding a useful tool to the diagnostic 
arsenal for encephalitic viruses of the Austalasian region. 
 
Future studies will validate the assay against a panel of clinical samples run in parallel on both gold 
standard tests and the encephalitic suspension microarray.    However, the following chapter details 
the successful use of suspension microarray to detect flavivirus positive serum samples.   
 
3.5 Conclusion 
We report the development of a multiplexed suspension microarray for the detection of encephalitic 
flaviviruses of importance in the Australasian region.  Validation has shown this assay capable of 
detecting strain variations and sensitive enough for detection of virus-positive mosquito pools.  The 
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assay is cost-effective compared to other assays currently used for surveillance and diagnostic 
purposes and has the potential to be multiplexed further to include other flaviviruses of importance 
in the region such as dengue viruses.  Development of cost-effective, multiplexed assays will 
improve our surveillance capabilities, which are increasingly critical in an era where global travel 
and urbanisation are resulting in the emergence and re-emergence of these viruses.  The success of 
the encephalitic multiplex suspension microarray lead to the expansion of the panel to include other 
flaviviruses detailed in the following chapter. 
 
The encephalitic panel could also be extended to incorporate other encephalitic pathogens, such as 
herpesvirus, enterovirus, lyssavirus and rubella viruses to produce a syndrome based diagnostic 
assay. Alternatively, the assay could be tailored for veterinary diseases with the incorporation 
EEEV, VEEV, WEEV, Herpesvirus and Hendra virus. 
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Chapter 4: Development of a Suspension 
Microarray for the Detection of 
Flaviviruses of Public Health 
Importance to Australia 
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4.1 Introduction 
This study developed and evaluated a flavivirus suspension microarray for the detection of the 
dengue viruses (DENV1-4), Japanese encephalitis virus (JEV), Murray Valley encephalitis virus 
(MVEV), West Nile virus (WNV), Yellow Fever virus (YFV), Kunjin virus (KUNV), Sepik virus 
(SEPV) and Stratford virus (STRV). These viruses are either important global pathogens or 
endemic flaviviruses of public health interest in Australia. The encephalitic panel discussed in the 
previous chapter was expanded by the introduction of new probes to produce the first multiplex 
assay, that we are aware of, that targets the flaviviruses of importance to Australia. The multiplex 
test was validated against a panel of reference viruses, clinical dengue samples and individual virus-
positive mosquitoes or mosquito pools and was found to be rapid, sensitive, specific and cost-
effective.  The assay shows potential as a vital screening tool for clinical diagnosis, arbovirus 
surveillance and exotic disease preparedness.  
 
The genus Flavivirus includes mosquito-borne arboviruses that are of serious public health 
importance globally, with billions of people potentially at risk of disease (Erlanger et al., 2009, 
Domingo et al., 2011). Globally, there has been a dramatic increase in the range and incidence of 
diseases caused by flaviviruses over the past 30 years, despite the availability of effective vaccines 
(Gubler, 2011).  Some of the most important of these are YFV, JEV, DENV and WNV.  Factors 
that may be contributing to their emergence and re-emergence include poor vector control, 
increasing global travel, urbanisation and expanding host ranges (Mackenzie et al., 2004).  An 
effective DENV or WNV vaccine is also yet to become available (Mansfield et al., 2011, Heinz & 
Stiasny, 2012, Franca et al., 2013).  This leaves a large proportion of the world unprotected against 
these diseases and there is potential for them to emerge in previously non-endemic regions.  All 
these viruses are exotic to Australia, but have the potential to instigate large outbreaks if introduced.   
 
Both JEV and DENV have been detected in Northern Queensland and pose high risks of becoming 
endemic due to the availability of competent vectors (Van Den Hurk et al., 2010).  DENV outbreaks 
in particular, have become increasingly common with 43 outbreaks in North Queensland between 
1990 and 2012 (Johansson et al., 2012).  Although still classified as an exotic disease, local 
transmission does occur due to the availability of the main vector Aedes aegypti.  In 2009, there 
were 28 laboratory-confirmed cases of dengue imported into North Queensland by travellers from 
overseas (Johansson et al., 2012).  This resulted in five separate epidemics, with all four serotypes 
of dengue represented, the largest of which involved 915 patients in Cairns (McBride, 2010).  
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Although vector control programs have managed to limit the establishment of dengue to date, they 
are under increasing pressure; and the potential establishment of the aggressive vector Aedes 
albopictus could alter the situation in the future (Williams, 2012).    Therefore, early detection of 
exotic virus incursions is crucial to allow rapid implementation of widespread vaccination 
programs; or, in the case of DENV and WNV, mosquito control measures. 
 
The public health importance of Australia’s numerous endemic flaviviruses is also not to be 
overlooked.  MVEV has caused several large outbreaks over the decades.  The most recent include 
an outbreak in 1974 which resulted in at least 58 human cases and a mortality rate of around 20%, 
while an outbreak in 2011 had 16 confirmed cases with a 12.5% mortality rate (Knox et al., 2012). 
A significant increase in neurological disease in equines in Australia was also noted in 2011 and 
this was found to be attributed to concurrent outbreaks of MVEV and a more virulent strain of 
KUNV (Mann et al., 2013).  MVEV and KUNV were also known to co-circulate during the 1974 
outbreak (Marshall et al., 1982b).  These results provide significant evidence to indicate that 
flaviviruses can co-circulate in outbreak situations and highlight the advantages that may be offered 
by multiplex tests, which have been shown to improve detection of dual infections which may be 
missed by sequencing or culture methods (Page et al., 2006, Lin et al., 2008).    
 
The public health importance of some endemic flaviviruses is not completely understood.  
However, information on seasonal activity and spread of endemic flaviviruses may provide a better 
understanding of vector and host patterns, which can be used to inform exotic public health policy.  
Kunjin virus is of great interest because of its close relationship with WNV.  Although not as 
pathogenic as WNV, the presence of KUNV in Australia indicates the potential for WNV to 
become established in Australia if introduced, by sharing the same vectors and hosts (Jansen et al., 
2008).  Therefore, surveillance data for KUNV activity could guide public health policy for WNV 
preparedness.  Similarly, Alfuy virus (ALFV), Kokobera virus (KOKV), Sepik virus (SEPV) and 
Stratford virus (STRV) are all present in Australasia and have been sporadically identified as the 
cause of clinical disease but surveillance data for these viruses is generally lacking.  However, there 
are many reasons why the availability of this data could be desirable.  There is always the potential 
for more pathogenic strains of these endemic viruses to emerge, as was seen in the recent KUNV 
outbreak involving neurological disease in equines (Frost et al., 2012).  Another recent example is 
the alphavirus, Chikungunya (CHIKV). Chikungunya virus had a fairly stable attack rate for 
decades, but a new strain emerged in 2007 and caused explosive outbreaks affecting millions of 
people in the Reunion Islands, the Indian subcontinent, South East Asia and Italy (Ng & 
Hapuarachchi, 2010). These examples, along with the re-emergence of WNV in the past decade, 
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show the potential for a more virulent strain of arbovirus to emerge.  As the endemic viruses other 
than MVEV are currently considered of lesser public health importance, diagnosis of clinical cases 
relies on serological assays; which are notoriously cross-reactive (Taylor et al., 2005).  Therefore, 
the development of a molecular assay which can screen for these additional viruses at no extra cost 
is considered highly desirable, to address issues such as the possible under-reporting of clinical 
cases, the potential for new, more virulent strains to emerge and an improved understanding of the 
vector and geographic ranges of endemic viruses. 
 
The clinical signs associated with flaviviral disease are non-specific and a laboratory diagnosis is 
required to distinguish exotic and endemic diseases. This means that specific and sensitive 
diagnostic tests are critical for the management of flaviviral disease. The use of PCR in conjunction 
with serological tests can greatly improve the chances of reaching a specific diagnosis.  In the case 
of WNV, one study has shown an increase in sensitivity from 45% for serological testing alone, to 
94% when a combined molecular and serological approach was adopted (Tilley et al., 2006). 
Reaching a specific diagnosis is very important from a case management and disease control 
perspective but can be very reliant upon the selection of appropriate tests and obtainment of an 
accurate travel history.  Additionally, the capacity to routinely screen for both endemic and exotic 
flaviviruses is important, as highlighted by recent outbreaks of DENV in North Queensland.  
Studies have found that up to 30% of patients with symptoms compatible with dengue during a 
regional outbreak were not tested, while a significant proportion of confirmed dengue cases had no 
history of travel in the three previous weeks (Johansson et al., 2012). The development of a 
multiplex molecular assay for the panel of flaviviruses discussed above would help overcome issues 
such as under-reporting.   
 
Globally, the importance of flavivirus surveillance is recognised as an important public health 
requirement to control disease outbreaks.  Clinical disease associated with DENV, KUNV, MVEV 
and YFV is notifiable in Australia as part of the National Notifiable Diseases Surveillance System.  
However, relying on reportable disease notifications is undesirable as control strategies can only be 
implemented in a reactive manner, to address an already established problem.  In contrast, vector 
surveillance systems provide early warning of arboviral activity thus allowing more proactive 
measures and timely public health warnings to be issued, thus reducing the risks of large outbreaks 
occurring and exotic viruses becoming permanently established.   
 
Currently arbovirus surveillance in Australia is neither widely implemented nor broad ranging.  In 
addition to the notifiable diseases, it comprises sentinel animal and mosquito surveillance systems 
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which focus on MVEV and RRV (van den Hurk et al., 2012).  However, animal sentinel systems 
can be costly and there are risks associated with maintaining host species in close proximity to 
communities (Ritchie et al., 2007). Mosquito based surveillance has proven to be a useful tool 
overseas and is expected to be increasingly used in the future.  However, although the collection 
system for mosquitoes may be more cost effective than the animal sentinel systems, costs escalate 
for the diagnostic component, especially if screening for multiple pathogens.  Therefore, cost-
effective, sensitive, molecular diagnostic tests are required for this purpose. 
 
No single test is currently ideal for surveillance of endemic and exotic flaviviruses of public health 
importance to Australia, although there are many available.  Virus culture has widely been 
considered the gold standard diagnostic test but is very labour intensive.  It is also of limited use for 
surveillance as there can be a time delay of up to several weeks for a diagnosis, when a rapid result 
is desirable for outbreak prevention. The same argument also applies to serological assays. It can 
take several weeks for an immune response to develop by which time the opportunity for outbreak 
management may have passed. TaqMan Real-Time PCR has proven very useful for clinical cases 
and mosquito-based surveillance due to its excellent sensitivity (Domingo et al., 2011, Nasci et al., 
2001).  However, the test is expensive for testing mosquito pools and can only be multiplexed for a 
smaller number of targets than we would like to target with our panel (Chisenhall et al., 2008).  
Therefore, TaqMan RT was not suitable for the purpose of developing a diagnostic test targeting a 
number of both exotic and endemic flaviviruses.   
 
Expanding on the protocols developed for the alphavirus and encephalitic suspension microarrays 
discussed in the previous chapters offered an exciting opportunity for the development of a 
diagnostic test with the potential to screen for multiple flaviviruses simultaneously.  This feature 
was identified as the most highly desirable for our surveillance test, however it needed to be cost-
effective.  Expanding the encephalitic panel from five probes to fourteen involved minimal 
additional cost because the assay used consensus primers and there was no significant increase in 
labour.  However, the cost was markedly less than traditional chip microarrays, which cost over 
$500 per sample using the Combimatrix system or individual TaqMan assays which were estimated 
to be up to fifty times as expensive, at the time the project commenced.   
 
Validation of the multiplex flavivirus suspension microarray has shown it is capable of detecting a 
large panel of flaviviruses, offering for the first time a novel test to screen for the endemic and 
exotic flaviviruses of public health importance in Australia. We believe that this test could be 
adopted for routine surveillance, to improve preparedness for exotic virus incursions, and as a broad 
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ranging screening test for clinical samples; particularly those submitted from overseas travellers.  
The assay helps overcome some of the economic and practical limitations that are reducing the 
effectiveness of Australia’s current endemic and exotic disease surveillance programs. 
 
4.2 Materials and Methods 
4.2.1 Viruses 
The virus strains used for the preliminary development of the flavivirus suspension microarray are 
listed in Table 4.1. All viruses were propagated in either porcine stable equine kidney (PSEK) or 
Aedes albopictus (C6/36) cell lines.  The additional 51 virus strains used to validate the suspension 
microarray were obtained from Queensland Health Forensic and Scientific Services (QHFSS), 
Brisbane, Australia or the University of Queensland, with the exception of the NY-99 (4132) strain 
of WNV, originally isolated from the brain of an American crow during the 1999 New York 
outbreak and obtained from the Division of Vector-Borne Infectious Diseases, Centers for Disease 
Control, Fort Collins, USA. 
To ensure validation was as comprehensive as possible, sequencing data and phylogenetic 
information were used where available to select virus strains.  This was particularly relevant for 
DENV, for which the archive library at QHFSS is extensive.  Multiple genotypes and distantly 
related strains were selected from the archive based on this information to ensure the robustness of 
the assay.  The validation panel of 65 viruses is listed in Table 4.2, including available details on the 
year of isolation and location it was collected from.  
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Table 4.1: Virus strains used for preliminary development of the flavivirus suspension 
microarray 
Virus  Strain Virus Titre Before Extraction 
(PFU/mL or TCID50/mL) 
Alfuy (ALFV) MRM3929 N/A
 
Dengue 1 (DENV1) ET00.423 10
7* 
Dengue 2 (DENV2) ET00.300 10
6.6 * 
Dengue 3 (DENV3) ET00.209 10
5.8 * 
Dengue 4 (DENV4) ET00.288 10
6.7 * 
Japanese encephalitis  (JEV) TS00 2.1 x 10
7 
Kokobera (KOKV) MRM32 2.7 x 10
5 
Kunjin (KUNV) MRM16 1.8 x 10
7 
Murray Valley encephalitis (MVEV) MRM66 1.6 x 10
7 
Sepik (SEPV) MK7148 9.5 x 10
7 
Stratford (STRV) C338 4.5 x 10
6 
West Nile (WNV) Sarafend 1.1 x 10
7 
West Nile (WNV) NY99 1 x 10
7 
Yellow fever (YFV) 17D 1 x 10
7 
 
N/A indicates viral titre is not available; ( 
*
)
 
indicates TCID50 units per mL 
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Table 4.2: Flavivirus isolates used for the validation of the flavivirus suspension microarray 
Virus  Strain Location, Year  Virus  Strain Location, Year 
ALFV MRM3926 Australia, 1966 JEV TS6516 Unknown 
DENV1 ET00.423 East Timor, 2000  M96 Unknown 
 CI107 Cook Island, 2007  PNG6544 Papua New Guinea, 1998 
 PNG100 Papua New Guinea, 2000  FU1028 Torres Strait, 2000 
 MA103 Mareeba, Australia 2003  Mabuig2576 Torres Strait, 1998 
 ET108 East Timor, 2008  BI146 Badu Island, 2001 
 SR104 Sri Lanka, 2004  Nakayama Japan, 1935 
 VI108 Vietnam, 2008 KOKV MRM32 Queensland, Australia, 1960 
 MA101 Malaysia, 2001 KUNV MRM16 Queensland,  Australia, 1960 
DENV2 ET00.300 East Timor, 2000  Sarawak Borneo, 1966 
 ET204 East Timor, 2004  CX288  Kimberley, Australia, 1982 
 CA204  Cairns, Australia 2004  HU6744   New South Wales Australia 1991 
 PH203 Philippines, 2003  K1738 Ord River, Australia, 1989 
 PNG203 Papua New Guinea, 2003  KUNV Boort Victoria, Australia, 1984 
 CA203 Cairns, Australia 2003 MVEV MRM66 Queensland, Australia, 1959 
 TO203 Townsville, Australia 2003  MV02  Unknown, 2002 
 PNG203 Papua New Guinea, 2003  341/2001  Mt Isa, Australia, 2001 
 IN203 India, 2003  326/2001  Mt Isa, Australia, 2001 
DENV3 Cairns08 Cairns, Australia 2008  OR156 Western Australia, 1973 
 TO306 Townsville, Australia 2006  MVEV15109 Queensland, Australia, 1972 
 SE307 SE Asia, 2007  MVE16219 Charleville, Australia, 1974 
 CA306 Cambodia, 2006  MK6684 Papua New Guinea, 1966 
 CA308 Cairns, Australia 2008  PNG156 Papua New Guinea, 1956 
 TO307 Townsville, Australia 2007 SEPV MK7148 Papua New Guinea, 1966 
 TH397 Thailand, 1997 STRV C338 Cairns,  Australia, 1961 
 BR302 Brazil, 2002 WNV Sarafend Israel, 1974 
DENV4 ET00.288 East Timor, 2000  NY99 USA, 1999 
 PI405 Philippines, 2005  Wengler (B956) Uganda, 1938 
 ET407 East Timor, 2007  G22886  India, 1958 
 HO40u Honiara, unknown  MGAR978 Unknown 
 SA408 Samoa, 2008  Koutango Senegal, 1968 
 UT41u Unknown YFV 17D Vaccine strain, 1937 
 TI05 Thursday Island, 2005    
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4.2.2 Virus-positive serum samples 
Archived samples submitted to QHFSS for DENV testing during 2008 and 2009 were used for 
validation. These samples were submitted for routine diagnostic services by general practitioners, 
hospitals or public health workers from regions around Australia and the Pacific and can be found 
listed in Table 4.3. The samples were screened with the DENV-Universal TaqMan RT-PCR and 
positive samples were then typed using four genotype-specific TaqMan RT-PCR assays (Warrilow 
et al., 2002).  The samples were stored at -80°C until tested with the flavivirus suspension 
microarray. All samples were tested in triplicate following one round of asymmetrical 
amplification.  A total of 54 positive samples and 38 negative samples were tested (refer Table 4.3).  
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Table 4.3: Clinical dengue samples tested in this study 
Geographic 
Source 
Travel 
History 
DENV 
Genotype 
Number of 
Samples 
Tested 
Sample  
Identification Numbers 
Cairns  
 
No Concurrent 
outbreaks of 
DENV1, 
DENV2, 
DENV3 
30 V1.05, V2.01, V2.05, V3.01, 
V3.02, V3.03, V3.04, V3.05, 
V3.06, V3.07, V3.08, V3.09, 
V3.10, V3.11, V3.12, V3.13, 
V3.14, V3.15, V3.16, V3.17, 
V3.18, V3.19, V3.20, V3.21, 
V3.22, V3.23, V3.24, V3.25, 
V3.26, V3.27, V3.30  
Fiji No DENV1 1  V1.11  
East Timor No DENV1 3 V1.01, V1.03, V1.06  
Townsville No DENV1 4 V1.02, V1.04, V1.07, V1.09, 
V1.10 
Cairns/PNG? unknown DENV2 1 V2.05 
South Australia Yes, Bali DENV2 1 V2.02 
Innisfail No DENV4 5 V4.01, V4.02, V4.03, V4.05, 
V4.06 
Brisbane No (lab 
infection) 
DENV2 1 V2.03 
Cook Islands No DENV4 3 V4.07, V4.08 
Unknown Unknown DENV1, 
DENV2, 
DENV4 
5  V1.08, V2.04,  V3.28, V3.29, 
V4.04 
 
4.2.3 Virus-positive mosquitoes 
Virus-positive mosquitoes from previously published vector-competence studies were used to 
validate the suspension microarray. These samples included Culex gelidus mosquitoes infected with 
JEV strain TS00 or KUNV strain 2002-1412 (Johnson, 2009); Culex annulirostris infected with 
NY-99 (4132) strain of WNV (Jansen et al., 2008); Aedes aegypti mosquitoes infected with a 
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DENV2 strain originally isolated from a patient on Thursday Island (Moore et al., 2007); and Aedes 
aegypti mosquitoes infected with the DENV3 strain from outbreaks in Queensland during 2008 and 
2009 (van den Hurk, in press).   
4.2.4 RNA extraction  
4.2.4.1 RNA extraction from viral culture 
Viral RNA was extracted from cell culture using the QIAmp® Viral RNA Mini kit (Qiagen, 
Victoria, Australia) according to manufacturer’s instructions. The extracted RNA was serially 
diluted 10-fold in RNase-free water and stored at -80°C.  
  
4.2.4.2 RNA extraction from clinical samples 
The serum samples submitted to the diagnostic laboratory for DENV screening were extracted 
using the Qiagen BioRobot Universal System and the QIAamp Virus BioRobot MDx Kit (Qiagen, 
Clifton Hill, Australia) according to manufacturer’s directions. The samples were tested by TaqMan 
RT-PCR immediately after extraction, and then stored at -80°C. The validation of the suspension 
microarray was conducted using samples which had been archived for 6 to 12 months. The 92 
clinical samples were run as a blind panel on the suspension microarray. As the samples had been 
tested previously, the samples were not repeated on the TaqMan assay unless the results were 
discordant with the suspension microarray. Therefore, these samples underwent an additional extra 
freeze-thaw cycle before testing on the suspension microarray.   
4.2.4.3 RNA extraction from mosquitoes 
Individual mosquitoes were homogenized by shaking in a SPEX 8000 Mill (Spex Industries, 
Edison, NJ) for approximately 3 minutes. The grind was then filtered through a 0.2µm Supor® 
membrane filter (Pall Corporation, Ann Arbor, MI) and a 140µL aliquot was extracted using the 
QIAmp® Viral RNA Mini kit (Qiagen, Victoria, Australia), according to manufacturer’s 
instructions. 
 
Individual mosquitoes used to spike the mosquito pools were confirmed to be positive prior to 
addition to the pool by excising the head and testing by TaqMan RT-PCR.  The samples were then 
refrozen at -80°C until results were confirmed.  The virus-positive body was then spiked into a pool 
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of 99 laboratory bred Aedes aegypti mosquitoes. Mosquito pools were extracted using the Trizol 
method discussed in Chapter 2. 
4.2.5 Polymerase Chain Reaction (PCR) 
4.2.5.1 Symmetric PCR 
For RT-PCR, a one-step kit SuperScript III with Platimun® Taq (Invitrogen, Victoria, Australia) 
was used according to manufacturer’s instructions.  A 4µL volume of extracted RNA was added to 
each 50µL reaction. Amplification was carried out using previously described universal primers 
EMF and VD8 (Pierre et al., 1994) as described in Chapter 3.   
4.2.5.2 Asymmetric PCR 
Asymmetrical PCR products were generated as discussed previously in Chapter 3.  
4.2.5.3 Amplification controls, including gel electrophoresis 
Positive and negative controls were included for every amplification experiment.  The positive 
amplification control used synthetic RNA as the template and the negative amplification control 
used the negative extraction control as the sample template.  All first round amplified products were 
separated on a 1.5% agarose gel at 90 volts for 45 minutes and viewed by UV transillumination to 
confirm amplification of positive samples, and lack of contamination in negative controls.  The 
second round amplified products could not be viewed in this manner as single-stranded DNA is not 
visible by this method (Spiro et al., 2000, Deregt et al., 2006a). 
4.2.6 Sequencing 
When required, PCR products were sequenced and analysed as described in previous chapters. 
4.2.7 Oligonucleotide probe design 
Previously validated TaqMan probes met the above design requirements for suspension microarrays 
and targeted the amplified NS53’NTR region.  The published probes for JEV, KUNV and WNV 
(Pyke et al., 2004, Lanciotti et al., 2000), as well as unpublished TaqMan probes routinely used in 
our laboratory for the detection of KOKV and STRV were included in the suspension microarray.   
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Probes for the detection of DENV1, DENV2, DENV3, DENV4, MVEV, SEPV, and YFV were 
designed specifically for the suspension microarray using the program Primer Express™ 2.0 (PE 
Applied Biosystems, USA).  The target region for the probe was based on the NS5/3’UTR region 
amplified by the universal primers EMF & VD8 (Pierre et al., 1994). The GenBank accession 
numbers used for probe design were AY762084 (DENV1), AY037116 (DENV2), DQ675526 
(DENV3), AY947539 (DENV4), AF161266 (MVEV), DQ859063 (SEPV) and U17066 (YFV).  
Probes with a similar length (20-27 nucleotides), GC content (40-70%) and melting temperature 
were selected.  Probes that bound to the middle or 3’end of the amplicon were preferentially 
selected where possible. Probes were excluded that formed hairpins or strong secondary structures, 
or displayed a run of more than three Gs or Cs at the 5’ or 3’ end. A NCBI Blast (Altschul et al., 
1990) was conducted with the candidate probes to ensure they matched as many specific virus 
strains as possible and showed no indication of cross-reactivity with other flaviviruses, 
microorganisms or contaminants. These probes are listed below in Table 4.4. 
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Table 4.4: Nucleotide sequences of primers and probes used for the flavivirus suspension 
microarray  
 Sequence Size 
Primers   
EMF
a 
TGGATGACSACKGARGATATG 21 
VD8
a 
GGGTCTCCTCTAACCTCTAG-Biotin 20 
M13-VD8 AACAGCTATGACCAGGGTCTCCTCTAACCTCTAG 34 
Probes   
DENV-Universal TGAGCAAACCGTGCTGCCTGTAGCT 25 
DENV1 TCAGGCCGAAAGCCACGGTTTG 22 
DENV2 TGTAAAAATCTGGGAGGCCACAAACCA 27 
DENV3 AGAAGTCAGGCCCAAAAGCCACGG 24 
DENV4 AACCGTGCTGCCTGTAGCTCCGC 23 
JEV TI
b 
CGGAACGCGATCCAGGGCAA 20 
KOKV TGGGCAGAAAACATCAAGGTAGCCAGT 27 
KUNV
b 
CGATGTTCCATACTCTGGCAAACG  24 
MVEV
 
CGCCGCCATCAACCAAGTGAGG 22 
MVEV2 TGGAGATGAAGCCCGTGTCAGAT 23 
SEPV ACCTGGGCGCGTGATGTGAAGC 22 
STRV CGGCTCAGGGTGATGCCCTGA 21 
WNV
c 
TCTGCGGAGAGTGCAGTCTGCGAT 24 
YFV AGGCAGTGCAGGCTGGGACAGC 22 
Flavi-Synthetic Control AGTTGCTCTTGCCCGGCGTCAA 22 
 
 
Referenced in: 
a 
(Pierre et al., 1994)
; b 
(Pyke et al., 2004);
 c 
(Lanciotti et al., 2000) 
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4.2.8 Amplification controls 
Positive and negative controls were included for every amplification experiment.  The positive 
amplification control used synthetic RNA as the template.  
 
Briefly, for the preparation of synthetic controls, first round primer pairs were chosen using the 
primer design software Primer Express™ Version 2.0.0 (Perkin-Elmer, Applied Biosystems, USA) 
to produce an amplicon of approximately 702 bp in length from pUC18 DNA (New England 
Biolabs, USA).  This amplicon was approximately the same size as the amplicons generated for the 
suspension microarray. The first round primers were designed so that the restriction site ApaLI 
would be located approximately in the middle of the resulting amplicon to allow later digestion of 
the product by ApaLI. Digestion of the PCR product would allow for the differentiation of 
contaminating amplicon if required. The primers were designed to incorporate the flavivirus 
forward primer sequence EMF to the 5′ end of a pUC18 specific forward sequence (5′1879-
GCCGGGAAGCTAGAGTAAGRTAGTTC 
1894
-3′) to produce a primer 47 bp in length in the order 
5’[EMF][pUC18for sequence]-3’.  The VD8 reverse primer sequence was added to the 5’ end of a 
pUC18 specific reverse sequence (5’-2533TCATGAGCGGATACATATTTGAATG2558-3’) in the 
order 5’-[VD8]-[pUC18 (rev) sequence]-3’ to produce a primer of 45 bp (Table 4.5). An optimal 
working dilution was then determined by performing serial dilutions (data not shown).  Finally, a 
probe with similar design parameters to those used for the suspension microarray was designed that 
was complementary to the amplified region of pUC18.  This 22bp probe was named Flavi-Synthetic 
Probe AGTTGCTCTTGCCCGGCGTCAA.  
 
Table 4.5: Primers used for the generation of synthetic controls for the flavivirus suspension 
microarray 
Primer Sequence (5’-3’)*  Size 
FlaviEMFpUCF TGGATGACSACKGARGAYATGGCCGGGAAGCTAGAGTAAGTAGTTC 702bp 
FlaviVD8pUCR GGGTCTCCTCTAACCTCTAGCATTCAAATATGTATCCGCTCATGA  
 
*pUC18 sequence underlined 
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4.2.9 Oligonucleotide probe bead preparation and multiplex suspension 
microarray 
Bead coupling of the probes to carboxylated beads was performed according to the manufacturer’s 
guidelines, as described in the previous chapter.  To confirm successful bead coupling and 
consistency of results, the same panel of samples was used to validate all coupling reactions, to 
ensure there was no great variation in signal between batches.   
 
Hybridisation of the probes and PCR product was performed according to the manufacturer’s 
guidelines, as discussed in the previous chapter.   
4.2.10 Analysis of hybridisation results 
The BioPlex xMap system calculated the median fluorescent intensity (MFI) values of each bead set 
in a well. The MFI value was calculated from the signal of at least 100 beads. Raw data was 
exported from the Bio-Plex™ Manager Software 4.0 to Microsoft Excel for analysis. The sample-
to-background (S/B) ratio was calculated for each sample by dividing the mean MFI of the sample 
by the mean background fluorescent intensity (BFI) of the negative controls of that run, using a 
modified protocol from Das, et al. (2006). A positive sample was defined as a sample with a MFI at 
least twice the BFI for that bead-probe set.  This definition for a positive sample was found to be 
more stringent than a cut-off of twice the standard deviation above the negative during the 
preliminary studies, and is the most widely used method in the literature relating to suspension 
microarrays. 
4.2.11 TaqMan RT-PCR   
Virus samples were run in triplicate, in parallel on the TaqMan RT-PCR and flavivirus suspension 
microarray. Previously published TaqMan RT-PCRs were used for the detection of JEV, KUNV, 
MVEV and WNV (Pyke et al., 2004); and DENV (Warrilow et al., 2002). Validated TaqMan assays 
routinely used at QHFSS were used for the detection of the remaining flaviviruses (Table 4.6).   
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Table 4.6: TaqMan primers and probes for unpublished assays 
Virus Oligonucleotide Sequence 5’-3’ 
KOKV Forward primer GCTACCGGCCKCGTTCAAC 
 Reverse primer CTCCAATYTTRACCCGGATCAC 
 Probe FAM-TGGGCAGAAAACATCAAGGTRCCAGT-TAMRA 
SEPV
 
Forward primer TGCGAACGATTGAGATTGAAAA 
 Reverse primer GCTTCCTTCATTTCACTGAGGACTA 
 Probe FAM-TCCCAYTGGCACACGTCCCTCAG-TAMRA 
STRV Forward primer GGTGAAGATGCTGCCTGCTT 
 Reverse primer GGCTCCATTGGTTGTTTATCCA 
 Probe FAM-CGGCTCAGGGTGATGCCCTGA-TAMRA 
YFV Forward primer TGTGCTAATTGAGGTGCATTGG 
 Reverse primer TCTCTGCTAATCGCTCAAIGAA 
 Probe FAM-CAAATCGAGTTGCTAGGCAATAAACACA-TAMRA
 
 
 
In brief, amplification and detection of the flavivirus RNA was conducted in a single tube one-step 
RT-PCR in a final volume of 20µL. Amplification and real time detection were performed with the 
ABI Prism 7700 sequence detection system (PE Applied Biosystems, Foster City, CA).  The 
reaction mix was prepared using the Superscript III Platinum one-step qRT-PCR system 
(Invitrogen, Carlsbad, CA) and contained 0.4 µL Superscript™ III RT/Platinum® Taq mix, 9.5 µL 
of 2x Reaction Mix, 370nM primers, 180nM dual labelled probe, 47nM ROX Reference Dye, and 5 
µL of extracted viral RNA or diluted synthetic control. The cycling conditions were as 
recommended by the manufacturer (Fast Mode, PE Applied Biosystems, Foster City, CA) and 
consisted of one cycle at 50°C for 5 minutes, one cycle at 95°C for 10 minutes, and 40 cycles at 
95°C for 3 sec and 60°C for 30 sec. The threshold cycle number (Ct) was determined for each 
sample.  All oligonucleotides and probes were synthesized by GeneWorks Pty. Ltd. (Adelaide, 
Australia). 
4.2.12 Specificity and sensitivity studies 
To investigate specificity, each virus-specific probe was tested against a preliminary panel of 14 
flaviviruses following one round of amplification (Table 4.1). For further validation and to 
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determine whether any undesirable cross-reactivity was observed, each probe was tested against the 
panel of 65 flaviviruses listed in Table 4.2. 
 
The sensitivity of the flavivirus suspension microarray was compared to both virus-specific 
TaqMan assays and RT-PCR followed by gel electrophoresis.  The titres of the validation panel of 
viruses listed in Table 4.1 were determined using either a plaque forming assay (PFA) or tissue 
culture infective dose assay (TCID50).  PFAs were performed for all viruses, with the exception of 
the dengue viruses. As the DENV did not plaque, TCID50 was used for virus quantification.  As 
discussed in previous chapters, four replicates of each virus were performed and the mean 
determined, before aliquots of 140µL from each dilution were extracted. The extracts were tested in 
triplicate using both the TaqMan and flavivirus suspension microarrays to determine the detection 
limit of each test, and were also run on gel electrophoresis.  Additionally, mosquito-positive 
infected mosquitoes were tested to determine the sensitivity of the assay for mosquito-surveillance 
purposes. 
 
4.3 Results 
4.3.1 Probe design 
The probes were designed for the conserved NS5/3’UTR region of the flavivirus genome. The 
screening process involved testing each probe against positive and negative samples in both uniplex 
and multiplex assays.  Suitable probes had a high sample-to-background ratio and low cross-
reactivity. All probes were tested individually against the preliminary validation panel of relevant 
flaviviruses (Table 4.1).  Most probes required only one design attempt before a probe suitable for 
inclusion in the microarray was identified.   
 
The inclusion of a universal probe, to act as a positive control would be highly desirable.  However, 
several attempts to design a flavivirus-universal probe were unsuccessful.  The program ClustalX 
(Thompson, et al., 1997) was used to identify regions of consensus using sequence alignments 
available on GenBank; however, these regions did not match the ideal design parameters required 
for probes in this assay.  Three potential areas of consensus were targeted as the focus of a probe, 
but all failed validation.   
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Similarly, the inclusion of a DENV-universal probe as an internal positive control was considered 
desirable given the clinical importance of these viruses.  Design of a DENV-universal probe was 
successful, with the universal probe able to detect all 32 strains of DENV tested on the validation 
panel.  As will be discussed further in the results section, cross-reactivity amongst the DENV 
probes was observed.  Therefore, the potential exists to include just the DENV-universal probe, 
rather than virus-specific probes for each, if desired.    
  
4.3.2 Optimisation  
Factors were investigated that would optimise amplification, hybridisation and detection of 
biotinylated, PCR product.   
 
4.3.2.1  Optimisation of PCR amplification 
Preliminary validation of the flavivirus suspension microarray examined both symmetrical and 
asymmetrical PCR. Symmetric PCR generates double stranded PCR product, while asymmetric 
PCR favours the production of single stranded PCR product.  Therefore, an asymmetrical 
amplification strategy was examined for the flavivirus suspension microarray, to determine the 
optimal ratio of forward to reverse primers.  This was investigated in combination with the MgS04 
concentration in a checkerboard titration for several flaviviruses (data not shown) and a 
amplification strategy using the reverse primer at 8 times the concentration of the forward, at a 
MgSO4 concentration of 2mM was adopted for the experiments that relied on the primer ratio to 
generate asymmetric PCR product.   
4.3.2.2 Optimisation of probe conditions 
As recommended by the manufacturers, the optimal amount of probe to conjugate to the 
microspheres was determined by titration, according to directions. 
 
4.3.2.3 Optimisation of hybridisation & detection of PCR product 
The hybridisation conditions of the suspension microarray were optimised after evaluating 
hybridisation temperatures and TMAC concentration.  In brief, a range of hybridisation 
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temperatures (56-62°C) TMAC concentrations (1.5M to 3M TMAC), and conjugate dilutions were 
examined to determine the optimal conditions.     
 
4.3.2.4  Minimisation of background signal 
The value of a wash step to reduce the background signal generated in the negative control samples 
was investigated.  The centrifuge method recommended by Bio-Plex (Biorad,USA) was compared 
to a no-wash protocol to establish the effect on the signal between the two methods.  The inclusion 
of a wash step was not found to increase the strength of the signal-to-background ratio for a positive 
sample (data not shown). Additionally, the potential for sample contamination or laboratory error to 
occur was increased by the inclusion of such a step.  Therefore, a no-wash protocol was adopted for 
the suspension microarray. 
 
4.3.2.5 Multiplexing capability of flavivirus suspension microarray 
To determine the effect of multiplexing the fourteen probes in the suspension microarray, the signal 
generated in response to a PCR product was compared when the probes were uniplex or all fourteen 
probes were multiplexed.  This was important to ensure that no undesirable probe interactions were 
observed on multiplexing the assay.  It was variable as to whether a particular probe produced a 
higher signal in multiplex than uniplex. However, no undesirable probe interactions were observed 
with any of the probes after multiplexing all 14 probes together.  The multiplexing capability of the 
flavivirus suspension microarray is a great advantage for a diagnostic laboratory as it allows 
samples to be screened for multiple viruses with minimal additional costs with respect to time, 
reagents or labour. 
4.3.3 Specificity of the flavivirus suspension microarray 
The suspension microarray was validated by testing it against a total of sixty-five flaviviruses 
selected from the reference collection. All viruses were detected by the multiplex suspension 
microarray, with the exception of ALFV for which a specific probe was not included.  Of the 64 
samples tested for which a specific probe was included, 61 (95%) were correctly identified to the 
virus level based on a defined signal pattern (Table 4.7).  That is, for all viruses except DENV1, the 
highest signal was produced by the specific probe and for DENV-1, a strong signal was generated 
by all DENV probes. 
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Table 4.7: Specificity of the flavivirus suspension microarray (See Appendix 2 for results of all 
strains listed individually) 
Virus  Stats Mean S/B ratio of probe (SE) 
  DEN
VU2 
DEN
V1 
DEN
V2 
DEN
V3 
DEN
V4 
JEV KO
KV 
KUN
V 
MV
EV 
MV
EV2 
SEP
V 
STR
V 
WN
V 
YFV 
ALFV 
(n=1) 
  
Mean 0.9 0.9 1.2 1.1 1.0 0.8 1.3 1.0 1.1 1.7 1.3 1.2 1.0 1.0 
SE 0.0 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.3 0.2 0.2 
DENV1 
(n=8) 
  
Mean 35.2 18.8 20.0 34.9 21.5 0.9 2.0 1.2 5.5 1.2 1.0 1.0 1.1 1.0 
SE 0.6 2.2 3.9 1.4 2.9 0.0 0.4 0.0 1.0 0.1 0.0 0.0 0.0 0.0 
DENV2 
(n=9) 
  
Mean 15.3 1.0 61.1 27.4 5.7 1.0 4.4 1.0 1.0 2.1 1.2 1.0 1.1 1.2 
SE 3.4 0.0 0.8 1.6 1.0 0.0 0.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 
DENV3 
(n=8) 
  
Mean 38.9 3.7 13.6 37.3 26.9 0.9 1.2 2.0 1.1 2.5 1.2 1.1 1.2 1.0 
SE 1.1 1.4 1.3 2.5 1.3 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 
DENV4 
(n=7) 
  
Mean 25.5 1.0 6.8 4.5 18.8 0.9 1.2 1.1 1.1 1.5 1.1 1.1 1.1 1.0 
SE 3.1 0.0 2.2 1.1 3.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 
JEV 
(n=7) 
  
Mean 1.2 1.0 3.0 4.2 1.0 13.1 1.2 1.1 1.3 1.6 1.0 1.0 0.9 1.1 
SD 0.0 0.0 0.5 1.1 0.0 1.2 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 
KOKV 
(n=1) 
  
Mean 1.1 1.4 1.2 9.5 1.0 1.2 21.0 0.9 0.9 2.0 1.5 2.1 1.1 1.1 
SE 0.1 0.1 0.1 1.2 0.2 0.1 1.6 0.0 0.1 0.3 0.3 0.1 0.1 0.2 
KUNV 
(n=5) 
  
Mean 1.2 1.1 1.8 13.8 1.0 1.0 4.8 21.5 3.0 4.4 1.1 1.0 12.9 1.0 
SE 0.0 0.0 0.5 1.5 0.0 0.0 0.6 1.6 1.1 0.4 0.0 0.0 1.3 0.0 
MVEV 
(n=9) 
  
Mean 1.0 1.1 6.8 3.3 0.9 1.1 1.4 1.0 14.9 25.9 1.2 0.9 0.9 1.0 
SE 0.0 0.0 0.7 0.4 0.0 0.0 0.1 0.0 3.3 0.6 0.1 0.0 0.0 0.0 
SEPV 
(n=1) 
  
Mean 1.1 1.0 4.9 1.1 1.1 0.9 1.4 1.1 1.2 2.0 6.3 1.2 1.3 0.9 
SE 0.3 0.2 0.7 0.2 0.3 0.1 0.3 0.2 0.3 0.3 0.4 0.2 0.1 0.1 
STRV 
(n=1) 
  
Mean 1.1 1.3 6.0 12.4 1.1 0.9 5.9 1.0 1.3 8.5 1.4 14.0 1.1 1.0 
SE 0.2 0.2 0.7 2.2 0.2 0.1 1.4 0.1 0.1 1.2 0.1 2.1 0.1 0.1 
WNV 
(n=4) 
Mean 1.1 1.1 3.1 10.4 1.0 1.0 3.8 2.4 1.2 4.5 1.2 1.0 18.8 1.0 
SE 0.1 0.1 1.7 1.1 0.1 0.1 2.4 1.3 0.1 0.9 0.2 0.1 1.1 0.1 
 
YFV 
(n=1) 
  
 
Mean 
 
1.0 
 
1.0 
 
7.1 
 
1.2 
 
1.1 
 
0.9 
 
1.1 
 
0.9 
 
1.1 
 
0.7 
 
0.9 
 
1.0 
 
1.1 
 
31.9 
SE 0.2 0.2 0.4 0.1 0.0 0.0 0.2 0.0 0.2 0.1 0.1 0.1 0.2 3.1 
 
“n” is the number of strains tested for each virus.  Samples were run in triplicate and the S/B 
(sample-to-background) ratio of each replicate was calculated by dividing the MFI of the sample by 
the MFI of the negative control. The mean S/B ratio for the probe (±SE) was then calculated from 
the mean S/B ratio of the virus strains tested   
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Variation in the signal strength on microarrays is known to occur between different strains of virus, 
and this is reflected in the standard deviations.  Appendix 2 details the individual results for each 
strain and the standard deviations seen are much lower, showing high inter-assay reproducibility.  
 
Three viruses were detected but showed cross-reactivity with other flavivirus probes (Table 4.8).   
Table 4.8: Virus strains which were detected but did not have a virus-specific signal 
Virus 
Strain 
 Stats Mean S/B ratio of probe (SE) 
  DE
NV
U2 
DEN
V1 
DEN
V2 
DEN
V3 
DEN
V4 
JEV KO
KV 
KUN
V 
MV
EV 
MV
EV2 
SEP
V 
STR
V 
WN
V 
YFV 
KUNV 
Sarawak 
Mean 1.1 1.1 4.7 5.0 1.1 1.1 1.1 1.0 1.5 1.5 1.0 1.0 10.6 1.0 
SE 0.0 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 1.1 0.1 
WNV 
Koutango  
Mean 1.3 1.0 1.1 1.2 1.2 1.0 6.7 1.2 1.1 2.1 1.4 1.1 1.5 1.1 
SE 0.2 0.1 0.1 0.1 0.1 0.0 0.7 0.1 0.1 0.5 0.1 0.0 0.1 0.0 
WNV 
G22886 
Mean 0.9 1.0 1.2 14.9 1.0 1.2 1.1 2.7 1.2 2.6 1.4 0.9 1.9 1.1 
SE 0.1 0.1 0.1 1.9 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was 
calculated by dividing the MFI of the sample by the MFI of the negative control.  The mean of these 
replicate values is the mean S/B ratio of the probe (±standard error) 
 
Cross-reactivity was observed with some probes. The dengue probes were especially cross-reactive, 
with all DENV probes capable of detecting a DENV1 positive sample.  However, the DENV1 
probe was reasonably specific, cross-reacting with only one DENV3 and DENV4 strain.  Therefore, 
a specific DENV1 diagnosis could tentatively be made based on a signal observed in association 
with the DENV1 probe.  Although cross-reactivity was seen in association with the other DENV 
serotypes, the highest signal was always associated with the specific probe.  The DENV-Universal 
probe reacted with all dengue virus serotypes and did not cross-react with any other flavivirus; 
confirming the virus-specific probe results. 
 
Some additional cross-reactivity was observed; however a preliminary diagnosis could be made by 
identifying the virus based on the probe with the strongest signal.  The DENV2, DENV3, KOKV, 
MVEV, MVEV2 and WNV probes showed some cross-reactivity with other flavivirus strains. 
While this cross-reactivity is not ideal, the suspension assay still shows potential as a screening 
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assay for a wide-range of flaviviruses. Using the criteria discussed above, every virus in the 
validation panel was detected and in 95% of cases was identified correctly. 
 
4.3.4 Sensitivity  
The detection limit of the flavivirus suspension microarray was compared to the TaqMan assay and 
gel electrophoresis; both standard tests currently used in our laboratory for clinical samples.  The 
TaqMan is considered the current gold standard molecular diagnostic test for flaviviruses. Gel 
electrophoresis was also performed on the first round product, to confirm amplification had 
occurred using the primers EMF/VD8. Each virus was serially diluted ten-fold and quantified by 
either plaque forming or TCID50 assays; then extracted and tested in parallel on all three tests (Table 
4.9).   
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Table 4.9: Comparison of the detection limits of three diagnostic tests for mosquito-borne 
flaviviruses 
Virus Strain Detection Limit of Test (PFU or TCID50/mL
#
) 
  Suspension 
microarray   
TaqMan  
 
Gel Electrophoresis  
 
DENV1 ET00 0.009
#
 119
# 
0.95
# 
DENV2 ET300 0.037
#
 3.71
# 
0.00037
# 
DENV3 ET209 0.005
#
 7.36
# 
0.58
# 
DENV4 288/2000 0.05
#
 0.55
# 
0.05
# 
JEV BI146 250 0.25 2 
KOKV  MRM32 0.026 0.03 32 
KUNV MRM16 0.17 0.02 0.17 
MVEV MRM66 0.154 1.93 1.54 
SEPV MK7148 11 0.11 11 
STRV C338 525 52 5.25 
WNV NY99 0.93 116 0.09 
WNV Sarafend 1.05 ND* 1.05 
YFV 17D 116 1166 116 
*ND sample was not detected 
# 
TCID50/mL    
 
No assay consistently out-performed the others. The TaqMan assay was the most sensitive of the 
assays for the detection of JEV, KUNV, SEPV and STRV; while the suspension microarray was 
more sensitive for the detection of the dengue viruses, MVEV and WNV.  The limit of detection for 
the KOKV virus was the same on both assays.  The TaqMan result for the WNV NY99 strain was 
discussed in Section 3.3.4.3 of the previous chapter. All three assays were equally insensitive for 
YFV. 
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These results indicate the flavivirus suspension microarray may be useful for diagnostic purposes; 
however, they cannot provide a definitive comparison between the three assays as the limit of 
detection may be influenced by the virus strain. This limitation is typical for molecular studies, the 
majority of which determine the limit of detection for just one strain.  However, as discussed in 
Section 4.2.7, BLAST analysis was performed to verify the probes selected would detect multiple 
strains of the targeted virus.  There were some challenges with this approach, as discussed in 
Section 5.2.1.  However, laboratory validation also included multiple strains of a virus, where 
possible, to confirm the probes suitability for inclusion in the assay. Overall the suspension 
microarray proved to have good sensitivity compared to the current TaqMan assays for the 
detection of the exotic flaviviruses, WNV and the dengue viruses. The suspension microarray was 
further validated as a diagnostic test for clinical samples and mosquito surveillance by testing 
archived clinical samples and spiked mosquito pools. 
4.3.5 Evaluation of the assay with clinical samples 
Ninety-two samples submitted to QHFSS during 2008-2009 were tested on the suspension 
microarray as a blind panel.  Of these samples, 38 had previously tested negative and 54 positive on 
the TaqMan RT-PCR (Table 4.10).  The suspension microarray correctly identified all 38 negative 
samples.  Of the positive sample, 49/54 (91%) tested positive following one round of PCR; and 
46/49 (93%) of the virus-positive samples were correctly identified to the DENV serotype using the 
guidelines discussed previously.  One sample failed to be detected on the suspension microarray or 
when retested by TaqMan; suggesting a possible sample issue following repeat freeze-thaw cycles 
or an initial false positive result.  Although cross-reactivity was observed, it was possible to identify 
the majority of samples to the correct serotype, using the guidelines discussed above in the section 
on specificity. 
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Table 4.10: DENV positive serum samples identified to the serotype level by the flavivirus 
suspension microarray after one round of amplification.  (See Appendix 3 for individual 
sample results) 
 
“n” is the number of clinical samples tested for each virus.  Samples were run in triplicate and the 
S/B (sample-to-background) ratio of each replicate was calculated by dividing the MFI of the 
sample by the MFI of the negative control. The mean S/B ratio for the probe (±SE) was then 
calculated from the mean S/B ratio of the clinical samples tested   
 
 
 
The viral load and virus strain varied for these clinical samples and therefore a wide variation in 
standard error was seen in this summary.  However, Appendix 3 details the results for each sample 
individually and shows lower values for the standard error, reflecting high intra-assay 
reproducibility for each sample 
4.3.6 Detection of virus-infected mosquitoes 
The multiplexed flavivirus suspension microarray has the proven capable of detecting either 
individual virus-infected mosquitoes or pools spiked with one virus-infected mosquito in a 100.  
The sensitivity of the assay was sufficient that only one round of asymmetric PCR was required to 
detect the individual virus-infected mosquitoes.  The ability of the suspension microarray to detect 
an infected mosquito in a pool of 100 was similar to the requirements of a diagnostic test used for 
mosquito surveillance. 
 
Virus   Stats Mean S/B ratio of probe  (SE) 
  DEN
VU2 
DEN
V1 
DEN
V2 
DEN
V3 
DEN
V4 
JEV KO
KV 
KUN
V 
MV
EV 
MV
EV2 
SEP
V 
STR
V 
WN
V 
YFV 
DENV1 
(n=10) 
Mean 36.4 11.5 11.8 30.9 20.8 1.0 1.8 1.2 4.0 2.1 1.0 1.0 1.0 1.0 
SE 4.0 3.0 3.8 5.0 4.0 0.0 0.4 0.1 1.0 0.4 0.0 0.0 0.0 0.0 
DENV2 
(n=4) 
Mean 11.5 1.0 46.5 27.8 5.5 1.0 4.8 1.0 1.0 7.5 1.5 1.0 1.0 1.0 
SE 6.9 0.0 9.6 14.9 3.9 0.0 2.3 0.0 0.0 2.2 0.5 0.0 0.0 0.0 
DENV3 
(n=25) 
Mean 29.9 1.7 5.7 31.5 13.0 1.0 1.0 1.4 1.0 2.8 1.0 1.0 1.0 1.0 
SE 2.2 0.2 0.7 2.3 1.4 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 
DENV4 
(n=7) 
Mean 31.9 1.0 14.1 8.6 21.9 1.0 1.3 1.0 1.0 2.0 1.0 1.0 1.0 1.0 
SE 6.9 0.0 6.3 3.6 7.1 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 
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4.3.6.1 Detection of individual virus-infected mosquitoes 
Initially, the suspension microarray was tested to ensure it was capable of detecting a single, virus-
positive mosquito.  To validate the assay, eighteen individual virus-exposed mosquitoes were tested 
in parallel on both the flavivirus suspension microarray and the TaqMan assay.  The suspension 
microarray detected positive mosquitoes for the flaviviruses DENV2, JEV, KUNV and WNV 
(Table 4.11). No other flavivirus positive mosquitoes were available for testing. Of the eighteen 
virus-positive mosquitoes tested, 100% were detected using one round of amplification.  All 
negative mosquito controls returned negative test results. 
 
Table 4.11: Detection of individual virus-positive mosquitoes with the flavivirus suspension 
microarray following one round of amplification 
Individual  
Virus-Positive 
Mosquito 
Mean S/B ratio of probe (SD) 
 DEN
VU2 
DEN
V1 
DEN
V2 
DEN
V3 
DEN
V4 
JEV KOK
V 
KUN
V 
MVE
V 
MVE
V2 
SEP
V 
STR
V 
WN
V 
YFV 
DENV2 
(n=5) 
Mean 14.0 1.0 64.4 35.0 8.4 1.0 6.0 1.0 1.0 5.6 1.0 1.0 1.0 1.0 
SD 1.4 0.0 1.1 1.0 1.1 0.0 1.4 0.0 0.0 1.7 0.0 0.0 0.0 0.0 
JEV    
(n=5) 
Mean 1.0 1.0 3.0 5.6 1.0 19.2 1.0 1.0 3.0 2.2 1.0 1.0 1.0 1.0 
SD 0.0 0.0 0.7 0.9 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 
KUNV 
(n=4) 
Mean 1.0 1.0 1.0 11.3 1.0 1.0 10.5 24.5 5.0 2.3 1.0 1.0 12.0 1.0 
SD 0.0 0.0 0.0 1.5 0.0 0.0 0.6 1.0 0.8 0.5 0.0 0.0 0.0 0.0 
WNV 
(n=4) 
Mean 1.0 1.0 1.0 11.3 1.0 1.0 9.5 1.0 1.0 3.8 1.0 1.0 22.3 1.0 
SD 0.0 0.0 0.0 1.0 0.0 0.0 0.6 0.0 0.0 0.5 0.0 0.0 1.3 0.0 
 
“n” is the number of virus-positive mosquitoes tested for each virus.  Samples were run in triplicate 
and the S/B (sample-to-background) ratio of each replicate was calculated by dividing the MFI of 
the sample by the MFI of the negative control. The mean S/B ratio for the probe (±SD) was then 
calculated from the mean S/B ratio of the virus-positive mosquitoes tested   
 
 
The sensitivity and specificity of the flavivirus suspension microarray when compared to the 
TaqMan assay was 100%.  Some cross-reactivity was observed on the suspension microarray, 
however, the highest signal was always observed in association with the correct virus-specific 
probe.  This enabled identification of flavivirus positive samples, and a presumptive virus-specific 
diagnosis to be made. 
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4.3.6.2 Identification of virus-positive mosquitoes in mosquito pools 
Vector surveillance programs typically do not process mosquitoes individually, but in pools of 
between 50 and 100 mosquitoes, to reduce labour and costs.  Therefore, we validated the flavivirus 
suspension microarray against mosquito pools of 100, to determine its sensitivity for this purpose.   
 
Mosquitoes suspected to be virus positive were confirmed to be so by removal of the head, which 
was then tested by the virus-specific TaqMan assay.  If the mosquito was virus positive, the body 
was then spiked into a pool of 99 mosquitoes, extracted and tested in parallel on both the flavivirus 
suspension microarray and the TaqMan assay.  A total of ten mosquito pools, for five different 
flaviviruses, were tested. To investigate the sensitivity of the assay, the samples were run in parallel 
following either one or two rounds of amplification (Table 4.13 and Table 4.14).  All samples were 
run in triplicate. Aliquots of the extracted mosquito pools were also run on TaqMan assay, to 
confirm the results (Table 4.12).  These were run in duplicate due to the limited volume of extract 
available. 
 
Table 4.12: Detection of virus-positive mosquito pools using virus-specific TaqMan assays 
 Virus-positive mosquito pool 
 DENV3 
Pool1 
DENV3 
Pool 2 
DENV3 
Pool 3 
DENV3 
Pool 4 
DENV3 
Pool 5 
JEV 
Pool 
KUNV 
Pool 
WNV 
Pool 1 
WNV 
Pool2 
WNV 
Pool 3 
Mean 
TaqMan  
(Ct) 
 
33 
 
30 
 
28 
 
29 
 
28 
 
ND 
 
ND 
 
16 
 
ND 
 
17 
  
The sensitivity of the TaqMan virus-specific assays for the detection virus-positive pools was 
unexpectedly low at 70%.  However, the sensitivity of the flavivirus suspension microarray, when 
the extract underwent two rounds of amplification was 100%.  Cross-reactivity was observed 
between some of the probes in the suspension microarray, particularly the WNV probe.  This issue 
was identified during earlier validation.  KUNV is considered a subtype of WNV, and so the 
distinction between the two by molecular methods is difficult.  However, the highest signal was 
again associated with the virus-specific probe of interest, regardless of cross-reactivity, allowing a 
preliminary diagnosis to be made. 
 
The sample numbers used in this preliminary study are too low to allow definitive comparison of 
the suitability of the TaqMan assays and flavivirus suspension microarray for the detection of virus-
positive mosquito pools; although the results are surprising as it was anticipated both assays would 
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perform similarly.  However, when dealing with low titre samples the two rounds of amplification 
used on the suspension microarray would offer an advantage with respect to sensitivity, although it 
has disadvantages with respect to time, labour and potential for cross-contamination. Similarly, with 
low titre samples, there is always the potential for sample error to occur when small volumes, such 
as 5µL of sample, are used for the assay.  Additionally, a different extraction method was used to 
those previously published for validation of the TaqMan assays, and this may have an influence on 
the results due to the presence of inhibitors.  Ideally, samples of the mosquito pools pre-extraction 
would have been kept and tested on cell culture to confirm the samples as positive.  However, this is 
beyond the scope of this preliminary study and will require further evaluation on larger sample 
sizes. 
Table 4.12: Detection of virus-positive mosquito pools with the flavivirus suspension 
microarray following two rounds of amplification 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was 
calculated by dividing the MFI of the sample by the MFI of the negative control.  The mean of these 
replicate values is the mean S/B ratio of the probe (±standard deviation) 
Sample Stats Mean S/B ratio of probe (SD) 
  DENV
-U2 
DEN
V1 
DEN
V2 
DEN
V3 
DEN
V4 
JEV KO
KV 
KU
NV  
MV
EV 
MV
EV2 
SEPV STRV WNV YFV 
                
DENV3 
Pool 1 
Mean 34.9 1.9 5.2 21.2 15.1 1.0 0.9 1.2 0.9 0.5 0.9 0.9 1.0 1.1 
SD 1.0 0.1 0.9 0.6 1.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 
DENV3 
Pool 2 
Mean 32.1 1.8 3.8 20.5 11.7 1.0 0.9 1.0 0.9 0.5 0.9 1.0 1.0 1.2 
SD 1.7 0.2 0.5 1.0 0.8 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 
DENV3 
Pool 3 
Mean 32.4 1.8 4.7 19.8 13.3 1.0 1.0 1.1 0.9 0.5 0.9 1.0 1.0 1.1 
SD 0.9 0.2 0.6 0.2 0.6 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 
DENV3 
Pool 4 
Mean  27.5 1.4 2.6 28.9 11.8 1.1 0.9 0.9 0.9 0.9 1.0 0.9 1.0 1.0 
SD 0.5 0.1 0.4 0.3 0.2 0.1 0.1 0.0 0.0 0.0 0.2 0.1 0.1 0.1 
DENV3 
Pool 5 
Mean  27.1 3.4 4.6 31.5 16.9 1.0 0.9 0.9 1.0 0.9 0.9 0.9 1.0 1.0 
SD 0.6 0.5 0.8 0.7 0.4 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 
JEV 
Pool  
Mean 0.9 1.0 0.9 1.2 1.0 9.1 1.0 1.0 1.1 1.0 1.1 0.9 1.0 1.0 
SD 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 
KUNV 
Pool  
Mean 1.0 0.9 0.9 1.1 1.0 1.1 7.4 18.1 2.7 1.0 1.0 1.0 9.2 1.0 
SD 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 
WNV 
Pool 1 
Mean 1.0 1.2 1.2 1.2 1.1 1.2 10.9 1.1 1.1 1.0 1.1 1.2 13.6 1.1 
SD 0.0 0.1 0.1 0.1 0.0 0.0 0.3 0.0 0.1 0.1 0.1 0.0 0.8 0.1 
WNV 
Pool 2 
Mean 1.0 1.1 1.0 4.3 1.1 1.0 16.7 1.0 1.0 0.9 0.9 1.1 20.1 0.9 
SD 0.1 0.2 0.1 0.2 0.0 0.1 0.7 0.0 0.2 0.3 0.1 0.1 1.0 0.1 
WNV 
Pool 5 
Mean 1.0 1.0 1.1 4.1 0.9 1.1 15.4 1.0 1.1 1.0 0.9 1.2 19.3 0.9 
SD 0.1 0.1 0.1 0.2 0.1 0.1 0.5 0.1 0.2 0.2 0.1 0.1 1.2 0.0 
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Table 4.13: Detection of virus-positive mosquito pools with the flavivirus suspension 
microarray following one round of amplification 
Virus-Pos 
Mosquito 
Pool 
Stats Mean S/B ratio of probe (SD) 
  DE
NV-
U2 
DE
NV1 
DE
NV2 
DE
NV3 
DEN
V4 
JEV KO
KV 
KU
NV  
MV
EV 
MV
EV2 
SEP
V 
STR
V 
WN
V 
YF
V 
DENV3 Pool1 Mean 19.9 1.2 1.2 25.2 3.5 0.9 1.0 1.0 0.9 1.1 1.0 0.9 1.0 1.0 
SD 0.4 0.1 0.0 0.6 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 
DENV3 Pool2 Mean 18.3 1.3 1.1 22.1 3.6 0.9 1.0 1.0 0.9 1.0 1.1 1.1 1.1 1.0 
SD 0.3 0.1 0.0 0.5 0.4 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 
DENV Pool3 Mean 29.6 1.5 1.4 35.8 6.8 0.9 1.0 1.0 0.9 0.9 1.0 1.0 1.0 1.1 
SD 1.2 0.1 0.2 0.8 0.5 0.0 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.0 
DENV Pool4 Mean 30.8 1.2 1.5 34.3 8.2 1.0 1.0 0.9 1.1 1.0 0.8 1.0 0.9 1.0 
SD 3.4 0.1 0.0 3.5 1.2 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 
DENV Pool5 Mean 39.7 1.5 2.6 42.6 15.2 1.1 1.1 0.9 1.2 1.0 0.9 1.0 1.0 1.1 
SD 1.5 0.1 0.2 1.1 0.7 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.0 
JEV Pool  Mean 0.7 0.8 0.7 1.0 0.7 0.6 0.6 0.6 0.8 0.7 0.7 0.9 0.7 0.6 
SD 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.0 
KUNV Pool  Mean 1.1 1.1 0.9 1.1 1.0 1.1 1.0 1.5 1.1 1.0 1.0 1.3 9.0 1.2 
SD 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.2 0.2 0.1 0.0 0.1 0.3 0.1 
WNV Pool1 Mean 1.1 1.0 1.0 4.0 1.0 1.0 9.5 0.9 1.1 1.2 1.1 1.0 20.4 1.0 
SD 0.1 0.1 0.1 1.4 0.1 0.1 0.3 0.1 0.0 0.5 0.1 0.0 0.4 0.0 
WNV Pool2 Mean 1.1 1.0 1.2 5.2 1.1 0.9 23.3 1.0 1.1 0.9 0.9 1.3 30.9 0.9 
SD 0.1 0.1 0.1 1.0 0.0 0.1 1.2 0.1 0.2 0.1 0.1 0.1 2.5 0.0 
WNV Pool5 Mean 1.1 1.1 1.1 4.8 1.2 0.9 23.3 1.0 1.1 0.9 0.9 1.3 31.1 1.0 
SD 0.1 0.1 0.0 1.7 0.1 0.1 1.7 0.1 0.2 0.0 0.1 0.0 2.9 0.1 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was 
calculated by dividing the MFI of the sample by the MFI of the negative control.  The mean of these 
replicate values is the mean S/B ratio of the probe (±standard deviation) 
 
 
The sensitivity of the flavivirus suspension microarray, when the extract underwent one round of 
amplification was 90%. All pools were positive with the exception of JEV (Table 4.14).  
Interestingly, although the KUNV-positive pool was identified as being flavivirus positive, it was 
actually the WNV probe that produced the highest signal.  This may suggest that the WNV probe 
has the greater hybridisation efficiency when amplicon is in limited supply.   
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Although these results only represent a small sample size and will require validation on a much 
larger number of samples, they suggest that the flavivirus suspension microarray has potential for 
use in the screening of mosquito pools for surveillance purposes and that further work is warranted. 
4.3.7 Repeatability of results 
To determine reproducibility of results, several samples were amplified on separate days with 
different batches of mastermix and then run on the suspension microarray with good consistency of 
results (data not shown). 
 
Duplicate assays, in which the mosquito pool samples were run in triplicate on each assay, were 
conducted to determine the repeatability of the results.  All results were in concordance (data not 
shown). 
4.4 Discussion 
This study aimed to develop a multiplexed suspension microarray for twelve flaviviruses of public 
health importance to Australia.  Development of rapid and cost-effective diagnostic tests for 
flaviviruses has been identified as an important research priority globally (Domingo et al., 2011).  
We investigated the use of suspension microarray technology for this purpose and our preliminary 
validation shows the assay has promise for clinical diagnosis and surveillance purposes.  
Suspension microarray technology has already proven a useful molecular tool for the diagnosis of 
fungal (Das et al., 2006, Page et al., 2006, Diaz et al., 2006, O'Donnell et al., 2007, Diaz & Fell, 
2004, Etienne et al., 2009), bacterial (Cowan et al., 2004, Huang et al., 2008, Wilson et al., 2005, 
Lin et al., 2008, Boving et al., 2009, Dumonceaux, 2009, Liu et al., 2012), protozoal (Ros-Garcia et 
al., 2012) and viral pathogens (Boving et al., 2009, Lee et al., 2007, Kuriakose et al., 2012, Mahony 
et al., 2010) of veterinary and medical importance.  However, this is the first report we are aware of 
that this technology has been used to develop a test for the detection of flaviviruses of importance in 
the Australiasian region or for vector-based surveillance. 
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4.4.1 Adaptation of validated molecular tests to suspension microarray 
The successful modification of methods from validated molecular tests to suspension microarray 
technology was clearly demonstrated with respect to primers, probes and amplification strategies.  
Previously published and validated consensus primers were used for amplification, while four 
published TaqMan RT-PCR virus-specific probes were adapted for use in the flavivirus suspension 
microarray by the addition of a 12-C amino linker at the 5’end (Pierre et al., 1994, Pyke et al., 2004, 
Lanciotti et al., 2000).   The study also reports a novel amplification method adapted from chip 
microarray to suspension microarray format for the first time (Lodes et al., 2007). The ability to 
assimilate previously validated molecular techniques into the suspension microarray format is a 
significant benefit to the robustness of the assay and the time and costs involved in development.  
The proven potential to expand the panel further by the inclusion of additional probes to be more 
comprehensive and adaptable is also a significant advantage. 
  
4.4.2 Probe design and evaluation 
Nine new probes were designed and passed evaluation to be included with the five encephalitic 
flavivirus probes from the previous chapter, to create the fourteen-plex flavivirus suspension 
microarray. The DENV-universal probe showed 97.7% sensitivity in the detection of DENV 
positive virus culture and clinical samples tested, making it an excellent internal positive control.  
The potential to include a flavivirus genus-specific probe in the assay as a positive control was also 
investigated.  However, this did not prove possible, as the identified areas of consensus within the 
amplified region did not meet the design criteria for the probes required in our assay.  We were able 
to address this issue in part by the inclusion of multiple probes for several viruses, and with the 
inherent cross-reactivity of some of the probes, as discussed below. The novel approach to the 
inclusion of a synthetic control to act as a positive amplification control was again successfully 
incorporated into this assay. The inherent advantages of the multiplex suspension microarray with 
respect to flexibility, cost, labour and sensitivity were highlighted in comparison to standard uniplex 
assays; and by the ease with which additional probes could be included as controls or designed to 
address sequence mismatches.   
 
Cross-reactivity was seen between some probes and closely related viruses. The cross-reactivity 
was most notable for viruses within the same phylogenetic clade, for example the dengue viruses, or 
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KUNV and WNV.   This was not surprising as we targeted a highly conserved region of the genome 
in the NS5-3’UTR region, in order to allow universal primers to be used. We chose to use universal 
primers rather than a multiplex PCR for a number of reasons, including simplification of the 
protocol, limiting potential primer-probe interactions and reduced costs.   
 
In some cases the cross-reactivity improved the sensitivity of the assay as will be discussed further 
in this chapter. However, although cross-reactivity did show advantages, we attempted to limit it by 
designing alternative probes.  For example, multiple attempts to design more specific probes for the 
dengue viruses proved unsuccessful.  However, although cross-reactivity proved impossible to 
eliminate in some cases, we believe the flavivirus suspension microarray shows potential as a 
screening test.  In the majority of cases the highest signal is associated with the relevant virus-
specific probe, allowing a preliminary diagnosis to be made.  Further testing can be conducted to 
confirm a specific diagnosis, by alternative molecular tests or sequencing of the product produced. 
4.4.3 Protocol optimisation 
The optimal PCR and suspension microarray conditions for the flavivirus panel were assessed 
before being adopted for validation of this assay. The experiments were conducted in an identical 
manner to the optimisation of the alphavirus and encephalitic suspension microarrays. Although 
there is great variation in the literature as to the optimal conditions for suspension microarrays, 
there was a general concordance between the assays we developed, including the adoption of a 
novel amplification technique. This has been discussed more fully in previous chapters.  
Additionally, multiplexing the fourteen probes in this assay again showed no significant effect on 
assay sensitivity. The key importance of these findings is that it may allow the potential for further 
multiplexing of the flavivirus and alphavirus assays at a later date.  
 
A drawback of multiplex assays is the difficulty in optimising conditions for all viruses of interest.  
Further optimisation of the flavivirus suspension microarray may have improved the detection limit 
for some viruses.  However, this could potentially adversely affect the sensitivity of the other 
probes.  It was also too costly and time-consuming to include all viruses in the initial optimisation 
experiments, which investigated parameters such as the optimal MgS04 concentration during 
amplification, hybridisation temperature during microarray annealing and wash protocols.  This 
problem is difficult to overcome, and is an issue for all multiplex assays. However, every effort was 
made during the design stage to ensure that probe annealing conditions would be as consistent as 
possible. 
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4.4.4 Specificity, sensitivity and validation 
Of primary importance for validation was to ensure the flavivirus suspension microarray was 
specific, with the ability to detect sequence variation between virus strains. We tested the flavivirus 
suspension microarray against 64 reference viruses, 92 clinical samples, 18 individual virus-positive 
mosquitoes and 10 mosquito pools. We found the flavivirus suspension microarray to have good 
specificity during validation with 95% of the reference viruses, 93% of the serum samples, 100% of 
the individual virus-positive mosquitoes and 90% of the virus positive mosquito pools identified to 
the specific virus, with just one round of amplification. The results not only confirmed the flavivirus 
suspension microarray’s ability to effectively detect and discriminate between the viruses of 
interest, but also its utility with a broad range of sample types. 
 
An acknowledged disadvantage of molecular diagnostics is that their sensitivity can be affected by a 
small number of nucleotide changes in the virus, resulting in false negatives (Das et al., 2008). This 
is highly undesirable, especially for exotic virus incursions where a rapid diagnosis and early 
response is critical.  Therefore, the validation panel was specifically selected to include viruses from 
different geographical regions and time periods.  The reference collection contained numerous 
strains for some viruses, such as DENV and JEV.  However, for the other viruses, the number of 
strains available was limited.  This was especially undesirable for Yellow fever virus, a virus of 
vital public health importance in our panel. However, due to regulations restricting the movement of 
exotic viruses, it was not possible to overcome this problem during the timeframe of the project. 
The use of synthetic oligonucleotides for further evaluation of this probe may be desirable in the 
future validation of this assay, although BLAST alignments with sequences available on GenBank 
confirmed the probe shared identical sequence to many YFV strains. 
 
Cross-reactivity was seen between some probes and closely related viruses but was considered 
acceptable, and in some cases advantageous. A previous study which used consensus primers also 
reported probe cross-reactivity, but found that the pattern of probe reactions still allowed species 
identification (Page & Kurtzman, 2005).  We also found this to be the true and in the vast majority 
of cases the pattern of the highest signals enabled correct preliminary diagnosis of the specific virus. 
For example, the DENV-2 and DENV-3 probes were quite cross-reactive, producing low signals 
with several other viruses.  However, the signal produced by the DENV-universal probe, was 
specific for the DEN viruses.  Thus, a sample positive on both the DENV-universal and either the 
DENV2 or DENV3 probe could be considered specific for that virus. Although the cross-reactivity 
seen between the dengue strains was not ideal, as it made specific genotyping difficult, multiple 
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attempts to improve the specificity of these probes by redesigning them were unsuccessful.   
However, the correct specific diagnosis was still made in 93% of the dengue serum samples, while 
the cross-reactive probes also acted as internal positive controls for the assay. 
 
Investigation of the DENV probe cross-reactivity included literature review and sequence 
alignments.  Similar to other suspension microarray studies, we used NCBI BLAST analysis 
(Altschul et al., 1990) during the design process to screen probes for specificity (Diaz and Fell, 
2005, Dumonceux et al., 2009, Kuriakose et al., 2012). However, one study which also used 
concensus primers, reported that probe verification by BLAST analysis provided limited prediction 
of specificity during laboratory testing, with probes showing three or more nucleotides of mismatch 
still cross-reactive with closely related species (Page and Kurtzman, 2005). In an attempt to trouble-
shoot, sequences from GenBank were aligned using ClustalX (Thompson et al., 1997) to locate 
candidate regions for new probes showing high conservation within the serotype but variability 
between the serotypes. Ideally, we hoped to identify suitable regions towards the 3’end of the 
amplicon, as we had had most success designing probes for this region, as discussed previously.  
We then attempted to design probes that both targeted these regions and met the requirements of 
assay with the assistance of the program Primer Express
™
.  However, due to the high degree of 
sequence identity in the region and the design criteria for the probes, only a few target regions were 
identified and the small number of probes ordered did not pass validation. As discussed previously, 
probe design for suspension microarrays requires a trial and error approach, with many factors 
potentially influencing the ability of a probe to bind to PCR amplicon. Screening a larger panel of 
candidate probes should be considered for future studies and may prove more successful. 
 
Other suspension microarray studies which have utilised universal primers to target conserved 
regions of genome have detailed similar issues with cross-reactivity and another study concluded 
the cross-reactivity between probes was “undoubtedly the result of the close genotypic similarities 
among the species” in the targeted region (Deak et al., 2010).  Overcoming the issue of cross-
reactivity between the DENV probes would require the design and validation of four new serotype-
specific probes.  However, the sensitivity of the suspension microarray for detection of DENV was 
good during validation and virus identification could be reached based on the guidelines discussed 
above.  Therefore, further design of alternative probes was not attempted at the time, as the 
indications were that the assay would be most suitable for a low-cost screening test and due to the 
restrictions of the project timeline. Future studies could reinvestigate this issue, as the availability of 
a greater number of sequences now on GenBank means there is potential to repeat the alignments to 
identify alternative target regions, either for each DENV serotype, or for sub-groups within the 
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serotype.  Alternatively, the DENV-Universal probe had good sensitivity and consideration was 
given to using it as a replacement for all four serotype-specific probes; however inclusion of 
multiple probes did provide additional information on the serotype, as well as some protection 
against false negatives due to strain variation. 
 
An additional advantage of the cross-reactivity observed in the flavivirus suspension microarray 
was that it helped prevent false negative results.  The WNV Koutango strain could not be detected 
in the five-plex encephalitic panel (reported in the previous chapter); however, when the panel was 
expanded to fourteen-plex the sample tested positive. The KOKV probe produced a positive signal, 
preventing a false negative result.  There is potential to extend the panel to include multiple probes 
for each virus for this purpose. A specific probe could be designed and incorporated to specifically 
detect WNV Koutango is desired.  Likewise, the panel can easily be adapted by the addition of new 
probes if mutations or strain variations for certain viruses are noted.  This flexibility is a real 
advantage of the suspension microarray technology.  It also highlights the advantages of using 
consensus primers, to aid in the detection of viruses which may not have been specifically targeted 
based on a clinical history or geographical location alone. 
 
Therefore, although cross-reactivity was observed, we believe the flavivirus suspension microarray 
would still make an excellent screening test.  Few false negatives were observed and the assay 
offers a new level of cost, time and labour reduction compared to tests currently available.  The cost 
of screening this panel of flaviviruses alone would be 25 to 50 times greater per sample using 
individual TaqMan assays over the flavivirus suspension microarray, without taking into account 
the considerable labour cost. If a positive diagnosis is reached on the suspension microarray, further 
testing can then be performed to confirm the specific diagnosis, by either TaqMan RT-PCR or 
sequencing of the product produced.   
 
To evaluate the sensitivity of the flavivirus suspension microarray, it was compared to TaqMan RT-
PCR and RT-PCR followed by gel electrophoresis in an identical method to that discussed in the 
previous chapters.  No particular assay consistently performed superiorly. The flavivirus suspension 
microarray was the most sensitive assay for the detection of DENV1, DENV2, DENV3, DENV4, 
MVEV, WNV and YFV when two rounds of amplification were used.  Identical probes for WNV 
were used in both the TaqMan RT-PCR and flavivirus suspension microarray and the suspension 
microarray was found to be more sensitive.  The improved sensitivity may be due to the use of the 
consensus primers, the two rounds of amplification or a combination of the two.  Both assays were 
 145 
equally sensitive for KOKV.  Therefore, the flavivirus suspension microarray shows real potential 
as an alternative to TaqMan for the diagnosis of these viruses. 
 
The TaqMan RT-PCR was the most sensitive assay for the detection of JEV, KUNV, SEPV and 
STRV.  The TaqMan RT-PCR and flavivirus suspension microarray used identical probes for JEV 
and STRV, yet the TaqMan was the most sensitive assay. This was noted previously in the 
encephalitic suspension microarray and possible explanations for this were discussed in that 
chapter.  The detection limit on gel electrophoresis and flavivirus suspension microarray was 
generally the same when one round of amplification was used for both assays (results not shown).  
However, as double stranded DNA is required for visualisation of DNA by gel electrophoresis,  it 
was not possible to directly compare sensitivities when two rounds of PCR, one preferentially 
generating single stranded DNA, was used for the suspension microarray (Spiro et al., 2000, Deregt 
et al., 2006b). Gel electrophoresis after one round of amplification still provided useful information 
and acted as a positive control, ensuring that all strains in the panel were amplified.  Despite being 
less sensitive than the TaqMan for a small number of viruses, the flavivirus suspension microarray 
still showed excellent sensitivity for the majority of these, in particular KUNV and SEPV; and 
offers a viable alternative. 
 
For this study, we defined the gold standard test for quantification of virus as virus culture.   As the 
purpose of this study was to compare the sensitivity of several assays, we opted to use viral culture 
methods to quantify the viral titre and then use the same aliquot of sample for all three assays to 
allow a direct comparison of their sensitivity.  Likewise, it allowed comparison with the real-world 
situation, where virus-positive clinical and mosquito samples are usually quantified by virus culture. 
Not all viruses form plaques in cell culture and this has been observed with the dengue viruses.  
Therefore, TCID50 assays were performed for quantification of these viruses. It should be noted that 
virus culture does not take into account the non-viable virus particles which may be detected in a 
molecular assay.  However, this issue was not considered to be a major concern as the main aim 
was to directly compare three molecular assays, which was achieved by utilising the same dilution 
series and aliquots for all assays. 
 
The sensitivity of the TaqMan RT-PCR assay was lower than expected for YFV.  TaqMan assays 
are typically very sensitive and a YFV specific TaqMan assay recently published had a detection 
limit of 3.5pfu/ml (Chao et al., 2007).  The detection limit of both the TaqMan RT-PCR and 
flavivirus suspension microarray were higher than this for the YFV sample tested in the sensitivity 
study. Gel electrophoresis confirmed virus extraction and amplification occurred, however, it is not 
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possible to completely rule out suboptimal extraction without repeating the experiment. As the main 
aim of the study was to address whether the flavivirus suspension microarray would offer a better 
alternative than the individual TaqMan assay currently offered for YFV the matter was not 
investigated further at this point. Parallel testing showed that the TaqMan and flavivirus suspension 
microarray had a similar limit of detection for YFV. However, in the future it may be worth 
repeating the experiment and evaluating both these tests again to determine if further optimisation is 
required.  Although the detection limits were not as low as desired for all probes, these results 
suggest the flavivirus suspension microarray would be capable of detecting positive samples in the 
real-life situation; as the validation process determined the sensitivity of the microarray was 
appropriate for a range of samples.   
 
4.4.5 Multiplexing 
As discussed in the previous chapters, the MFI values for probes tested either in uniplex or 
multiplex were similar.  The flavivirus suspension microarray expanded the encephalitic suspension 
microarray’s panel of five probes to fourteen probes, and found it did not affect the diagnostic 
result.  Other studies have also found multiplexing of up to 16 probes to produce no significant 
effect on MFI (Diaz et al., 2006).  Only one study has reported a subsequent loss of sensitivity 
following multiplexing of the suspension microarray (Wilson et al., 2005).  However, in this case 
the multiplex suspension microarray also involved multiplex PCR; and the loss of sensitivity was 
attributed to the multiplexing of the PCR reaction.  Of particular note was that they were able to 
improve the sensitivity of the assay be doubling the amount of Taq polymerase added to the PCR 
reaction.  This protocol should be considered if the alphavirus and flavivirus suspension 
microarrays are eventually multiplexed at a later date. 
4.4.6 Clinical diagnosis 
A retrospective study was conducted using 92 serum samples submitted to QHFSS during 2009, 
when concurrent DENV outbreaks involving multiple genotypes were occurring in northern 
Queensland and the Pacific.  This clinical study confirmed that the flavivirus suspension microarray 
was sensitive enough for use in a diagnostic laboratory for the diagnosis of dengue from serum 
samples.   
 
 147 
 
The flavivirus suspension microarray had a 100% negative predictive value and a 91% positive 
predictive value for the dengue clinical samples used in this study compared to the gold standard 
TaqMan assays, when one round of amplification was used.  However, the samples available were 
retrospective and so each sample had an additional freeze-thaw cycle before being run on the 
suspension microarray, which could affect the quality of the extracted RNA. Further validation in 
the future should include the opportunity to test these two assays in parallel during routine 
diagnostic procedures, to enable comparison with the current gold standard tests. 
 
These preliminary results are highly promising.  Firstly, they indicate that only one round of 
amplification may be appropriate for screening DENV clinical samples during outbreaks.  This 
would offer a cost and time-saving component.  The DENV-universal probe also proved to be an 
excellent internal positive control and was capable of detecting not only all genotypes but also 
different strains from a variety of locations.  Finally, although cross-reactivity was seen, using the 
highest signal or pattern of signals, it was possible to identify the correct DENV genotype in the 
majority of cases.  Therefore, the flavivirus suspension microarray proved to be a useful tool for the 
diagnosis of dengue in clinical samples. 
4.4.7  Application of the flavivirus suspension microarray to mosquito 
surveillance 
The flavivirus suspension microarray was compared to the TaqMan assays and found to be more 
sensitive for screening of mosquito pools.  As mosquito pools were in limited supply, the heads of 
suspected virus-positive mosquitoes were tested first by TaqMan assay to ensure they were virus 
positive before being spiked into the pools.  These pools were therefore known to be true positives 
and the results from the evaluation of the flavivirus suspension microarray and individual TaqMan 
assays were compared directly to these.  The ability of the suspension microarray to detect an 
infected mosquito in a pool of 100 was similar to the requirements of a diagnostic test used for 
mosquito surveillance. 
 
We found the flavivirus suspension microarray was 100% sensitive with two rounds of 
amplification, compared to 70% sensitivity for the individual TaqMan assays, when tested on 10 
mosquito pools.  The Taqman results for the JEV, KUNV and one WNV pool were negative.  Even 
when only one round of amplification was used for the suspension microarray, it outperformed the 
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TaqMan assays with 90% sensitivity.  Therefore, the flavivirus suspension microarray shows great 
potential as an alternative diagnostic test for mosquito screening, although much larger sample sizes 
will be required to further validate the assay. 
 
The results for JEV pool tested on the flavivirus suspension microarray are in accordance with our 
sensitivity study which indicated that the flavivirus suspension microarray has a lower sensitivity 
for JEV than some other viruses.   However, we only had the resources to test one pool, and sample 
handling or extraction issues may also have contributed to this result.  The results from the 
encephalitic study, which used a different JEV pool, produced a much higher signal following just 
one round of amplification.  Therefore, this would suggest that further investigation is warranted 
before the flavivirus suspension microarray is considered to be inferior for the detection of JEV 
positive pools.  The assay could potentially be used for routine mosquito based surveillance, as it is 
sensitive enough to detect one positive mosquito in a pool of a hundred. 
 
The specificity of the flavivirus suspension microarray was good, although cross-reactivity was 
observed between some of the probes, particularly the KUNV and WNV probe.  This issue was 
identified during earlier validation.  KUNV is considered to be closely related to WNV, and so the 
distinction between the two by molecular methods is difficult.  Of particular interest was the fact 
that the KUNV positive pool tested positive with the WNV probe after one round of amplification, 
but not the KUNV probe.  After two rounds of amplification both the WNV and KUNV probes 
gave a positive signal, with the KUNV probe signal twice that of the WNV probe.  This may 
indicate that the WNV probe is more sensitive than the KUNV probe and has better hybridisation 
efficiency.   However, we know from the validation study that the KUNV probe is more specific 
than the WNV probe.  This signal pattern will need to be considered in interpreting results from the 
flavivirus suspension microarray in the future when looking for a specific diagnosis. 
 
The flavivirus suspension microarray has potential for use in the screening of mosquito pools for 
surveillance purposes. The results from this study suggest that in a surveillance situation, this would 
be sufficient for a low-cost preliminary screening and positive samples could undergo further 
confirmatory testing to specifically identify the virus.  Although ideally the assay would have been 
validated on a larger number of mosquito pools, this preliminary investigation suggests that a larger 
scale study, potentially run in parallel with a real-life mosquito surveillance program would be 
warranted.  The fact the flavivirus suspension microarray was also tested on 18 individual virus-
positive mosquitoes after one round of amplification and was found to have 100% specificity and 
sensitivity compared to the TaqMan, adds further weight to this evaluation. 
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4.4.8 Repeatability 
Finally, of critical concern with any diagnostic assay is its repeatability and reproducibility.  All 
samples were run in triplicate on the suspension microarray and the standard error between results 
was determined.  Intraplate repeatability was high and all samples consistently returned the same 
diagnostic result and the standard error was low. Reproducibility is also important and was 
evaluated by running the samples from the mosquito pools through the assay twice on different 
days, in triplicate.  Again, the results from both days produced consistent results. These findings are 
consistent with previous studies that have investigated the repeatability and reproducibility of 
suspension microarrays (Schmitt et al., 2006, Kuriakose et al., 2012). Although we have not had the 
opportunity to test this reproducibility between laboratories, this would be the next step in 
evaluation.  We would expect excellent inter-laboratory reproducibility from suspension 
microarrays due to the ease of the laboratory protocol and the use of a median signal, based on 
analysis of 100 beads.  These factors all contribute to a repeatable, robust assay. 
4.5 Conclusion 
The flavivirus suspension microarray is the first multiplexed molecular assay to target the endemic 
and exotic flaviviruses of public health importance to Australia. The expansion of the encephalitic 
suspension microarray that detected four encephalitic flaviviruses to an assay that was capable of 
detecting 12 flaviviruses was successful through the inclusion of 9 new probes designed specifically 
for this assay. This was accomplished without a loss in diagnostic sensitivity in the assay from 
multiplexing.  The flavivirus suspension microarray was also validated against a panel of clinical 
samples and mosquito pools and was proven to have the necessary sensitivity and specificity to 
make it a useful diagnostic tool for these samples.  This is the first reported use of a suspension 
microarray for mosquito surveillance or diagnosis of clinical flavivirus cases.   
 
The flavivirus suspension microarray has shown great promise as a diagnostic assay for arboviruses 
of great public health significance globally, such as DENV, JEV, WNV and YFV.  The flaviviruses 
targeted in this assay have non-specific clinical signs that require laboratory diagnosis for correct 
identification (Barnard et al., 2011). The assay has been found to be highly sensitive and specific 
when validated against a panel of 65 reference strains, 92 serum samples submitted for dengue virus 
screening and ten pools of mosquitoes.  Ideally, the validation panel would be expanded to include 
more clinical samples and virus strains, as the extent of our validation was limited by the exotic 
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status of several viruses in the panel, in particular YFV.  Future studies would involve further 
validation of the assay by running it in parallel with current diagnostic tests for flaviviruses in the 
diagnostic setting.  However, this preliminary study has demonstrated the utility of the flavivirus 
suspension microarray for several purposes.   
 
The multiplexing capability of the flavivirus suspension microarray is a great advantage for a 
diagnostic laboratory as it allows samples to be screened for multiple viruses with minimal 
additional costs with respect to time, reagents or labour. The use of multiplex, suspension 
microarrays for other pathogens has been found to decrease under-reporting and in some cases 
increase detection of concurrent infections (Brunstein & Thomas, 2006, Mahony et al., 2007, Oh et 
al., 2007, Liu et al., 2012). These issues have previously been noted of concern for flavivirus 
diagnosis (Korimbocus et al., 2005, Mohammed et al., 2010, Kularatne et al., 2009). Suspension 
microarrays have been reported to be sensitive and specific; with key advantages over current 
molecular techniques. Our experience with this technology is in accordance with these reports, with 
the flavivirus suspension microarray being easy to use, flexible and cost-effective. 
   
There are numerous new avenues to explore for this assay to further exploit the advantages of 
suspension microarray technology. The potential to multiplex the assay with an alphavirus 
suspension microarray, which was developed concurrently by identical methods, should be 
investigated.  This would allow screening for other viruses of public health importance to Australia, 
such as Barmah Forest virus, Ross River virus and Chikungunya virus to be included in the one 
assay.  Recent outbreaks of arboviral disease in horses in Australia has also highlighted the 
usefulness of this assay for veterinary diagnostics (Roche, 2013).  Recent progress in mosquito-
based arbovirus surveillance may also prove compatible with the suspension microarray, with the 
utilisation of the assay to detect virus in sugar-baited nucleic preservation acid cards rather than 
mosquito pools (Lothrop et al., 2012, van den Hurk et al., 2012). This could be investigated as a 
means to further reduce the costs associated with mosquito-based surveillance. The potential also 
exists to further expand the panel to include other emerging flaviviruses, such as Zika virus. The 
adoption of a multiplexed suspension microarray as a screening test for flaviviruses has the 
potential to improve both clinical outcomes and exotic disease preparedness.  
 
In conclusion, we report a multiplex assay which has the potential to improve surveillance and 
diagnosis of endemic and exotic flaviviruses in Australia.  The flavivirus suspension microarray is a 
specific, sensitive and rapid diagnostic test for the detection of twelve flaviviruses of public health 
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importance to Australia.  At the time of development, it was estimated the cost was potentially up to 
fifty-times less than the alternative uniplex assay used for this purpose in our laboratory. 
 
 
 
 152 
Chapter 5: Challenges, Future 
Perspectives and Conclusions 
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5.1 Introduction 
The focus of this project was to develop new diagnostic tests for emerging disease threats in the 
Australian region.  The biosecurity risks that exotic viruses pose to Australia that were identified at 
the time the project commenced in 2007 have been supported by later events and research.  An 
explosive epidemic of dengue occurred in North Queensland in 2008-2009 (Ritchie et al., 2013), 
while unprecedented cases of chikungunya virus (CHIKV) have been detected in travellers to 
Australia, with a peak in 2010 (Viennet et al., 2013). Other recent research has supported the 
identified risk of the introduction and establishment of competent vectors for arboviruses to 
Australia (Beebe et al., 2013)  and the vector competence of endemic vectors for exotic viruses (van 
den Hurk et al., 2010, van den Hurk et al., 2011), which could also greatly impact public health if 
these exotic diseases were introduced. Economic studies also continue to support the public health 
importance of surveillance and early detection for management of exotic viruses (Vazquez-
Prokopec et al., 2010).   
 
The overarching aim of these studies was to develop multiplex assays for the detection of the 
alphaviruses and flaviviruses of public health importance in the Australasian region.  The first 
priority was to assess suspension microarray technology; a method not previously used in the 
QHFSS virology laboratory and which was only just emerging as a potential molecular diagnostic 
tool.  Over the course of this project, suspension microarray technology has proven itself to be a 
very useful diagnostic tool for the molecular detection of fungal, bacterial, protozoal and viral 
pathogens of veterinary and medical importance (O'Donnell et al., 2007, Etienne et al., 2009, Huang 
et al., 2008, Lin et al., 2008, Boving et al., 2009, Dumonceaux, 2009, Lee et al., 2007, Liu et al., 
2012, Ros-Garcia et al., 2012, Kuriakose et al., 2012, Mahony et al., 2010, Liao et al., 2012, Foord 
et al., 2013, LeBlanc et al., 2010, Navidad et al., 2013). We found the advantages of the suspension 
microarray format to be as described in the literature; in that it was cost effective and rapid, with 
excellent multiplexing capabilities.  Additionally, we found it was a flexible tool that was not only 
capable of incorporating previously validated molecular techniques but compatible with the 
microarray chip technology we aimed to use in the future for genotyping.  This made the suspension 
microarray format a highly desirable diagnostic tool to develop for our laboratory.   
 
The flavivirus suspension microarray developed during the course of this project is the first 
multiplexed molecular assay to target the endemic and exotic flaviviruses of public health 
importance to Australia; namely DENV(1-4), JEV, KOKV, KUNV, MVEV, SEPV, STRATV and 
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YFV.  Similarly, the alphavirus suspension microarray is the first suspension microarray reported 
that we are aware of to target the medically important BFV, CHIKV, RRV and SINV.  There is 
currently no multiplex molecular test available for the detection of all alphaviruses and flaviviruses 
of public health significance to Australia.  It is hoped that these two assays will provide the 
foundation to create one in the near future.  The alphavirus and flavivirus suspension micorarrays 
were validated against a range of samples and showed appropriate specificity and sensitivity for 
clinical and vector surveillance purposes.  Together, these assays help bridge the identified need for 
molecular assays to target these important emerging diseases, and are the first suspension 
microarrays to have been evaluated for screening vector-surveillance samples.    
 
Molecular genetics and diagnostics are rapidly evolving fields. Since this project commenced there 
have been advances in both molecular diagnostics and surveillance techniques. The availability of 
this new information would have helped to overcome some of the significant challenges faced at the 
commencement of the project.  However, the suspension microarray format has proven to be very 
adaptable and has the potential to be compatible with some of the recent scientific advances in the 
field. The results from this project provide an alternative tool to address the current limitations of 
effective diagnosis and surveillance for endemic and exotic flaviviruses of public health concern to 
Australia. 
5.2 Challenges Encountered 
5.2.1 Sequence availability on GenBank 
One of the initial challenges encountered with this project was obtaining sequence data for use in 
probe design.  Although many of the viruses included in the test panel cause significant medical 
disease, there was little data available on the GenBank database.  Since this project commenced, the 
number of full genome sequences on GenBank has been increasing exponentially.  In 2005, less 
than 30 out of over 70 complete flavivirus genome sequences were known and there was similarly a 
limited number of partial sequences, especially in the relevant NS5 region (Bollati et al., 2010). 
This was a problem for the development of both diagnostic tests and drugs and lead to the funding 
of a large scale genomics project, VIZIER, in 2004 (Coutard & Canard, 2010).  However, 
sequencing progress was not rapid, particularly in the NS5 region and by 2007 there were only 
approximately 10 relevant sequences on GenBank for even the clinically important viruses such as 
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dengue virus. This number has increased into the hundreds over the past six years, which would 
enable some aspects of the project to be revisited.   
 
Exhaustive characterisation of the mosquito-borne flaviviruses still needs to be achieved. Even now, 
sequence availability for some medically important endemic flaviviruses is very limited (Mann et 
al., 2013). However we still believe the NS5/3’NTR and NS1 regions of the flavivirus and 
alphavirus respectively are good targets due to their conserved nature. Additionally, at least one 
sequence was available for the targeted region of all viruses at the time, and even when this was 
only a partial sequence, it was used for probe design if it overlapped with the anticipated region of 
the amplified product.  In this way we were able to design a probe for all viruses we aimed to target.   
 
Despite the difficulties imposed due to the limitations of the sequence availability, the approach we 
adopted appears to have been robust. For example, based on sequence alignment using BLAST, the 
probes designed have proved to have 100% homology with the most recent strains of KUNV and 
MVEV to cause outbreaks in Australia.  This is despite the fact that mutations have occurred in the 
KUNV strain, making it more neurovirulent (Frost et al., 2012).  By using consensus primers that 
target a highly conserved region of genome under decreased selection pressure, the assay is less 
likely to be affected by point mutations that may occur in more variable regions of the genome.  
Therefore, as the list of sequences available on GenBank over the past years has expanded, so has 
the list of virus strains which show homology with the probes used in our assay  
5.2.2 Probe design 
Probe design guidelines from previously published suspension microarray studies were adopted for 
the development of both the alphavirus and flavivirus suspension microarrays.  However, as with 
previous studies, we found probe design required a trial and error approach and some probes 
required redesigning despite care taken in the design process (Diaz et al., 2006, Ros-Garcia et al., 
2012).  Nonetheless, our experience in successfully creating numerous probes did not enable the 
creation of specific rules to make the process quicker and more effective. Each probe needed to be 
tested individually to determine its suitability for inclusion in the suspension microarrays.   
 
Of the forty-two probes we designed, only twenty-two passed preliminary validation.  Some probes 
failed to detect a positive sample and in these cases the relevant virus was sequenced to determine 
whether sequence mismatch rather than probe failure was the cause.  In the case of MVEV, 
sequencing showed that there was a nucleotide difference with the original probe designed and 
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strains PNG156 and MK6684; and so a new probe was designed.  However, for other probes the 
most likely explanation was steric hinderance or an undesirable secondary structure.    In a small 
number of cases the probes produced a high background signal. These probes were re-coupled to a 
different beadset, to ensure the high background signal was not due to issues with either coupling or 
the beadset.  However, these probes invariably still failed validation and were excluded from the 
panel.  This problem has previously been encountered by other departments in our laboratory. 
 
It proved more difficult to design suitable probes for the alphavirus suspension microarray, with 
fewer probes successfully designed on the first attempt than for the flavivirus suspension 
microarray.  This may be because the amplicon size in the alphavirus assay is only 400bp compared 
to the 600-800bp amplicon used in the flavivirus assay. There is no general agreement in the 
literature on the optimal amplicon length for amplification. However, several studies have shown 
that 700bp amplicons yield superior results to smaller amplicon sizes (Diaz & Fell, 2004, Spiro et 
al., 2000). We found the small amplicon size of 400bp made it difficult to meet other criteria 
previously discussed as important for probe design; such as targeting the 3’region of the amplicon 
and avoiding secondary structures (Diaz & Fell, 2004, Page & Kurtzman, 2005).  However, there 
may be factors other than amplicon size, such as the efficiency of PCR amplification, that 
contribute to optimising the signal produced in a suspension microarray. Regardless of the 
difficulties encountered, we were able to successfully design four virus-specific probes for the 
alphaviruses of greatest public importance.     
 
With additional time, we believe it would also be possible to expand this panel to include additional 
probes for the detection of other viruses of interest such as Getah virus, Whataroa virus, Alfuy virus 
and Edge Hill virus. Time restraints during this project meant that a maximum of three, and often 
only one, attempt was made to design an appropriate probe.  The limited sequence data available at 
the time may also have contributed to the difficulties encountered. Therefore, we believe it is highly 
likely that appropriate probes for these viruses could be designed in the future.  Additionally, 
regular review of new submissions on GenBank would ensure the current panel of probes continue 
to detect circulating viruses.  Any new virus strains of clinical significance that lack complete 
homology with a probe could have a specific probe designed and incorporated into the panel with 
minimal additional cost.   
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5.2.3 Sensitivity and Specificity 
A well documented challenge for multiplex assays is the variation in sensitivity often seen between 
the different targets, an issue which we also encountered. Previously published suspension 
microarrays have also had detection limits that have varied between species, but which were still 
considered clinically useful, as they offered the opportunity to obtain significantly more information 
than the alternative diagnostic tests (Hindson et al., 2009, Boving et al., 2009).  The sensitivity of an 
assay can be adversely affected by a number of issues such as extraction method, PCR efficiency 
and hybridisation of the PCR product to the probe.  For example, further studies to determine the 
effect the extraction technique has on assay sensitivity for detecting virus in mosquito pools could 
be conducted, as discussed in Section 2.4.3, or the effect of mosquito pool size could be 
investigated.   PCR efficiency is a more difficult issue to address, as it is accepted in general that 
concensus primers will have a lower sensitivity than virus-specific primers (Moreau et al., 2007, 
Patel et al., 2013).  However, virus-specific primers could be designed and multiplexed with the 
consensus primers in a manner similar to Patel et al. (Patel et al., 2013), if further validation 
indicates that improved sensitivity for certain viruses should be investigated. Hybridisation 
efficiency may be influenced by linker design, an avenue which was not explored in this study.  To 
link the probe to the microsphere, an 18C spacer rather than a 12C spacer could be trialled, as 
detailed by Wilson et al. (Wilson et al, 2005), as they reported this improved coupling efficiency. 
Finally, claims that the sensitivity of probes can be improved by the addition of nucleotides to the 5’ 
and 3’ ends of the probe (Dunbar et al., 2006), could also be investigated further. Although further 
optimisation and validation may be required, the suspension microarray technology did show 
potential value for its prescribed goal as an initial screening or supplementary test and may enable 
exotic disease surveillance to occur while performing routine testing for endemic diseases.  
 
We aimed to develop diagnostic tests with high specificity, to enable the clear distinction between 
endemic and exotic viruses and facilitate rapid results.  The alphavirus suspension microarray 
showed 100% specificity for all viruses during our validation, including the exotic CHIKV.  
However, some cross-reactivity was seen with the flavivirus suspension microarray.   
 
Cross-reactivity is a well-known problem in flavivirus diagnosis and proved unavoidable in the 
flavivirus suspension microarray.  This problem was anticipated as we targeted a highly conserved 
region of the genome to enable the use of consensus primers.  The cross-reactivity was most notable 
for viruses within the same phylogenetic clade, for example the dengue viruses, or KUNV and 
WNV. A previous study which used consensus primers also reported probe cross-reactivity, but 
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found that the pattern of probe reactions still allowed species identification (Page & Kurtzman, 
2005).  We also found this to be the true and in the vast majority of cases the pattern of the highest 
signals enabled correct preliminary diagnosis of the specific virus.  Even for the highly cross-
reactive dengue virus probes, the correct specific diagnosis could be made in 93% of the clinical 
samples tested. This was considered acceptable for a low-cost screening assay, as it was combined 
with high sensitivity and the cross-reactivity showed some advantages.   
 
An advantage of the cross-reactivity observed in the flavivirus suspension microarray was that it 
improved the sensitivity of the assay.  The WNV Koutango strain could not be detected by either 
the KUNV or WNV probe, as expected.  However, the KOKV probe produced a signal, preventing 
a false negative result.  This example highlights the advantages of using consensus primers and a 
multiplex approach, which may enable the detection of viruses that have not been specifically 
targeted based on a clinical history or geographical location alone.  Therefore, although cross-
reactivity was observed, we believe the flavivirus suspension microarray would still make an 
excellent screening test.  Few false negatives were observed and the assay offers a new level of 
cost, time and labour reduction compared to tests currently available.  The cost of screening this 
panel of flaviviruses alone would be 25 to 50 times greater per sample using individual TaqMan 
assays over the flavivirus suspension microarray, without taking into account the considerable 
labour cost.  
 
Cross-reactivity between probes that target regions of concensus has also previously been described 
in association with suspension microarrays (Page et al., 2005, Brunstein et al., 2006, Deak et al., 
2010). The cross-reactivity issue may potentially be overcome by locating a different target region 
for the assay, utilising other universal primers or changing the probe design parameters (Maher-
Sturgess et al., 2008, Patel et al., 2013).  However, all these options were considered before 
commencement of the project and also offered drawbacks, which have been previously discussed.  
Even small changes, such as increasing the length of the probe, pose significant difficulty for a 
multiplex assay, as the design parameters of the probes need to be standard with respect to features 
such as melting temperature; and any changes may either prove unsuccessful under the current 
assay protocol or to require all probes in the assay to be modified. As was discussed in Section 
5.2.1, molecular genetics and diagnostics are rapidly evolving fields, and the rapid increase in 
relevant genetic sequences now available of GenBank, and published primers and probes, would 
allow review of some probes and target sequences with respect to avoiding cross-reactivity. As a 
number of other studies have also found, despite careful use of sequence analysis for the design of 
probes or primers, it can provide only a limited prediction of their utility and specificity in the 
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laboratory (Page et al., 2005, Diaz et al., 2006, Ros-Garcia et al., 2012, Patel et al., 2013). However, 
suspension microarray technology has proven compatible to adaptation with new molecular 
techniques, and review of published primers and probes with proven specificity may have potential 
for incorporation in this assay and could be investigated. The problem of cross-reactivity is 
therefore a difficult one to overcome, but we feel this assay still offers suitable specificity to be used 
as a preliminary screening test. 
5.2.4 Universal probes 
One of the key advantages of cell culture is that it can potentially detect a previously unidentified 
virus.  Molecular tests in general have the disadvantage of only being able to detect the viruses for 
which the test is designed.  To help overcome this issue, we hoped to incorporate a universal probe 
in the suspension microarrays, to enable the detection of flaviviruses or alphaviruses for which 
specific probes were not included.  A universal probe would also serve a dual purpose and act as an 
internal positive control.  Unfortunately, although highly desirable, this goal was not achieved.   
 
Sequence alignments of the amplified regions of the alphaviruses and flavirviruses respectively did 
not lead to the successful design of targets for genus-specific universal probes.  To overcome this, 
we also designed probes for consensus regions within sub-groups of viruses, for example the 
encephalitic flaviviruses.  However, with the exception of the dengue viruses, this was also 
unsuccessful and may be related to the strict probe design specifications selected for these assays.  
Therefore, cell culture does still maintain this advantage over the suspension microarrays developed 
during this project. However, as discussed above, there is potential that cross-reactivity with one of 
the other probes in the suspension microarray may allow identification of a sample positive with a 
previously unidentified virus.   
5.2.5 Restricted panel for validation 
The task of validating a multiplex assay is considerable compared to uniplex assays.  However, 
validation is a critical component of any assay development, to ensure appropriate sensitivity and 
specificity for a range of virus strains.  Our laboratory has an extensive reference library that 
includes strains from a wide geographic region, collected over a long period of time.  We were able 
to test the flavivirus suspension microarray against 65 cultured viruses and 54 clinical samples; and 
the alphavirus suspension microarray against 11 viruses, including the newly emergent strain of 
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CHIKV from the Reunion Island outbreak.  In addition, for viruses for which our reference library 
was extensive, such as DENV, we were able use sequencing data to select the most divergent 
strains, as well as clinical samples from different outbreaks. 
 
Ideally, an even larger panel of viruses would be used for validation but it proved difficult to obtain 
multiple strains of some viruses.  This was because there is either little genetic diversity in the virus, 
or the viruses are exotic and strictly controlled by the Department of Agriculture, Fisheries and 
Forestry regulations (for example, RRV and YFV respectively).  One opportunity to overcome this 
problem would be to collaborate with a laboratory overseas that has a reference collection of viruses 
and routinely tests clinical samples.  This should be a consideration for future studies.   However, 
based on sequences available on GenBank, the probes used in these assays showed 100% homology 
for the vast majority of viruses targeted.   
 
The availability of mosquito pools and virus-infected mosquitoes provided to practical restraint to 
our ability to further validate the suspension microarray for this purpose at this time. The 
availability of mosquitoes infected with exotic viruses will be of particular difficulty. It may prove 
necessary to prepare virus-infected pools of mosquitoes by using stock virus or diluted in vitro 
RNA transcript in the medium used to grind the mosquito pools, rather than a virus-infected 
mosquito to spike a pool.  Larger scale studies, using the suspension microarray in parallel with 
routine mosquito surveillance assays, will then be required to further evaluate the assay for this 
purpose.  
 
Validation of the suspension microarrays against a panel of viruses frequently diagnosed in public 
health laboratories, such as influenza, can be considered for future studies.  However, BLAST 
searches for the sequences used as probes, highlighted no concerns that cross-reactivity outside of 
the alphavirus and flavivirus genuses respectively would occur.  Our extensive experience with 
these consensus primers over a large number of years, for processing both clinical and vector 
surveillance samples, would also suggest that this is unlikely to be an issue. 
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5.3 Major Findings and Knowledge Gained 
5.3.1 Compatibility of suspension microarray technology with 
previously validated molecular techniques  
Consensus primers previously validated for classical RT-PCR and probes that had previously been 
designed for use in a validated TaqMan assay were successfully adapted for the suspension 
microarray format.  This has strong implications for the increased use of this technology.  Although 
the TaqMan real time assay is a highly sensitive tool, it is restricted by its capacity to be 
multiplexed and the high cost of the assay.  Despite the advantages that would be offered by using 
real-time assays in reference laboratories in developing countries, reviews by the European 
Network for Imported Viral diseases have found they are not widely adopted (Domingo et al., 
2011). In these countries, the cheaper alternative, classical RT-PCR is preferred.  Adaptation of 
previously validated TaqMan assays to the suspension array format may be of benefit in developing 
countries, where the costs of developing TaqMan assays are prohibitive.  By multiplexing the assay 
the cost is reduced even further as labour and reagents are decreased as well.  Additionally, the 
ability to adapt already validated molecular tools to the suspension microarray format offers 
benefits with respect to limiting the timeframe and cost of assay development; which can be 
substantial for multiplex assays. 
 
In our laboratory the suspension microarrays offered the opportunity to run multiplexed assays as 
preliminary screening tests against a panel of viruses.  Although individual TaqMan assays were 
available for all the viruses in this panel, the cost of routinely screening each sample in this way 
would be prohibitive. Therefore, it is possible that some infections fail to be diagnosed, as most 
arboviruses produce similar, non-specific clinical signs, thus making selection of an appropriate test 
difficult. The introduction of routine screening using multiplexed assays overseas has been shown 
to decrease disease under-reporting and improve the reporting of dual infections (Page et al., 2006, 
Mahony et al., 2007, Wallace et al., 2005, Bandyopadhyay et al., 2007).  We could expect a similar 
result in Australia, and this is particularly important with respect to the introduction of exotic 
viruses, as well as patient care. 
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5.3.2 Alternative methodologies for suspension microarrays  
The generation of asymmetrical PCR product has been shown to be critical for the development of 
some suspension microarrays. Double stranded PCR product will self-anneal at the hybridization 
temperature, rather than bind to the probe.  Therefore, single stranded PCR product is more 
desirable as it remains available to hybridise with the probe. Previously published suspension 
microarrays use a higher proportion of labelled to unlabelled primer to preferentially generate single 
stranded PCR product (Deregt et al., 2006b, Das et al., 2006, Lin et al., 2011). We investigated this 
method and compared it to an alternative method used for the amplification of nucleic acids in chip 
microarrays (Lodes et al., 2007).  We found the chip microarray amplification method, which 
involves the use of forward and reverse primers with different hybridisation temperatures, to be 
equally effective at producing single stranded PCR product for use in a suspension microarray.  
However, the chip microarray protocol offers the cost benefit of using reduced amounts of the 
biotinylated reverse primer; and the potential to use suspension microarray and chip microarray 
technology in tandem using the same amplicon. More recently an alternative method to generate 
single stranded PCR for use in suspension microarrays utilises exonuclease to digest one of the 
amplicon strands; this method, however, involves an additional step (LeBlanc et al., 2010).   
Therefore, the chip microarray method adapted for generating single stranded PCR in the alphavirus 
and flavivirus suspension microarrays offers a new cost and labour efficient alternative for 
consideration in the development suspension microarrays.   
 
The importance of internal controls is well recognized for diagnostic tests.  At the time of the 
alphavirus and flavivirus suspension microarray development two types of internal controls for 
suspension microarrays were reported.  The first used a human myoglobin gene not found in 
bacteria to spike the sample and included specific primers for the gene in the multiplex PCR 
reaction (Wilson et al., 2005).  We decided to instead utilise a synthetic control, so that not only the 
PCR reagents but also the PCR primers we were using could be evaluated.  This approach had not 
previously been attempted in association with suspension microarrays, though a similar method has 
recently been reported (Ros-Garcia et al., 2012).  The synthetic control was successfully 
incorporated into our suspension microarrays and allows the success of the PCR to be evaluated 
without the need for gel electrophoresis.  The other potential type of internal control we investigated 
was the inclusion of a universal probe to target a region on consensus (Page & Kurtzman, 2005, 
Deregt et al., 2006b).  However, as discussed previously, we have been unable to design such a 
probe despite multiple attempts.  However, we have successful incorporated a synthetic control into 
the suspension microarray using a different method to any previously reported. 
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The suspension microarrays were successfully multiplexed for up to fourteen different probes, and 
were sensitive enough to provide a useful tool in the clinical diagnosis of arboviruses. Other 
diagnostic tests, such as TaqMan assays, demonstrate a loss of sensitivity when multiplexed, as 
decreased PCR efficiency can result due to the addition of multiple primers and probes in a tube, 
primer-dimer formation and potential competition from varying template concentrations (Exner & 
Lewinski, 2002). The few studies available at the time this project commenced suggested this 
problem was overcome with suspension microarray technology (Diaz & Fell, 2004, Diaz et al., 
2006).  However, these studies were for the detection of yeasts.   The RNA viruses with which we 
were working are more fragile and potentially more difficult to amplify (Cann, 2005).  Therefore, 
we were initially uncertain as to the results we would obtain.  Nevertheless, suspension microarray 
technology has since proven very useful for diagnosis of RNA viruses and no reduction in 
sensitivity was observed on multiplexing the suspension microarrays developed during this project. 
5.3.3 Application of the suspension microarrays to mosquito 
surveillance  
The emergence and re-emergence of arboviruses globally has seen an increasing focus on vector-
surveillance strategies to help guide public health policy.  However, the availability of cost-
effective and rapid diagnostic tests is currently a limiting factor in effectively implementing vector 
surveillance. The alphavirus and flavivirus suspension microarrays developed during this project 
have shown great potential for this purpose during validation and are the first reported studies 
which have verified the use of suspension microarray technology for detection of virus in mosquito 
pools.   
 
During the course of this project we have seen a great transition in arbovirus surveillance globally.  
Arbovirus surveillance once widely relied on the use of animal sentinel systems.  However, the high 
cost and public health implications of maintaining amplifying hosts near communities, and 
logistical issues associated with remote locations has seen a transition from sentinel animals to 
vector surveillance systems in Australia (van den Hurk et al., 2012).  Overseas, particularly with 
respect to WNV monitoring, vector surveillance has also demonstrated advantages over the use of 
sentinel animals (Brownstein et al., 2004, Chevalier et al., 2011, Angelini et al., 2010).  Vector 
surveillance systems have proven to be more sensitive indicators of human risk from arboviruses 
than sentinel animals, as the presence of infected mosquitoes indicates direct human risk.  Vector 
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surveillance is also particularly useful when dealing with a virus such as dengue, which does not 
have animal hosts. When combined with RT-PCR, vector surveillance has also been proven to be 
very useful to screen for new viruses and co-infections which may otherwise have been undetected 
(Vazquez et al., 2012, Lee et al., 2013, Cook et al., 2009).  The use of degenerate primers for 
screening of mosquito pools for these purposes is proving particularly useful (Roiz et al., 2009, 
Pabbarak et al., 2009). Therefore, mosquito surveillance is increasingly utilised and provides 
information on which public health guidance can be provided.   
 
However, despite the general trend towards replacement of animal sentinel programs with mosquito 
surveillance, there remains a need for appropriate diagnostic tests to effectively make this transition. 
Typically, mosquito pools collected for surveillance are either analysed using virus isolation or 
TaqMan assays.  There are many problems with this approach.  Virus isolation takes several weeks 
to provide a result, while TaqMan assays are cost-prohibitive, especially as often a separate test is 
required for each virus of interest.  Very recently, a number of new technologies have been 
evaluated for use in association with vector surveillance.  These include mass spectrometry, high-
throughput pyrosequencing, field-portable DNA microarrays, and massively parallel sequencing 
(Grant-Klein et al., 2010, Bishop-Lilly et al., 2010, Grubaugh et al., 2013, Hall-Mendelin et al., 
2013).  However, to date these remain proof-of-concept studies. The assays evaluated were 
associated with either prohibitive costs or low sensitivity and are not currently feasible for routine 
laboratory use. 
 
The suspension microsphere microarrays developed during this project provide a cost-effective, 
rapid alternative to the routine screening tests in Australia for samples, cell culture or TaqMan 
assays.  The turn-around time for the suspension microarrays is within 48 hours for mosquito pools 
and 24 hours for clinical samples.  Suspension microarray technology is significantly cheaper than 
TaqMan assays, and this cost-saving is many-fold when the assay is multiplexed.  As vector 
surveillance methods frequently utilise pools of between 50 to 75 mosquitoes for screening 
(Pabbarak et al., 2009, Yang et al., 2010, Roiz et al., 2009) and the suspension microarray assay 
was able to detect a single infected mosquito in a pool of 100, this establishes that this assay is 
sensitive enough to be utilised in vector surviellance.  The alphavirus and flavivirus suspension 
microarrays therefore offer a suitable, multiplex alternative to support the increasing usage of vector 
surveillance for public health programs.   
 
Other molecular assays which have recently been published would offer economical alternatives to 
the suspension microarray.  These include a Pan-Flavivirus TaqMan, which can be used to broadly 
 165 
detect the flavivirus family (Patel et al., 2013).  It has the advantage of being able to provide 
quantitative information, but requires additional diagnostic testing to confirm the flavivirus species.  
Similarly, other assays for the universal detection of flaviviruses using Sybr-Green technology have 
been developed (Moureau et al., 2007, Yang et al., 2010).  Sybr-Green real-time assays can 
incorporate multiplex PCR reactions, and post-amplification analysis of the melting temperature can 
enable product identification.  This enabled distinction between flavivirus and alphavirus amplicons 
in the study by Yang.  However, additional diagnostic testing in the form of sequencing was 
required to reach a specific diagnosis as the melting curves can be difficult to interpret.  In 
comparison, suspension microarray technology has an excellent multiplexing capacity, which 
enables the use of virus-specific probes to reach a specific diagnosis without any additional steps.  
This has many advantages as a rapid and specific diagnosis can be of critical importance with 
respect to distinguishing endemic from exotic viruses and patient care. 
 
Sample handling will remain an important quality control issue with this assay.  A secure cold chain 
until testing may be important to maintain the integrity of this assay.  However, new alternatives are 
also emerging in this field. Nucleic acid preservation cards, onto which trapped mosquitoes 
expectorate during feeding, are proving viable alternatives to processing mosquito pools (Hall-
Mendelin et al., 2010, Lothrop et al., 2012). The combination of economical, multiplex assays, such 
as the suspension microarrays developed in this project, with these new techniques, has the potential 
to improve the accessibility of vector surveillance.  
5.4 Future Work: 
5.4.1 Multiplexed PCR 
Ideally, the microsphere suspension microarray would be multiplexed to allow concurrent screening 
of the alphaviruses and flaviviruses of public health importance in Australia. This was the original 
aim of the project and would eliminate the need to run two separate tests.  This goal has proven to 
be possible, with such a test being developed and validated to detect alphaviruses and flaviviruses 
of public health importance in Brazil (de Morais Bronzoni et al., 2005, Terzian et al., 2011).  In 
these assays, duplex RT-PCR using genus-specific primers were used; including the same 
alphavirus consensus primers M2W/cM3W that we utilised. The assays were validated against 
human and animal clinical samples and showed adequate sensitivity.  However, these assays 
required several second round PCRs to then identify the virus specifically, involving additional 
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turn-around time, labour and cost. Similarly, screening mosquito pools using SYBR-Green RT-PCR 
with duplex consensus primers has also shown to have appropriate sensitivity for the detection of 
alphaviruses and flaviviruses in Taiwan (Yang et al., 2010). If the sensitivity of these duplex RT-
PCR assays was appropriate for clinical diagnostics and vector based surveillance, then it is 
expected that a duplex RT-PCR should also be able to be successfully employed with suspension 
microarray technology. Future studies will further investigate multiplexing the alphavirus and 
flavivirus suspension microarrays, as such an assay is technically feasible.   
 
Our optimisation studies for the alphavirus and flavivirus suspension microarrays found that 
amplification and hybridisation conditions for both were similar.  This allowed the same method to 
be used for both suspension microarrays and should pave the way for both assays to be multiplexed. 
Our first approach to achieve this was to use a duplex RT-PCR, instead of two individual RT-PCRs.  
This approach was attempted during the preliminary validation stage but a significant loss of 
sensitivity was observed.  In general, it is recognised that multiplexed PCRs do show a loss of 
sensitivity (Exner & Lewinski, 2002). However, if time had permitted, we would have attempted 
additional work to overcome this problem.  One option would include using increased Taq 
polymerase in the assay, as was successfully adopted by Wilson et al., (2005).  The other would be 
to perform separate amplifications and then combine the products in the one hybridisation reaction.  
A recent study has confirmed this approach to be viable (Kuriakose et al., 2012).  Therefore, we 
believe there is potential to overcome the issues with sensitivity and eventually multiplex the 
alphavirus and flavivirus suspension microarrays.  
 
5.4.2 Further Optimisation  
As experience with suspension microarray technology has increased over the past few years, the 
methodologies employed have been refined.  Two simple changes to the method currently used for 
the alphavirus and flavivirus suspension microarrays could further improve their quality assurance.  
Although we confirmed and validated bead coupling by testing the panel against the same panel of 
RT-PCR products each time, an alternative would be to use synthetic oligonucleotides, as was 
employed by Kuriokose et al., (2012).  This could prove a useful tool, particularly in ensuring long-
term consistency and availability of a quality assurance panel, and also to enable inter-laboratory 
validation. A commercially available bead-set, LumAvidin (Luminex), could also be included as a 
quality assurance tool in the suspension microarrays.  The LumAvidin control bead set contains an 
outer layer of Avidin, to enable covalent binding of the reporter phycoerythrin-R-streptavidin 
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(Wilson et al., 2005).  Inclusion of this beadset in the suspension microarrays would ensure the 
reporter dye is functioning properly and allow inter-assay comparison of the reporter signal.  These 
slight changes in method would improve the quality assurance of the alphavirus and flavivirus 
suspension microarrays and would be simple and inexpensive to implement. 
 
The extraction method we used on the mosquito pools also proved to be an important step in 
optimising the suspension microarrays.  However, it is also a labour-intensive component.  New 
methods, such as the use of super-pools or nucleic acid preservation cards have emerged as useful 
tools for vector surveillance (Chisenhall et al., 2008, Hall-Mendelin et al., 2010).  Investigating the 
use of these new methodologies with the current suspension microarray methods may be warranted, 
to further improve the efficiency and speed of vector surveillance.   
 
Finally, very recent publications have indicated the potential for future development of the 
suspension microarray platform.  A new, probe-based real-time PCR system, PrimRglo has been 
combined with Luminex microspheres to allow nucleic acid amplification and detection of 
microspheres (Liang et al., 2013).  This system offers similar properties to TaqMan assays, but 
offers the potential to multiplex up to 100 targets.  The development and commercial application of 
this platform should be followed, to determine its potential adaption to the suspension microarrays 
developed during the course of this project. 
5.4.3 Validation  
Preliminary validation of these suspension microarrays has shown they have potential for use in a 
diagnostic laboratory, but further validation will be required before they can be used for routine 
diagnostic testing.  There are several options for further validation. Where clinical samples are not 
available, virus-spiked human blood, serum or urine samples have proven useful for validation 
(Grant-Klein et al., 2010).  Future work should include validation of the suspension microarrays 
against a larger panel, including spiked human and animal samples.  This will be of particular 
benefit for viruses such as YFV, for which clinical samples were unavailable.   Further validation of 
the suspension microarrays by running them concurrently with routine diagnostic and surveillance 
assays would also be recommended; until sufficient data is available for further evaluation.    
 
Surveillance for arboviruses in Australia could be greatly improved by the adoption of the One 
Health principles and the validation of the alphavirus and flavivirus suspension microarrays in 
veterinary diagnostic laboratories would hold merit.  The largest epidemic of equine arboviral 
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disease in Australia’s history occurred in 2011 (Studdert, 2013, Roche, 2013). Of particular note 
was that both KUNV and MVEV were co-circulating during the outbreak, causing similar clinical 
signs and making diagnosis difficult, especially in the early phase of the outbreak.  Molecular 
diagnosis by PCR did prove to be a useful tool for diagnosis during the outbreak (Holmes et al., 
2012, Tee et al., 2012).  Therefore, the suspension microarrays developed during this project would 
also offer the same advantages from a veterinary diagnostic perspective as a public health one.  As 
outbreaks of arboviruses frequently occur in both animal and human populations together, and 
vector surveillance can help indicate periods of increased risk, there is the potential to improve both 
animal and human health.  
 
The adoption of broad target arbovirus screening has resulted in valuable information about co-
circulation to be gathered in outbreak situations overseas (Terzian et al., 2011).    A conclusion of 
these studies has been that in outbreak situations, patients can be mis-diagnosed based on negative 
results in association with clinical signs.  The same situation may arise in Australia with respect to 
endemic arboviruses, for which routine screening is not conducted.  This may lead to a mis-
representation of their importance.  Introduction of the diagnostic assays developed in these studies 
into both public health and veterinary diagnostic laboratories would help address these problems.  
 
Finally, an important aspect of any assay validation is to ensure reproducibility between 
laboratories. There have been movements toward the harmonisation and establishment of 
international validation standards over the past few years, although they are still not yet at fruition.  
In the meantime, the opportunity to collaborate with another laboratory would be highly desirable, 
especially one with either access to veterinary samples or exotic samples. This should be a focus of 
future studies.     
5.4.4 Expansion of panel to include emerging viruses  
The range of pathogens targeted by the suspension micorarrays could be expanded to include other 
flaviviruses and alphaviruses.  These could include other important exotic alphaviruses such as 
Eastern equine encephalomyelitis virus, Western equine encephalomyelitis virus and Venezualean 
equine encephalomyelitis virus.  Since commencement of the project, several new viruses have 
emerged and that could also be included in the panel.  Although first isolated in 1947, Zika virus 
has only recently caused large disease outbreaks in Micronesia in 2007 (Duffy et al., 2009).  
Meanwhile, Usutu virus, although first isolated in 1959, was linked to neuroinvasive infection for 
the first time in 2009 (Pfeffer & Dobler, 2010) Additionally, new flaviviruses continue to be 
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discovered either by unbiased, high-throughput pyrosequencing  or traditional cell culture screening 
methods (Epstein et al., 2010, Huhtamo et al., 2009).  Future work could include the expansion of 
the current suspension microarray panels to include additional virus species. The inherent flexibility 
and multiplexing capability of the suspension microarray technology readily allows the 
incorporation of new probes for additional viruses that may emerge of public health importance.   
 
Expansion of the suspension microarrays to detect members of the bunyaviruses could also be 
considered.  A recent diagnostic test developed for arbovirus surveillance overseas targets not only 
the flaviviruses and alphaviruses, but also the bunyaviruses which cause similar clinical signs 
(Terzian et al., 2011).  There are currently no routine tests performed in Australia for bunyaviruses, 
despite the fact that endemic bunyaviruses, such as Gan Gan virus, have been associated with 
human disease (Mackenzie et al., 1994, Boughton et al., 1990).  However, the bunyaviruses are 
associated with significant disease overseas and incorporating these viruses in routine surveillance 
would improve our understanding of their public health importance.  Consensus primers have been 
published for the bunyavirus family (Lambert & Lanciotti, 2009).  Therefore, the potential exists for 
the development of a bunyavirus suspension microarray, which could then be multiplexed with any 
of the suspension microrarrays developed during this project. The ability to design suspension 
microarrays on a modular system and combine them into assays of increasing complexity is another 
key advantage of the suspension microarray technology (Foord et al., 2013). 
 
Finally, there is also the potential to refine the suspension micorarray panels to target clinical 
presentations, such as encephalitis or rash.  In this case, the panel may also be expanded to include 
other viruses of interest such as herpesvirus, enterovirus, lyssavirus, rubella viruses and Hendra 
virus. The concept of multiplex arrays for syndromes has already proven feasible for chip 
microarrays (Korimbocus et al., 2005).  Therefore, this is another potential avenue to explore with 
the suspension microarray technology. 
5.5 Conclusion 
The global emergence and remergence of arboviral disease due to flaviviruses and alphaviruses is 
an ongoing concern; and development of improved diagnostic tests for arbovirus surveillance was 
identified as a key goal for this project.  Since the project commenced, there have been 
unprecedented arboviral outbreaks.  These include the CHIKV outbreak, which commenced on the 
Reunion Islands and has since spread to many continents, causing disease in millions of people 
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(Gould et al., 2010).  Likewise, we have seen the continued introduction of exotic viruses into new 
regions, with subsequent disease outbreaks, such as WNV in Sardinia, Turkey and Greece (Spissu 
et al., 2013, Kalaycioglu et al., 2012, Danis et al., 2011).  Finally, closer to home, we have seen the 
emergence of a more pathogenic strain of the endemic virus KUNV, which has resulted in 
unprecedented neurological disease outbreaks in equines (Studdert, 2013). With much of the 
world’s population at risk from arboviral disease, and an absence of vaccines for many viruses, the 
public health importance of arboviruses remains high. 
 
World-wide, the incidence of disease caused by arboviruses has increased due to global changes 
(Laine, 2004).  The contributing factors to increased arboviral disaese are many-fold and unlikely to 
diminish in the future, including urbanisation, and expanding vector and host ranges.  Global travel 
continues to be a route by which exotic diseases are introduced into new territories (Mohammed et 
al., 2010). However, the trend for global travel shows no sign of abating; the number of travellers 
has risen from 450 to 950 million between 1990 and 2010 (Cleton et al., 2012).  Therefore, accurate 
clinical diagnosis of arbovirus infections is critical, and multiplex assays which remove reliance 
upon accurate travel history, clinician discretion and economical impediments can help overcome 
some of the challenges.  Likewise, vector based surveillance is recognised to offer key advantages 
over animal sentinel systems, and the transition to vector based surveillance would be facilitated by 
the availability of sensitive, multiplex, cost-effect assays for this purpose.  
 
During the course of this project we were able to demonstrate that suspension microarray 
technology makes an excellent platform for the molecular diagnosis of alphaviruses and 
flaviviruses.  Although this technology was only just emerging as a molecular tool at the start of 
this project, it has since been demonstrated to have many key advantages over current molecular 
techniques (Foord et al., 2013, Lin et al., 2008, Bandyopadhyay et al., 2007).  Our experience with 
this technology is in accordance with these reports, with the alphaviruses and flavivirus suspension 
microarrays being easy to use, rapid, cost-effective, flexible and with excellent multiplexing 
capabilities. Most importantly, the suspension microarray platform has shown great potential for 
disease surveillance, with the development of suspension microarrays specifically to facilitate 
detection of endemic and emerging viruses through routine testing (Hindson et al., 2008, Mahony et 
al., 2007).    
 
We report for the first time the development of suspension microarrays that target the alphaviruses 
and flaviviruses of greatest public health concern in the Australasian region.  These suspension 
micorarrays have been validated against a large panel of viruses. Parallel studies were conducted 
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against the current molecular tests used in our laboratory, and the multiplexed suspension 
microarrays showed good comparative sensitivity.  This was confirmed by studies using clinical 
samples and mosquito pools, and the suspension microarrays were found to perform with acceptable 
sensitivity and specificity for these purposes.  The introduction of these cost-effect suspension 
microarrays for the routine testing of clinical and vector surveillance samples for arboviral disease, 
would greatly improve our knowledge of Australia’s circulating endemic viruses and capacity to 
detect exotic disease incursions.  Although these studies are only preliminary, the further 
development and validation of these assays appears warranted, especially as the inherent flexibility 
of the suspension microarray systems offers many advantages for tailoring the assays as specific 
needs arise.  
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Appendix 1: Comparison of the S/B (sample-to-background) ratios produced by flavivirus 
probes following hydridisation with either symmetrical (Sym) or asymmetrical
+
 (Asym) 
PCR product 
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Appendix 2: Specificity study for flavivirus suspension microarray 
Virus Strain Mean S/B ratio of probe  (SD) 
  DENVU2 DENV1 DENV2 DENV3 DENV4 JEV KOKV KUNV MVEV MVEV2 SEPV STRV WNV YFV 
ALFV MRM3926 0.9 (0.0) 0.9 (0.2) 1.2 (0.1) 1.1 (0.1) 1.0 (0.1) 0.8  (0.1) 1.3 (0.2) 1.0 (0.1) 1.1 (0.1) 1.7 (0.3) 1.3 (0.1) 1.2 (0.3) 1.0 (0.2) 1.0 (0.2) 
DENV1 MA101 37.5 (8.3) 12.0 (0.9) 17.9 (2.4) 26.9 (6.3) 21.2 (3.3) 0.8 (0) 1.7  (0.4) 1.2 (0) 11.1 (1.0) 1.1 (0.1) 1.2 (0.1) 1.1 (0.2) 1.0 (0.2) 1.0 (0) 
DENV1 ET00.423 36.0 (4.9) 21.3 (1.8) 35.5 (4.7) 38.1 (3.0) 25.4 (1.3) 0.9 (0.1) 4.7 (0.4) 1.2 (0.1) 7.4 (0.7) 2.0 (0.3) 0.9 (0.1) 1.0 (0.0) 0.9 (0.2) 1.0 (0.1) 
DENV1 CI107 37.9 (2.9) 26.5 (3.1) 35.9 (1.1) 41.4 (5.4) 30.2 (3.7) 0.9 (0.1) 2.0 (0.9) 1.0 (0.3) 3.8 (0.9) 1.1 (0.1) 0.9 (0.0) 0.9 (0.1) 1.1 (0.2) 1.0 (0.1) 
DENV1 PNG100 32.9 (3.0) 22.9 (2.9) 15.0 (0.9) 34.9 (5.8) 26.1 (2.8) 0.9 (0.1) 1.7 (0.5) 1.0 (0.1) 7.8 (1.0) 1.0 (0.1) 1.0 (0.1) 1.0 (0.2) 1.1 (0.2) 1.0 (0.1) 
DENV1 MA103 33.5 (3.0) 23.7 (2.4) 18.0 (2.6) 34.5 (5.4) 24.7 (2.7) 0.9 (0.1) 1.2 (0.3) 1.1 (0.2) 2.8 (0.3) 0.9 (0.1) 1.0 (0.1) 1.0 (0.0) 1.1 (0.1) 1.0 (0.1) 
DENV1 ET108 35.8 (3.2) 22.8 (2.8) 26.1 (2.7) 37.7 (6.3) 28.0 (2.5) 0.8 (0.1) 2.1 (0.8) 1.1 (0.1) 3.3 (0.5) 1.0 (0.2) 1.0 (0.1) 1.0 (0.3) 1.2 (0.1) 0.9 (0.1) 
DENV1 SR104 33.9 (2.1) 10.3 (0.9) 6.5 (0.8) 33.8 (5) 8.8 (1.2) 0.9 (0.1) 1.2 (0.1) 1.2 (0.1) 5.3 (0.2) 1.1 (0.1) 0.9 (0.1) 1.0 (0.2) 1.1 (0.2) 0.9 (0.1) 
DENV1 VI108 33.9 (2.3) 10.5 (0.9) 4.9 (0.4) 32.1 (3.9) 7.3 (1.4) 0.9 (0.1) 1.1 (0.2) 1.4 (0.2) 2.4 (0.1) 1.1 (0.1) 0.9 (0.1) 0.9 (0.0) 1.2 (0.2) 1.0 (0.0) 
DENV2 ET00.300 7.5 (1.1) 1.0  (0.1) 55.9 (6.7) 23.8 (2.3) 2.6 (0.1) 1.1 (0.1) 7.5 (0.5) 1.0 (0.2) 1.2 (0.0) 1.8 (0.2) 1.1 (0.1) 0.9 (0.0) 1.0 (0.1) 1.0 (0.2) 
DENV2 ET204 33.0 (1.7) 0.9  (0.0) 64.3 (1.9) 33.0 (1.5) 5.0 (0.4) 1.1 (0.2) 8.0 (1.3) 1.0 (0.1) 1.0 (0.3) 2.2 (0.2) 1.1 (0.1) 1.0 (0.2) 1.1 (0.1)  1.3 (0.1) 
DENV2 CA204  14.9 (1.1) 1.0  (0.1) 63.4 (1.6) 33.5 (2.0) 7.1 (0.2) 0.9 (0.1) 5.1 (0.9) 1.1 (0.2) 1.0 (0.2) 3.2 (0.4) 1.2 (0.1) 1.0 (0.1) 1.1 (0.1) 1.2 (0.3) 
DENV2 PH203 9.1 (0.7) 0.9 (0.1) 61.8 (2.0) 30.3 (1.5) 3.9 (0.2) 1.0 (0.2) 6.3 (1.0) 1.0 (0.1) 0.9 (0.3) 2.8 (0.3) 1.1 (0.1) 1.0 (0.1) 1.1 (0) 1.3 (0) 
DENV2 PNG203 8.1 (0.4) 1.0 (0.1) 60.7 (1.8) 29.0 (1.7) 4.8 (0.2) 1.1 (0.1) 2.7 (0.6) 1.0 (0.1) 1.0 (0.2) 1.9 (0.2) 1.3 (0.1) 1.1 (0.1) 1.0 (0.2) 1.2 (0.1) 
DENV2 CA203 19.4 (0.4) 1.1 (0.1) 60.4 (2.3) 22.5 (1.6) 12.9 (0.2) 0.9 (0.1) 3.0 (0.6) 1.1 (0.2) 0.9 (0.1) 1.7 (0.3) 1.0 (0.1) 1.0 (0.2) 1.1 (0.1) 1.4 (0) 
DENV2 TO203 6.2 (0.9) 0.8 (0.2) 59.7 (2.3) 26.7 (1.7) 4.2 (0.4) 1.1 (0) 2.6 (0.5) 1.0 (0.1) 1.0 (0.2) 1.9 (0.2) 1.1 (0.1) 1.0 (0.1) 1.2 (0.2) 1.1 (0.1) 
DENV2 PNG203 8.6 (0.4) 1.0 (0.1) 62.9 (1.4) 27.5 (1.3) 5.9 (0.4) 1.1 (0.1) 2.5 (0.4) 1.0 (0.2) 0.9 (0.1) 1.6 (0.2) 1.1 (0.1) 1.0 (0.1) 1.0 (0.1) 1.2 (0.2) 
DENV2 IN203 30.7 (1.1) 1.0 (0.1) 61.2 (1.8) 19.8 (1.9) 5.2 (0.3) 0.9 (0.2) 1.5 (0.3) 0.9 (0.2) 1.0 (0.2) 2.1 (0.2) 1.4 (0.1) 0.9 (0.1) 1.1 (0.2) 1.3 (0) 
DENV3 ET00 42.2 (7.5) 13.2 (1.6) 11.8 (1.5) 50.1 (10.5) 30.6 (3.7) 0.9 (0.1) 1.3 (0.3) 1.8 (0.1) 1.1 (0.2) 2.7 (0.2) 1.3 (0.1) 1.2 (0.2) 1.1 (0.1) 1.1 (0.2) 
DENV3 TO306 35.9 (6.1) 2.1 (0.3) 14.1 (1.7) 37.7 (7.5) 22.5 (2.3) 0.9 (0.1) 1.2 (0.1) 1.5 (0.1) 1.1 (0.2) 1.7 (0.1) 1.1 (0.1) 1.2 (0.1) 1.2 (0.2) 1.0 (0.1) 
DENV3 SE307 36.3 (5.1) 2.6 (0.2) 15.5 (2.2) 35.3 (4.6) 23.4 (2.3) 0.9 (0.1) 1.2 (0.2) 2.4 (0.3) 1.2 (0.2) 2.2 (0.1) 1.3 (0.2) 1.2 (0.1) 1.1 (0.2) 1.0 (0.1) 
DENV3 CA306 37.7 (5.7) 3.1 (0.5) 15.5 (2.1) 35.9 (5.3) 26.5 (1.9) 0.8 (0.1) 1.1 (0.4) 3.3 (0.3) 1.1 (0.2) 3.0 (0.2) 1.3 (0.1) 1.1 (0.2) 1.2 (0.2) 1.0 (0.1) 
DENV3 CA308 37.2 (5.0) 2.5 (0.3) 12.1 (1.8) 36.6 (5.1) 24.1 (2.6) 1.0 (0.1) 1.1 (0.3) 2.3 (0.1) 1.1 (0.1) 2.3 (0.4) 1.2 (0.2) 1.1 (0.2) 1.2 (0.3) 1.0 (0.1) 
DENV3 TO307 36.9 (5.2) 1.7 (0.2) 11.5 (1.7) 29.9 (4.7) 24.8 (2.4) 1.0 (0) 1.2 (0.1) 1.2 (0.1) 1.0 (0.1) 2.0 (2.1) 1.2 (0.1) 1.1 (0.2) 1.1 (0.1) 1.0 (0.1) 
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Virus Strain Mean S/B ratio of probe  (SD) 
  DENVU2 DENV1 DENV2 DENV3 DENV4 JEV KOKV KUNV MVEV MVEV2 SEPV STRV WNV YFV 
DENV3 TH397 41.6 (5.9) 2.4 (0.3) 20.6 (2.7) 44.3 (7.5) 31.0 (2.7) 1.0 (0.1) 1.2 (0.2) 2.1 (0.1) 1.1 (0.2) 3.5 (0.3) 1.2 (0.1) 1.1 (0.1) 1.2 (0.2) 1.1 (0.1) 
DENV3 BR302 43.2 (6.1) 1.7 (0.2) 7.9 (1.0) 28.8 (5.0) 32.0 (3.4) 0.8 (0) 1.3 (0.4) 1.6 (0.1) 1.1 (0.1) 2.5 (0.2) 1.2 (0.1) 1.1 (0.1) 1.2 (0.4) 1.1 (0.2) 
DENV4 ET00.288 26.7 (3.5) 1.0 (0.1) 13.6 (1.6) 7.5 (0.5) 20.5 (0.6) 1.0 (0.1) 1.2 (0.1) 0.9 (0.1) 1.1 (0.2) 2.2 (0.3) 1.0 (0.1) 1.1 (0.1) 0.9 (0.1) 1.0 (0.1) 
DENV4 PI405 29.9 (6.5) 1.1 (0.3) 1.8 (0.3) 2.6 (0.1) 24.4 (3.6) 0.9 (0.1) 1.1 (0.3) 1.0 (0.1) 1.1 (0.1) 1.0 (0.2) 1.1 (0) 1.1 (0.2) 1.1 (0.3) 1.1 (0.1) 
DENV4 ET407 10.8 (2.4) 1.1 (0.1) 3.2 (0.5) 1.5 (0.4) 4.8 (0.5) 1.0 (0.1) 1.2 (0.2) 1.1 (0.2) 1.2 (0.2) 3.0 (0.5) 1.3 (0.2) 1.2 (0.2) 1.2 (0.1) 1.0 (0.1) 
DENV4 HO40u 18.7 (4.6) 1.0 (0) 2.1 (0.3) 1.5 (0.2) 6.9 (1.4) 0.9 (0) 1.2 (0.3) 1.1 (0.2) 1.2 (0.2) 1.1 (0.1) 1.1 (0.1) 1.0 (0.2) 1.1 (0.2) 1.0 (0.2) 
DENV4 SA408 25.6 (5.9) 1.0 (0.1) 2.9 (0.8) 5.0 (0.7) 21.0 (2.1) 0.8 (0) 1.2 (0.2) 1.1 (0) 1.1 (0.2) 1.1 (0.1) 1.1 (0.1) 1.1 (0.2) 1.1 (0.1) 1.0 (0) 
DENV4 UT41u 34.3 (7.5) 0.9 (0) 16.0 (2.4) 8.5 (1.3) 27.6 (3.4) 0.9 (0.1) 1.3 (0.3) 1.1 (0.1) 1.1 (0.2) 1.0 (0.1) 1.2 (0.2) 1.0 (0.1) 1.0 (0.2) 0.9 (0) 
DENV4 TI05 32.8 (8.0) 1.0 (0) 7.7 (0.8) 5.1 (1.1) 26.6 (4.4) 0.8 (0.1) 1.2 (0.3) 1.1 (0.1) 1.2 (0) 1.2 (0) 1.1 (0.2) 1.0 (0.2) 1.0 (0) 1.0 (0.2) 
JEV TS6516 1.1 (0.2) 1.0 (0.1) 1.7 (0.2) 1.5 (0.2) 0.9 (0.1) 8.3 (1.3) 1.1 (0) 1.0 (0.2) 1.0 (0) 1.4 (0.2) 1.1 (0.2) 1.0 (0) 1.0 (0.1) 1.0 (0.1) 
JEV M96 1.3 (0.2) 1.0 (0.1) 3.5 (0.3) 4.1 (0.7) 1.0 (0) 16.3 (0.9) 1.4 (0.1) 1.1 (0.1) 1.1 (0) 1.3 (0.2) 0.9 (0.1) 1.0 (0.1) 0.9 (0.1) 1.1 (0.2) 
JEV PNG6544 1.1 (0.1) 1.0 (0.3) 2.4 (0.2) 2.8 (0.3) 1.1 (0.1) 13.3 (0.7) 1.2 (0.2) 1.1 (0.1) 1.2 (0.2) 1.4 (0.3) 1.0 (0.1) 1.0 (0.1) 0.9 (0.1) 1.1 (0.2) 
JEV FU1028 1.3 (0.2) 1.0 (0.1) 1.9 (0.1) 2.3 (0.2) 1.1 (0.1) 9.1 (0.5) 1.2 (0.1) 1.1 (0.2) 1.2 (0.2) 1.3 (0) 1.0 (0.1) 1.1 (0.1) 0.9 (0.2) 1.2 (0.1) 
JEV Mabuig2576 1.2 (0.1) 1.0 (0.1) 3.3 (0.2) 3.8 (0.1) 1.0 (0.1) 15.8 (0.7) 1.3 (0.1) 1.2 (0.2) 1.2 (0.1) 1.5 (0.3) 1.0 (0) 1.0 (0.1) 0.9 (0.1) 1.1 (0.1) 
JEV BI146 1.1 (0.3) 1.1 (0.2) 3.0 (0.3) 4.6 (0.5) 1.1 (0.1) 15.9 (0.8) 1.3 (0.1) 1.1 (0.2) 2.5 (0.2) 2.1 (0.5) 0.9 (0.1) 1.0 (0.2) 1.0 (0.1) 1.0 (0) 
JEV Nakayama 1.1 (0.1) 1.0 (0.1) 5.5 (0.5) 10.2 (1.6) 1.0 (0.1) 13.1 (0.4) 1.2 (0) 1.0 (0.2) 1.1 (0.2) 1.9 (0.3) 0.9 (0.1) 1.0 (0.1) 0.9 (0.1) 1.1 (0.1) 
KOKV MRM32 1.1 (0.1) 1.4 (0.1) 1.2 (0.1) 9.5 (1.2) 1.0 (0.2) 1.2 (0.1) 21.0 (1.6) 0.9 (0) 0.9 (0.1) 2.0 (0.3) 1.5 (0.3) 2.1 (0.1) 1.1 (0.1) 1.1 (0.2) 
KUNV Sarawak 1.1 (0) 1.1 (0.1) 4.7 (0.3) 5.0 (0.5) 1.1 (0.2) 1.1 (0.1) 1.1 (0.1) 1.0 (0.1) 1.5 (0.1) 1.5 (0) 1.0 (0.1) 1.0 (0) 10.6 (1.9) 1.0 (0.2) 
KUNV CX288  1.2 (0.1) 1.2 (0.2) 1.2 (0) 12.7 (1.0) 1.0 (0.1) 1.1 (0.1) 4.8 (0.5) 22.1 (2.8) 1.5 (0.1) 4.4 (0.1) 1.1 (0.1) 1.0 (0) 14.0 (2.2) 1.0 (0.1) 
KUNV HU6744  1.1 (0.1) 1.0 (0.1) 1.3 (0.1) 12.7 (1.1) 1.0 (0.1) 0.9 (0.2) 3.1 (0.1) 15.6 (2.0) 1.3 (0.1) 3.4 (0.2) 1.2 (0.1) 1.0 (0.1) 8.0 (1.5) 1.1 (0.1) 
KUNV K1738 1.2 (0.1) 1.1 (0.1) 1.2 (0.1) 9.4 (0.8) 1.1 (0.2) 1.0 (0.1) 4.3 (0.2) 21.7 (3.0) 1.2 (0.1) 3.5 (0.3) 1.1 (0.1) 1.1 (0.1) 12.9 (2.1) 1.1 (0) 
KUNV MRM16 1.1 (0.3) 1.1 (0.3) 4.0 (0.5) 17.9 (5.4) 1.0 (0.2) 1.0 (0.1) 5.0 (1.1) 22.7 (5.3) 4.6 (1.5) 5.1 (1.3) 1.0 (0.1) 1.0 (0.2) 14.1 (4.2) 1.0 (0.2) 
KUNV KUNV Boort  1.3 (0.2) 1.1 (0.3) 1.3 (0) 16.5 (1.1) 1.0 (0.1) 1.0 (0.1) 6.9 (0.5) 25.2 (2.5) 6.4 (0.8) 5.4 (0.3) 1.2 (0.1) 1.1 (0.2) 15.7 (2.3) 1.0 (0.1) 
MVEV MRM66 0.9 (0.2) 0.9 (0.1) 6.0  (1.3) 4.3 (1.6) 1.0 (0) 1.0 (0.1) 1.0 (0.1) 0.9 (0.1) 18.3 (3.9) 26.4 (2.4) 1.2 (0) 0.9 (0.1) 0.9 (0) 0.9 (0.1) 
MVEV MV02 1.0 (0.2) 1.1 (0.2) 3.6 (0.4) 2.0 (0.4) 1.0 (0.1) 1.1 (0.1) 1.4 (0.1) 1.0 (0) 22.9 (5) 24.8 (2.7) 1.0 (0.1) 0.9 (0) 1.0 (0.2) 0.9 (0.1) 
MVEV 341/2001 1.0 (0.2) 1.0 (0.2) 5.1 (1.1) 1.9 (0.4) 0.9 (0.1) 1.2 (0.1) 2.0 (0) 1.0 (0.1) 23.8 (4.5) 23.2 (1.8) 0.9 (0.1) 0.9 (0) 0.9 (0.1) 1.0 (0.1) 
MVEV 326/2001 0.9 (0.1) 1.1 (0.1) 5.6 (1.1) 1.8 (0.4) 0.9 (0.2) 1.1 (0.2) 2.0 (0.1) 1.0 (0.1) 24.5 (4.9) 23.2 (2.3) 1.0 (0) 1.0 (0.2) 1.0 (0.1) 0.9 (0.1) 
MVEV OR156 1.2 (0.2) 1.1 (0.1) 7.3 (0.4) 4.3 (0.9) 0.9 (0.1) 1.0 (0) 1.1 (0.1) 0.9 (0.2) 4.2 (0.4) 26.4 (2.5) 1.8 (0.5) 1.0 (0.20 0.9 (0.1) 0.9 (0.1) 
MVEV MVEV15109 1.0 (0.2) 1.0 (0.1) 6.5 (0.2) 2.7 (0.4) 0.9 (0.1) 1.1 (0.1) 1.6 (0.1) 1.0 (0) 18.8 (3.4) 25.8 (2.3) 1.2 (0.1) 0.8 (0.1) 1.0 (0.2) 0.9 (0.1) 
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Virus Strain Mean S/B ratio of probe  (SD) 
  DENVU2 DENV1 DENV2 DENV3 DENV4 JEV KOKV KUNV MVEV MVEV2 SEPV STRV WNV YFV 
MVEV MVE16219 1.1 (0) 1.1 (0.2) 10.5 (0.9) 4.0 (0.5) 0.9 (0.1) 1.2 (0) 1.6 (0) 0.9 (0.1) 18.8 (3.4) 28.4 (2.5) 1.1 (0.2) 0.9 (0.1) 1.0 (0) 1.1 (0.2) 
MVEV MK6684 1.0 (0.2) 1.1 (0.1) 9.2 (0.7) 4.1 (0.4) 0.9 (0.1) 1.1 (0.1) 1.2 (0.2) 1.0 (0.1) 1.5 (0.3) 27.4 (1.7) 1.6 (0.2) 0.9 (0.1) 1.0 (0.1) 1.0 (0.1) 
MVEV PNG156 1.0 (0.1) 1.1 (0.1) 7.1 (0.6) 4.7 (0.6) 0.9 (0.2) 1.0 (0) 1.1 (0.1) 1.0 (0) 1.0 (0.2) 27.8 (1.4) 1.3 (0.2) 1.0 (0.2) 0.8 (0.1) 1.0 (0) 
SEPV MK6684 1.1 (0.3) 1.0 (0.2) 4.9 (0.7) 1.1 (0.2) 1.1 (0.3) 0.9 (0.1) 1.4 (0.3) 1.1 (0.2) 1.2 (0.3) 2.0 (0.3) 6.3 (0.4) 1.2 (0.2) 1.3 (0.1) 0.9 (0.1) 
STRV C338 1.1 (0.2) 1.3 (0.2) 6.0 (0.7) 12.4 (2.2) 1.1 (0.2) 0.9 (0.1) 5.9 (1.4) 1.0 (0.1) 1.3 (0.1) 8.5 (1.2) 1.4 (0.1) 14.0 (2.1) 1.1 (0.1) 1.0 (0.1) 
WNV Wengler (B956) 1.0 (0.1) 1.1 (0.2) 1.9 (0.2) 7.9 (2.9) 1.0 (0.2) 1.1 (0.2) 1.1 (0.1) 6.2 (0.7) 1.0 (0.2) 3.6 (0.8) 1.0 (0.1) 0.9 (0.1) 17.5 (3.2) 0.9 (0.1) 
WNV G22886  0.9 (0.1) 1.0 (0.1) 1.2 (0.2) 14.9 (3.3) 1.0 (0.1) 1.2 (0.2) 1.1 (0.1) 2.7 (0.2) 1.2 (0.2) 2.6 (0.1) 1.4 (0) 0.9 (0.1) 1.9 (0.1) 1.1 (0.1) 
WNV MGAR978 1.0 (0.2) 1.0 (0.2) 1.1 (0.1) 9.2 (2.5) 0.9 (0.1) 1.0 (0.2) 1.6 (0.1) 1.0 (0.1) 1.0 (0.1) 2.9 (0.3) 1.0 (0.1) 0.9 (0.1) 17.1 (1.1) 1.0 (0.2) 
WNV Sarafend 1.1 (0.2) 1.1 (0.1) 8.0 (0.8) 12.8 (2.9) 1.0 (0.1) 1.0 (0.1) 1.5 (0.1) 1.1 (0.1) 1.3 (0.3) 4.7 (0.3) 1.7 (0) 0.9 (0.1) 18.8 (1.8) 1.1 (0.2) 
WNV Koutango 1.3 (0.4) 1.0 (0.1) 1.1 (0.2) 1.2 (0.2) 1.2 (0.2) 1.0 (0) 6.7 (1.2) 1.2 (0.1) 1.1 (0.1) 2.1 (0.9) 1.4 (0.2) 1.1 (0) 1.5 (0.2) 1.1 (0) 
WNV NY99 1.2 (0.3) 1.1 (0.1) 1.6 (0.3) 11.7 (2.4) 1.2 (0.1) 1.0 (0.1) 11.0 (1.8) 1.1 (0) 1.4 (0.2) 6.8 (0.9) 1.2 (0.1) 1.2 (0.3) 21.8 (2.5) 1.0 (0.1) 
YFV 17D 1.0 (0.2) 1.0 (0.2) 7.1 (0.4) 1.2 (0.1) 1.1 (0) 0.9 (0) 1.1 (0.2) 0.9 (0) 1.1 (0.2) 0.7 (0.1) 0.9 (0.1) 1.0 (0.1) 1.1 (0.2) (3.1) 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was calculated by dividing the MFI of the sample by the 
MFI of the negative control.  The mean of these replicate values is the mean S/B ratio of the probe (±standard deviation) 
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Appendix 3: Validation of the flavivirus suspension microarray using DENV clinical samples 
TaqMan ID Sample Mean S/B ratio of probe   
  DENVU2 DENV1 DENV2 DENV3 DENV4 JEV KOKV KUNV MVEV MVEV2 SEPV STRV WNV YFV 
DENV1 V1.01 51 33 38 53 43 1 4 2 6 3 1 1 1 1 
DENV1 V1.02 55 15 26 36 37 1 4 1 10 3 1 1 1 1 
DENV1 V1.03 24 8 4 23 10 1 2 1 1 1 1 1 1 1 
DENV1 V1.04 31 6 5 23 10 1 1 1 2 3 1 1 1 1 
DENV1 V1.05 49 6 17 58 30 1 1 2 1 3 1 1 1 1 
DENV1 V1.06 40 23 12 42 24 1 2 1 2 4 1 1 1 1 
DENV1 V1.07 34 8 5 25 16 1 1 1 6 1 1 1 1 1 
DENV1 V1.08 13 2 1 10 3 1 1 1 1 1 1 1 1 1 
DENV1 V1.09 34 7 5 20 18 1 1 1 6 1 1 1 1 1 
DENV1 V1.10 33 7 5 19 17 1 1 1 5 1 1 1 1 1 
DENV2 V2.01 30 1 63 54 17 1 10 1 1 9 1 1 1 1 
DENV2 V2.02 14 1 63 53 3 1 7 1 1 13 3 1 1 1 
DENV2 V2.03 1 1 33 2 1 1 1 1 1 4 1 1 1 1 
DENV2 V2.04 1 1 27 2 1 1 1 1 1 4 1 1 1 1 
DENV3 V3.01 26 2 6 26 15 1 1 2 1 3 1 1 1 1 
DENV3 V3.02 26 2 6 27 14 1 1 2 1 4 1 1 1 1 
DENV3 V3.03 27 2 6 26 15 1 1 3 1 4 1 1 1 1 
DENV3 V3.04 25 2 5 27 11 1 1 1 1 5 1 1 1 1 
DENV3 V3.05 26 2 6 29 14 1 1 2 1 5 1 1 1 1 
DENV3 V3.06 38 2 7 37 17 1 1 1 1 3 1 1 1 1 
DENV3 V3.07 31 1 3 36 8 1 1 1 1 2 1 1 1 1 
DENV3 V3.08 34 1 4 36 12 1 1 1 1 2 1 1 1 1 
DENV3 V3.09 5 1 1 6 1 1 1 1 1 2 1 1 1 1 
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TaqMan ID Sample Mean S/B ratio of probe   
  DENVU2 DENV1 DENV2 DENV3 DENV4 JEV KOKV KUNV MVEV MVEV2 SEPV STRV WNV YFV 
DENV3 V3.10 41 2 11 38 21 1 1 2 1 4 1 1 1 1 
DENV3 V3.11 42 2 10 36 21 1 1 2 1 4 1 1 1 1 
DENV3 V3.12 38 2 6 37 16 1 1 1 1 3 1 1 1 1 
DENV3 V3.13 44 2 11 40 22 1 1 2 1 5 1 1 1 1 
DENV3 V3.14 28 1 5 28 11 1 1 1 1 2 1 1 1 1 
DENV3 V3.15 30 1 4 29 11 1 1 1 1 2 1 1 1 1 
DENV3 V3.16 28 1 2 33 6 1 1 1 1 1 1 1 1 1 
DENV3 V3.17 29 2 4 32 12 1 1 1 1 2 1 1 1 1 
DENV3 V3.18 4 1 1 5 1 1 1 1 1 1 1 1 1 1 
DENV3 V3.19 29 1 4 32 11 1 1 1 1 1 1 1 1 1 
DENV3 V3.20 23 1 2 26 4 1 1 1 1 1 1 1 1 1 
DENV3 V3.21 31 1 3 32 11 1 1 1 1 1 1 1 1 1 
DENV3 V3.22 32 1 5 33 11 1 1 1 1 2 1 1 1 1 
DENV3 V3.23 48 4 14 57 28 1 1 2 1 3 1 1 1 1 
DENV3 V3.24 47 5 14 57 28 1 1 2 1 3 1 1 1 1 
DENV3 V3.25 16 1 2 23 4 1 1 1 1 5 1 1 1 1 
DENV4 V4.01 16 1 1 1 6 1 1 1 1 1 1 1 1 1 
DENV4 V4.02 26 1 1 1 13 1 1 1 1 1 1 1 1 1 
DENV4 V4.03 16 1 1 1 6 1 1 1 1 1 1 1 1 1 
DENV4 V4.04 14 1 1 1 5 1 1 1 1 1 1 1 1 1 
DENV4 V4.05 57 1 37 21 50 1 1 1 1 5 1 1 1 1 
DENV4 V4.06 51 1 32 18 40 1 2 1 1 3 1 1 1 1 
DENV4 V4.07 43 1 26 17 33 1 2 1 1 2 1 1 1 1 
DENV1 V1.11 2 1 1 1 1 1 1 1 1 4 1 1 1 1 
DENV4 V4.08 7 1 4 2 3 1 2 1 1 4 2 1 1 1 
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TaqMan ID Sample Mean S/B ratio of probe 
  DENVU2 DENV1 DENV2 DENV3 DENV4 JEV KOKV KUNV MVEV MVEV2 SEPV STRV WNV YFV 
DENV2 V2.05 3 1 1 2 1 1 1 1 1 5 1 1 1 1 
DENV3 V3.26 1 1 1 2 1 1 1 1 1 1 1 1 1 1 
DENV3 V3.27 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
DENV3 V3.28 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
DENV3 V3.29 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
DENV3 V3.30 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
 
Samples were run in triplicate and the S/B (sample-to-background) ratio of each replicate was calculated by dividing the MFI of the sample by the 
MFI of the negative control.  The mean of these replicate values is the mean S/B ratio of the probe  
 
 
 
 
 
 
 
 
